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Abstract 35 
By definition, an adrenal incidentaloma is an asymptomatic adrenal mass detected on 36 
imaging not performed for suspected adrenal disease. In most cases, adrenal incidentalomas 37 
are non-functioning adrenocortical adenomas, but may also represent conditions requiring 38 
therapeutic intervention including adrenocortical carcinoma, pheochromocytoma, hormone-39 
producing adenoma or metastasis. The purpose of this guideline is to provide clinicians with 40 
best possible evidence-based recommendations for clinical management of patients with 41 
adrenal incidentalomas based on the GRADE (Grading of Recommendations Assessment, 42 
Development and Evaluation) system.  43 
We predefined four main clinical questions crucial for the management of adrenal 44 
incidentaloma patients, addressing these four with systematic literature searches: A) How to 45 
assess risk of malignancy?; B) How to define and manage low level autonomous cortisol 46 
secretion, the so-called “subclinical” Cushing syndrome?; C) Who should have surgical 47 
treatment and how should it be performed?; D) What follow-up is indicated if the adrenal 48 
incidentaloma is not surgically removed? 49 
Selected Recommendations: 1) At the time of initial detection of an adrenal mass 50 
establishing whether the mass is benign or malignant is an important aim to avoid 51 
cumbersome and expensive follow-up imaging in those with benign disease. 2) To exclude 52 
cortisol excess a 1-mg overnight dexamethasone suppression test should be performed 53 
(applying a cutoff value of serum cortisol ≤ 50 nmol/l (1.8 µg/dl)). 3) For patients without 54 
clinical signs of overt Cushing's syndrome but serum cortisol levels post 1mg 55 
dexamethasone > 138 nmol/l (> 5 µg/dl) we propose the term ‘autonomous cortisol 56 
secretion’. 4) All patients with ‘(possible) autonomous cortisol’ secretion should be screened 57 
for hypertension and type 2 diabetes mellitus, to ensure these are appropriately treated. 5) 58 
Surgical treatment should be considered in an individualized approach in patients with 59 
'autonomous cortisol secretion' who also have comorbidities that are potentially related to 60 
cortisol excess. 6) In principle, the appropriateness of surgical intervention should be guided 61 
by the likelihood of malignancy, the presence and degree of hormone excess, age, general 62 
health and patient preference. 7) Surgery is not usually indicated in patients with an 63 
asymptomatic, non-functioning unilateral adrenal mass and obvious benign features on 64 
imaging studies. We provide guidance on which surgical approach should be considered for 65 
adrenal masses with radiological findings suspicious of malignancy. Furthermore, we offer 66 
recommendations for the follow-up of patients with adrenal incidentaloma who do not 67 
undergo adrenal surgery, for those with bilateral incidentalomas, for patients with extra-68 
adrenal malignancy and adrenal masses, and for young and elderly patients with adrenal 69 
incidentalomas. 70 
71 
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1. Summary of Recommendations* 72 
1.1  General remarks 73 
R.1.1  We recommend that patients with adrenal incidentalomas are discussed in a 74 
multidisciplinary expert team meeting, if at least one of the following criteria is met: 75 
- Imaging is not consistent with a benign lesion. 76 
- There is evidence of hormone excess (including “autonomous cortisol secretion”). 77 
- Evidence of significant tumor growth during follow-up imaging. 78 
- Adrenal surgery is considered. 79 
1.2  Assessment of the risk of malignancy 80 
R.2.1 We recommend aiming to establish if an adrenal mass is benign or malignant at the 81 
time of initial detection.  82 
R.2.2 We recommend that all adrenal incidentalomas undergo an imaging procedure to 83 
determine if the mass is homogeneous and lipid-rich and therefore benign (XOOO). 84 
For this purpose, we primarily recommend the use of non-contrast CT (XOOO).  85 
R.2.3 We suggest that if the non-contrast CT is consistent with a benign adrenal mass 86 
(Hounsfield units ≤ 10) that is homogeneous and smaller than 4 cm no further 87 
imaging is required (XOOO).  88 
R.2.4 If the adrenal mass is indeterminate on non-contrast CT and the results of the 89 
hormonal work-up do not indicate significant hormone excess, three options should 90 
be considered by a multidisciplinary team acknowledging the patient’s clinical context: 91 
immediate additional imaging with another modality, interval imaging in 6 to 12 92 
months (non-contrast CT or MRI), or surgery without further delay. 93 
R.2.5 We recommend against the use of an adrenal biopsy in the diagnostic work-up of 94 
patients with adrenal masses unless there is a history of extra-adrenal malignancy 95 
and additional criteria are fulfilled (see R6.3.5).  96 
1.3  Assessment for hormone excess  97 
R.3.1 We recommend that every patient with an adrenal incidentaloma should undergo 98 
careful assessment including clinical examination for symptoms and signs of adrenal 99 
hormone excess. 100 
R.3.2 We recommend that all patients with adrenal incidentalomas undergo a 1-mg 101 
overnight dexamethasone suppression test to exclude cortisol excess (XXOO). 102 
R.3.3 We suggest interpretation of the results of the 1-mg overnight dexamethasone test as 103 
a continuous rather than categorical (yes/no) variable (XOOO). However, we 104 
                                                            
*
 The recommendations are worded as recommend (strong recommendation) and suggest (weak 
recommendation). The quality of evidence behind the recommendations is classified as low very low 
(⊕ΟΟΟ), low (⊕⊕ΟΟ), moderate (⊕⊕⊕Ο) and strong (⊕⊕⊕⊕). See further Section 3.4. 
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recommend using serum cortisol levels post dexamethasone ≤ 50 nmol/l (≤ 1.8 µg/dl) 105 
as a diagnostic criterion for the exclusion of autonomous cortisol secretion (XXOO).  106 
R.3.4 We suggest that post dexamethasone serum cortisol levels between 51 and 138 107 
nmol/l (1.9 - 5.0 µg/dl) should be considered as evidence of ‘possible autonomous 108 
cortisol secretion’ and cortisol levels post dexamethasone > 138 nmol/l (> 5.0 µg/dl) 109 
should be taken as evidence of ‘autonomous cortisol secretion’. Additional 110 
biochemical tests to confirm cortisol secretory autonomy and assess the degree of 111 
cortisol secretion might be required. However, for the clinical management the 112 
presence of potentially cortisol-related comorbidities and age of the patient are of 113 
major importance. 114 
R.3.5 We recommend against considering ‘autonomous cortisol secretion’ as a condition 115 
with a high risk for the development of overt Cushing’s syndrome (XXOO). 116 
R.3.6 We recommend screening patients with ‘possible autonomous cortisol secretion’ or 117 
‘autonomous cortisol secretion’ for hypertension and type 2 diabetes mellitus (XOOO) 118 
and suggest offering appropriate treatment of these conditions. 119 
R.3.7 We suggest screening patients with ‘autonomous cortisol secretion’ for asymptomatic 120 
vertebral fractures (XOOO) and to consider appropriate treatment of these conditions 121 
(XOOO).  122 
R.3.8 We suggest an individualized approach to consider patients with ‘autonomous cortisol 123 
secretion’ due to a benign adrenal adenoma and comorbidities potentially related to 124 
cortisol excess for adrenal surgery (XOOO). Age, degree of cortisol excess, general 125 
health, comorbidities and patient’s preference should be taken into account. In all 126 
patients considered for surgery, ACTH-independency of cortisol excess should be 127 
confirmed.  128 
R.3.9 We recommend excluding pheochromocytoma by measurement of plasma free 129 
metanephrines or urinary fractionated metanephrines.  130 
R.3.10 In patients with concomitant hypertension or unexplained hypokalemia, we 131 
recommend the use of the aldosterone / renin ratio to exclude primary aldosteronism. 132 
R.3.11 We suggest measurement of sex hormones and steroid precursors in patients with 133 
clinical or imaging features suggestive of adrenocortical carcinoma. 134 
1.4  Surgical treatment  135 
R.4.1 We recommend adrenalectomy as the standard of care for unilateral adrenal tumors 136 
with clinically significant hormone excess.  137 
R.4.2 We recommend against performing surgery in patients with an asymptomatic, non-138 
functioning unilateral adrenal mass and obvious benign features on imaging studies 139 
(XOOO). 140 
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R.4.3 We suggest performing laparoscopic adrenalectomy in patients with unilateral adrenal 141 
masses with radiological findings suspicious of malignancy and a diameter ≤ 6 cm, 142 
but without evidence of local invasion (XOOO). 143 
R.4.4 We recommend performing open adrenalectomy for unilateral adrenal masses with 144 
radiological findings suspicious of malignancy and signs of local invasion (XOOO). 145 
R.4.5 We suggest an individualized approach in patients that do not fall in one of the above- 146 
mentioned categories (XOOO).  147 
R.4.6 We recommend perioperative glucocorticoid treatment at major surgical stress doses 148 
as recommended by guidelines, in all patients undergoing surgery for an adrenal 149 
tumor where there is evidence of ‘(possible) autonomous cortisol secretion’, i.e. who 150 
do not suppress to <50 nmol/L after 1mg dexamethasone overnight.  151 
1.5  Follow-up of patients not undergoing adrenal surgery after initial 152 
assessment 153 
R.5.1 We suggest against further imaging for follow-up in patients with an adrenal mass < 154 
4cm with clear benign features on imaging studies (XOOO).  155 
R.5.2 In patients with an indeterminate adrenal mass (by imaging) opting not to undergo 156 
adrenalectomy following initial assessment, we suggest a repeat non-contrast CT or 157 
MRI after 6-12 months to exclude significant growth (XOOO). We suggest surgical 158 
resection if the lesion enlarges by more than 20% (in addition to at least a 5 mm 159 
increase in maximum diameter) during this period. If there is growth of the lesion 160 
below this threshold, additional imaging after 6-12 months should be performed. 161 
R.5.3 We suggest against repeated hormonal work-up in patients with a normal hormonal 162 
work-up at initial evaluation unless new clinical signs of endocrine activity appear or 163 
there is worsening of comorbidities (e.g. hypertension and type 2 diabetes) (XOOO).  164 
R.5.4 In patients with ‘autonomous cortisol secretion’ without signs of overt Cushing’s 165 
syndrome, we suggest annual clinical re-assessment for cortisol excess comorbidities 166 
potentially related to cortisol excess (XOOO). Based on the outcome of this 167 
evaluation the potential benefit of surgery should be considered.  168 
1.6  Special circumstances 169 
1.6.1  Patients with bilateral adrenal incidentalomas 170 
R.6.1.1 We recommend that for patients with bilateral adrenal masses each adrenal lesion is 171 
assessed at the time of initial detection according to the same imaging protocol as 172 
for unilateral adrenal masses to establish if either or both masses are benign or 173 
malignant. 174 
R.6.1.2 We recommend that all patients with bilateral adrenal incidentalomas should 175 
undergo clinical and hormonal assessment identical to that in patients with unilateral 176 
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adrenal incidentaloma. The same applies for the assessment of comorbidities that 177 
might be related to autonomous cortisol secretion. In addition, 17-178 
hydroxyprogesterone should be measured to exclude congenital adrenal 179 
hyperplasia, and testing for adrenal insufficiency should be considered, if suspected 180 
on clinical grounds or if imaging suggests bilateral infiltrative disease or 181 
hemorrhages. 182 
R.6.1.3 We suggest that for patients with bilateral incidentaloma the same recommendations 183 
regarding the indication for surgery and follow-up are used as for patients with 184 
unilateral adrenal incidentalomas.  185 
R.6.1.4 We suggest that in patients with bilateral adrenal masses bilateral adrenalectomy is 186 
not performed for ACTH-independent ‘autonomous cortisol secretion’ without clinical 187 
signs of overt Cushing’s syndrome. In selected patients, a unilateral adrenalectomy 188 
of the dominant lesion might be considered using an individualized approach 189 
considering age, degree of cortisol excess, general condition, comorbidities and 190 
patient preference. 191 
1.6.2  Adrenal incidentalomas in young or elderly patients 192 
R.6.2.1 We recommend urgent assessment of an adrenal mass in children, adolescents, 193 
pregnant women and adults < 40 years of age because of a higher likelihood of 194 
malignancy.  195 
R.6.2.2 We suggest the use of MRI rather than CT in children, adolescents, pregnant 196 
women and adults < 40 years of age if dedicated adrenal imaging is required. 197 
R.6.2.3 We recommend that the management of patients with poor general health and a 198 
high degree of frailty be kept in proportion to potential clinical gain. 199 
1.6.3 Patients with a newly diagnosed adrenal mass and a history of extra-200 
 adrenal malignancy 201 
R.6.3.1  We recommend measurement of plasma or urinary metanephrines to exclude 202 
pheochromocytoma in patients with extra-adrenal malignancy with an indeterminate 203 
mass, even if the adrenal mass is likely to be a metastasis. We suggest additional 204 
hormonal work-up based on an individualized approach.  205 
R.6.3.2 We suggest that in patients with a history of extra-adrenal malignancy FDG-PET/CT, 206 
performed as part of investigations for the underlying malignancy, can replace other 207 
adrenal imaging techniques.  208 
R.6.3.3 We recommend that in patients with a history of extra-adrenal malignancy adrenal 209 
lesions characterized as benign (see also R.2.3) by non-contrast CT require no 210 
further specific adrenal imaging follow-up. 211 
Page 6 of 122
eje@bioscientfica.com
Manuscript submitted for review to European Journal of Endocrinology
For Review Only
7 
ESE and ENSAT guideline on adrenal incidentaloma 
R.6.3.4 For indeterminate lesions in patients with a history of extra-adrenal malignancy, we 212 
recommend imaging follow-up assessing the potential growth of the lesion at the 213 
same interval as imaging for the primary malignancy. Alternatively, FDG-PET/CT, 214 
surgical resection or a biopsy (see also R.6.3.5) can be considered. 215 
R.6.3.5 We suggest performing a biopsy of an adrenal mass only if all of the following 216 
criteria are fulfilled: (i) the lesion is hormonally inactive (in particular, a 217 
pheochromocytoma has been excluded), (ii) the lesion has not been conclusively 218 
characterized as benign by imaging, and (iii) management would be altered by 219 
knowledge of the histology.  220 
R.6.3.6 We recommend assessment of residual adrenal function in patients with large 221 
bilateral adrenal metastases.  222 
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2. Adrenal Incidentaloma – Clinical presentation and terminology  223 
2.1 Definition, etiology and epidemiology of adrenal incidentalomas 224 
An adrenal incidentaloma is an adrenal mass detected on imaging not performed for 225 
suspected adrenal disease. By this strict definition, the imaging study is not done for 226 
symptoms related to adrenal hormone excess (e.g. pheochromocytoma, Cushing’s or Conn’s 227 
syndrome) or an otherwise suspected adrenal mass, but rather for the evaluation of 228 
symptoms that are not obviously related to an adrenal problem, such as abdominal or back 229 
pain or kidney stones. Similarly, screening imaging in patients with a hereditary syndrome 230 
leading to adrenal tumors is outside the definition of an adrenal incidentaloma. In addition, 231 
adrenal masses discovered on an imaging study performed during tumor evaluation for 232 
extra-adrenal malignancies (“tumor staging” or follow-up) do not meet the strict definition of 233 
adrenal incidentaloma. However, as this is a clinically frequent scenario, we will address this 234 
in a specific chapter (see 5.6.4).  235 
Previous recommendations and reviews (1-13) have not considered adrenal incidentalomas 236 
smaller than 1 cm. Although this cut-off is obviously somewhat arbitrary, we agree with this 237 
approach and would perform additional diagnostic work-up only in lesions ≥ 1cm unless 238 
clinical signs and symptoms suggestive of adrenal hormone excess are present.  239 
The etiology of adrenal incidentalomas varies and includes benign and malignant lesions 240 
derived from the adrenal cortex, the medulla or of extra-adrenal origin. The reported 241 
frequency varies, depending on the context of the study and inclusion size criteria (see Table 242 
1). Some authors conclude, however, that the prevalence of malignant and functional lesions 243 
is likely to be overestimated (3), mainly because the prevalence of malignancy in surgical 244 
series is usually higher than in series including all patients presenting with an adrenal mass. 245 
There is, however, clear evidence that the vast majority of adrenal incidentalomas are benign 246 
adrenocortical adenomas.  247 
 248 
The incidence and prevalence of adrenal incidentalomas can only be extrapolated from 249 
imaging or autopsy studies. Autopsy studies suggest a prevalence of clinically unapparent 250 
adrenal masses of around 2% (range 1.0-8.7%), which increases with age (5-7). Radiological 251 
studies report a frequency of around 3% in the age of 50 years, which increases up to 10% in 252 
the elderly (2, 5-7, 14-16). In childhood, adrenal incidentalomas are extremely rare.  253 
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2.2. Remarks on terminology  254 
As already discussed above, the term 'adrenal incidentaloma' can be defined by very 255 
restrictive criteria, but is sometimes used in a much broader sense, referring to any adrenal 256 
mass. Therefore, in the guideline we frequently speak of adrenal masses or lesions.  257 
Another term, which is widely used in the literature in the context of adrenal incidentaloma, is 258 
‘subclinical Cushing’s syndrome’ (19). This term aims to define patients with biochemical 259 
evidence of cortisol excess, but without the so-called "specific" clinical signs of Cushing’s 260 
syndrome (mainly the lack of catabolic features, like myopathy and skin fragility). There is, 261 
however, clear evidence that patients with clinically unapparent cortisol excess very rarely 262 
develop Cushing’s syndrome (1, 2, 20-25) and that this condition is different from overt 263 
Cushing’s syndrome, which is clearly associated with severe morbidity and elevated mortality 264 
(26-30). Nevertheless, there is some evidence that this low-grade autonomous cortisol 265 
excess might be associated with certain comorbidities (see Table 2). Thus, the panel 266 
unanimously decided to avoid the term “subclinical Cushing’s syndrome” and to use instead 267 
the term “‘autonomous cortisol secretion’” in the context of an adrenal incidentaloma 268 
throughout the guideline text (for the exact definition see chapter 5.3).  269 
Although the term “laparoscopic adrenalectomy” is actually reserved for operations that use a 270 
transperitoneal approach and should be distinguished from the term retroperitoneoscopic 271 
adrenalectomy, this never gained general acceptance. Therefore, in this guideline we use the 272 
term “laparoscopic adrenalectomy” to refer to minimally invasive approaches including 273 
retroperitoneoscopic surgery.  274 
 275 
 276 
2.3. Short overview on adrenal imaging 277 
For the differentiation of malignant from benign adrenal tumors, there are three main imaging 278 
techniques in current use: computed tomography (CT), magnetic resonance imaging (MRI), 279 
and positron emission tomography with 18F-2-deoxy-D-glucose (mostly combined with CT; 280 
FDG-PET/CT). CT and MRI are techniques mainly aiming to identify benign lesions, 281 
therefore representing tools designed for the exclusion of adrenal malignancy (47-50). 282 
Conversely, FDG-PET/CT is mainly used for the detection of malignant disease (51-53). 283 
CT has a high spatial and quantitative contrast resolution, which allows assessment of tissue 284 
density by measuring X-ray absorption of tissues. This allows calculation of tissue 285 
attenuation or tissue density values, which are measured in Hounsfield units (HU) and 286 
quantify X-ray absorption of tissues compared to water, which is conventionally allocated a 287 
HU value of 0. For non-contrast (or ‘unenhanced’) CT, HU of ≤ 10 is the most widely used 288 
threshold attenuation value for the diagnosis of a lipid-rich, benign adrenal adenoma (54). 289 
However, on non-contrast CT, some 30% of benign adenomas have an attenuation value 290 
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of > 10 HU and are considered lipid-poor, overlapping in density with malignant lesions and 291 
pheochromocytomas (55-57).  292 
Contrast-enhanced washout CT utilizes the unique perfusion pattern of adenomas. 293 
Adenomas take up intravenous CT contrast rapidly, but also have a rapid loss of contrast - a 294 
phenomenon termed ‘contrast enhancement washout’. It is assumed that malignant adrenal 295 
lesions usually enhance rapidly but demonstrate a slower washout of contrast medium. This 296 
washout phenomenon can be quantified by ‘contrast washout values’, which involve lesion 297 
attenuation measurements at specific time points acquired in a dedicated adrenal CT: prior to 298 
injection of contrast medium (HUnativ), at 60 seconds following injection of contrast medium 299 
(HUmax) and then at 10 or 15 minutes after contrast injection. This allows calculation of the 300 
relative contrast enhancement washout (=100x(HUmax-HU10/15min)/HUmax) and absolute 301 
contrast enhancement washout (=100x(HUmax-HU10/15min)/(HUmax-HUnativ)). A relative 302 
washout > 40% and an absolute washout > 60% is assumed to suggest that an adrenal 303 
lesion is benign (56, 58-60). 304 
MRI is a non-ionising radiation based imaging modality utilizing weak radio wave signals 305 
emitted by body tissues when the body is placed in a strong magnetic field and radio 306 
frequency pulses are applied. The advantages of MRI over CT are its lack of radiation 307 
exposure, lack of iodine-based contrast media and its superior tissue contrast resolution. For 308 
the differentiation of benign and malignant adrenal masses the MRI technique of chemical-309 
shift imaging is most commonly used (60-65). Chemical shift imaging relies on the fact that, 310 
within magnetic fields, protons in water vibrate at a slightly different frequency than protons in 311 
lipid. As a result, water and fat protons oscillate in and out of phase with respect to one 312 
another. By selecting appropriate sequencing parameters, separate images can be 313 
generated with water and fat protons oscillating in-phase or out-of-phase to each other. 314 
Adrenal adenomas with a high content of intracellular lipid usually lose signal intensity on 315 
out-of-phase images compared to in-phase images, whereas malignant lesions and 316 
pheochromocytomas (but also lipid-poor adrenal adenomas) that all lack intracellular lipid 317 
remain unchanged (58, 65, 66). Simple visual assessment of signal intensity loss is 318 
diagnostic in most cases but quantitative methods may be useful in less clear cut cases. 319 
Quantitative analysis can be made using the adrenal-to-spleen signal ratio and the signal 320 
intensity index. MR signal intensity units are arbitrary units, unlike CT, and therefore are 321 
subject to numerous technical variations. 322 
18F-FDG-PET is a nuclear medicine modality that provides quantitative tomographic images 323 
after intravenous injection of a beta-radiation emitting radiotracer (18-Fluorine) used to label 324 
2-deoxy-D-glucose rendering Fluoro-deoxyglucose (18F-FDG). Both glucose and 325 
deoxyglucose enter cells via cell glucose transporters and undergo phosphorylation but while 326 
glucose undergoes further enzymatic breakdown, deoxyglucose becomes trapped in 327 
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intracellular compartments. Cancer cells have an increased requirement for glucose and, 328 
therefore, take up more glucose and deoxyglucose than normal cells (67). However, 18F-FDG 329 
is not a specific marker for cancer cells but a marker only for increased glucose metabolism 330 
thus uptake can also be increased in cells with an increased energy requirement due to 331 
conditions other than cancer. Quantitative measurement of 18F concentrations within tissues 332 
provides the most commonly used clinical measurement index, standard uptake value (SUV), 333 
which compares the intensity of uptake of 18F in the adrenal lesion to the average uptake of 334 
whole body. SUV values have been utilized to differentiate between benign from malignant 335 
adrenal lesions. FDG-PET has a high sensitivity for detection of metabolic changes but its 336 
spatial resolution for anatomical localization is poor. The solution is a hardware fusion 337 
between PET and CT (PET/CT) allowing simultaneous acquisition of PET and CT data. In 338 
clinical practice this involves injecting patients with 18F-FDG tracers at least one hour prior to 339 
the start of combined PET/CT. Once post processing is complete, PET and CT data can be 340 
viewed separately, side-by-side or as a fused images (68).  341 
Other potentially emerging imaging techniques (e.g. metomidate-based adrenal imaging) are 342 
not yet clinically widely available and, therefore, will not be discussed in this guideline.  343 
 344 
2.4. Remarks on the difficulties with hormonal testing 345 
Hormone assessment is crucial in the context of the work-up for an adrenal incidentaloma. 346 
However, there are several pitfalls that have to be considered (e.g. daily rhythm, sex-/ age-347 
dependency, limitations of assays, drug interactions). Furthermore, normal ranges vary 348 
substantially, depending on the method used, so it is essential to interpret test results in the 349 
context of the appropriate reference range. Due to space restrictions we refer to other 350 
guidelines that have addressed these issues in more detail (69, 70).   351 
 352 
 353 
3. Methods  354 
3.1. Guideline working group 355 
This guideline was developed by The European Society of Endocrinology (ESE) in 356 
collaboration with the European Network for the Study of Adrenal Tumours (ENSAT), 357 
supported by CBO (Dutch Institute for health care improvement). The chairs of the working 358 
group Martin Fassnacht (clinical) and Olaf Dekkers (methodology) were appointed by the 359 
ESE Clinical Committee. The other members were suggested by the chairs and approved by 360 
the Clinical Committee of ESE: endocrinologists (Wiebke Arlt (UK), Irina Bancos (USA), John 361 
Newell-Price (UK), Antoine Tabarin (France), Massimo Terzolo (Italy), Stylianos Tsagarakis 362 
(Greece), a radiologist (Anju Sahdev (UK), and an endocrine surgeon (Henning Dralle 363 
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(Germany)). Irina Bancos served as representative of The Endocrine Society USA. The 364 
working group had three in-person meetings (December 2013, October 2014, and June 365 
2015) and communicated by phone and email. Consensus was reached upon discussion; 366 
minority positions were taken into account in the rationale behind recommendations. Prior to 367 
the process, all participants completed conflict of interest forms. 368 
 369 
 370 
3.2 Target group  371 
This guideline was developed for healthcare providers of patients with adrenal 372 
incidentalomas ie, endocrinologists, radiologists, surgeons, and specialists in internal 373 
medicine. However, general practitioners might also find the guideline useful, as might our 374 
patients. In addition, the guideline document can serve as guidance for patient information 375 
leaflets. A draft of the guideline was reviewed by four experts in the field (see 376 
“Acknowledgment’ section) and has been submitted for comments by ESE and ENSAT 377 
members. All comments and suggestions were then discussed and implemented as 378 
appropriate by the panel.  379 
 380 
 381 
3.3 Aims  382 
The overall purpose of this guideline is to provide clinicians with practical guidance for the 383 
management of patients with adrenal incidentalomas.  384 
 385 
 386 
3.4 Summary of methods used for guideline development 387 
The methods used have been described in more detail previously (71). In short, the guideline 388 
used GRADE (Grading of Recommendations Assessment, Development and Evaluation) as 389 
a methodological base. The first step was to define clinical question(s) (see section 3.5), the 390 
second being a systematic literature search (see Section 3.6). After including relevant 391 
articles, we 1), estimated an average effect for specific outcomes (if possible), and 2), rated 392 
the quality of the evidence. The quality of evidence behind the recommendations is classified 393 
as very low (⊕ΟΟΟ), low (⊕⊕ΟΟ), moderate (⊕⊕⊕Ο) and strong (⊕⊕⊕⊕). Evidence tables 394 
are provided in the Appendix.  395 
For the recommendations we took into account: 1) quality of the evidence, 2) balance of 396 
desirable and undesirable outcomes, 3) values and preferences (patient preferences, goals 397 
for health, costs, management inconvenience, feasibility of implementation, etc). (72, 73). 398 
The recommendations are worded as recommend (strong recommendation) and suggest 399 
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(weak recommendation). Formal evidence syntheses were performed and graded only for 400 
recommendations addressing our initial questions. Additional recommendations based on 401 
good practice were not graded (74). Recommendations were derived from majority 402 
consensus of the guideline development committee, but if members had substantive 403 
disagreements, this is acknowledged in the manuscript. For transparency, all 404 
recommendations provided are accompanied by text explaining why specific 405 
recommendations were made.  406 
 407 
 408 
3.5.   Clinical question, eligibility criteria and endpoint definition 409 
At the beginning of the guideline development process, the panel agreed on the four most 410 
important clinical questions in the management of patients with adrenal incidentalomas 411 
(Table 3), for which a detailed literature search was subsequently performed.  412 
 413 
 414 
3.6 Description of search and selection of literature 415 
A literature search in electronic medical databases was performed for all four clinical 416 
questions separately. Of note, the approach for clinical question 1 (assessment of the risk of 417 
malignancy) differed as the search, study selection and also the evidence synthesis was 418 
performed in the context of a formal systematic review and meta-analysis published 419 
separately from the current guideline. For all four clinical questions details of the yield of the 420 
search are shown in Table 3. In summary, we included 37 studies for clinical question 1 (with 421 
18 fulfilling the criteria for inclusion in the meta-analysis), twelve studies for clinical question 422 
2a (biochemical profile in adrenal incidentaloma), four studies for clinical question 2b 423 
(therapeutic approach in mild glucocorticoid excess), nine studies for clinical question 3 424 
(surgery) and ten studies plus one relevant systematic review for clinical question 4 (follow-425 
up).  426 
 427 
 428 
4. Summary and conclusions from systematic literature reviews 429 
 430 
4.1  Assessment of the risk of malignancy (Question 1) 431 
4.1.1  Assessment of the risk of malignancy by imaging (Question 1a) 432 
The following paragraph represents a summary of a recent meta-analysis on the use of 433 
imaging for differentiating benign from malignant adrenal incidentalomas carried out with 434 
involvement of some of the guideline panel members (75). Studies were considered all 435 
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studies of CT, MRI or FDG-PET in adults eligible if: 1) included patients underwent imaging 436 
for any indications other than investigation of suspected adrenal mass; 2) index imaging test 437 
characteristics were reported; 3) at least 50% of patients had an optimal reference standard: 438 
histological diagnosis in malignant masses and availability of histology or imaging follow up 439 
of any duration in the case of benign adrenal masses. Exclusion criteria are summarized in 440 
Table 3. The review looked separately at patients with true adrenal incidentaloma and 441 
patients with adrenal mass and a history of extra-adrenal malignancy. 442 
We identified 37 studies for inclusion in the systematic review (49, 52, 61, 77-110), with only 443 
18 of them fulfilling the criteria for inclusion in the actual meta-analysis (61, 77-93). No 444 
randomized studies comparing imaging tests were identified. Risk of bias ranged from low to 445 
high, with the majority having unclear or high risk of bias (mainly due to unclear population 446 
selection, retrospective selection of the diagnostic threshold and inadequate reference 447 
standards with resulting concerns of the applicability of results). 448 
Five commonly used diagnostic thresholds were studied: (1) tumor density >10HU on non-449 
contrast CT; (2) CT with delayed contrast media washout: absolute percentage washout 450 
and/or relative percentage washout at any washout percentage % or delay time on enhanced 451 
CT; (3) MRI chemical shift analysis: loss of signal intensity between in and out of phase 452 
images (including both qualitative and quantitative estimates of signal loss); and, for FDG-453 
PET or PET-CT, (4) the maximum standardized uptake value (SUVmax), and (5) the ratio of 454 
SUVmax in the adrenal gland compared to the liver (adrenal liver ratio).  455 
The 37 studies included were generally small with a median sample size of 45 (range 12 to 456 
181). Of the 18 studies included in the formal meta-analysis, 7 addressed purely incidental 457 
adrenal masses and 11 studies focused on patients with known extra-adrenal malignancy. 458 
Limited data (two studies with 102 true incidentalomas) suggest that CT density >10 HU has 459 
a high sensitivity for detection of adrenal malignancy (100%, 95% confidence interval 91-460 
100%); meaning that adrenal masses with a density of ≤10 HU are unlikely to be malignant. 461 
In patients with a history of extra-adrenal malignancy five studies evaluating the >10 HU cut-462 
off as indicative of malignancy showed high sensitivity (93%) for detection of malignancy but 463 
variable specificity; this means that 7% of adrenal metastases were found to have a tumor 464 
density of ≤10 HU.  465 
Disappointingly, all other estimates of test performance are based on small numbers of 466 
studies with very few patients and accompanying wide 95% confidence intervals, indicating 467 
much uncertainty in test performance for all other imaging markers. For true adrenal 468 
incidentalomas, two of three MRI studies reported slightly lower sensitivity and specificity 469 
than CT for measures of adrenal-liver and adrenal-spleen ratios and loss of signal intensity. 470 
The performance of PET for adrenal liver ratio and SUVmax measures in the two included 471 
studies was not clearly better than CT. In patients with a history of extra-adrenal malignancy, 472 
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only one study reported on CT contrast-enhanced washout tests, which showed very low 473 
sensitivity (16%). Four of the five studies of MRI used 1.5 Tesla machines and reported high 474 
sensitivity (89%-99%) for measures of adrenal-liver, adrenal-spleen, adrenal-muscle ratios 475 
and loss of signal intensity. Specificity varied (60%-93%) but was high for most MRI 476 
measures. The performance of PET was similar to MRI for ALR and max SUV measures. 477 
Although more studies had evaluated CT, MRI and PET in the pathway for follow-up of 478 
known extra-adrenal malignancy than for incidentally discovered adrenal lesions, estimates 479 
of test performance are still based on too small numbers of studies to be able to discern 480 
whether any test performs adequately or better than alternative tests from the available data. 481 
 482 
4.1.2  Value of an adrenal biopsy (Question 1b) 483 
The following paragraph represents a summary of a recent systematic review carried out with 484 
involvement of some of the guideline panel members on published experience with adrenal 485 
biopsy and its outcomes (76). Inclusion criteria and definition of reference standard differed 486 
from the imaging meta-analysis mainly in population selection criteria (as adrenal biopsy is 487 
not indicated in incidentaloma population but rather in patients at high risk for malignancy) 488 
and in reference standard (where we accepted imaging and clinical follow up in addition to 489 
histopathology as most metastases would not undergo adrenalectomy). We identified 32 490 
studies (88, 111-138) with a total of 2174 patients which reported at least one outcome of 491 
interest (complication rate, non-diagnostic rate, diagnostic accuracy parameters). Of these, 492 
only 8 studies(88, 124, 125, 128-131, 138) were included for the diagnostic accuracy 493 
analysis, reasons for exclusion being lack of any or optimal reference standard for at least 494 
50% patients (n=20) and more than 30% patients with non-adenomas in benign cohort (n=4). 495 
Included studies were assessed to be at a moderate risk for bias, most limitations relating to 496 
patient selection, assessment of outcome and adequacy of follow up of the study population.  497 
Studies had diverse population inclusion criteria, reference standards and biopsy techniques. 498 
Pathology of adrenal lesion was reported only for 1600/2207 cases. Out of these 819 were 499 
malignant (703 metastases, 67 ACCs, 49 other malignancies or not specified), 690 were 500 
benign and 91 were various other non-malignant lesions (36 pheochromocytomas, 29 501 
granulomas, 16 other). Pooled non-diagnostic rate derived from 30 studies (2030 adrenal 502 
biopsy procedures) was 8.6% (CI 6.1%-11%; I2 = 84%, p<0.001). Pooled overall 503 
complication rate derived from studies (1356 biopsies) was 2.4% (CI 1.5%-3.3%; I2 = 21%, 504 
p=0.175), though likely under-represented due to differences in both assessment and 505 
reporting of complication as well as retrospective nature of the studies. The diagnostic 506 
performance of adrenal biopsy was calculated using the data from the 8 studies (323 adrenal 507 
biopsy procedures) meeting pre-established eligibility criteria. Performance of adrenal biopsy 508 
in the diagnosis of malignancy overall was: sensitivity 87% (CI95% of 78-93%), specificity 509 
Page 15 of 122
eje@bioscientfica.com
Manuscript submitted for review to European Journal of Endocrinology
For Review Only
16 
ESE and ENSAT guideline on adrenal incidentaloma 
100% (CI95% of 76-100%), positive likelihood ratio of 229 (CI95% of 2.9-18145) and 510 
negative likelihood ratio of 0.13 (CI95% of 0.07-0.23). Performance was lower (and with even 511 
wide 95%CIs) for ACC: sensitivity 70% (CI95% of 42-88%), specificity 98% (CI95% of 86-512 
100%), positive likelihood ratio of 100.43 (CI95% of 8-1245) and negative likelihood ratio of 513 
30.9 (CI95% of 4.16-229). 514 
 515 
 516 
4.2 Assessment of autonomous cortisol secretion in adrenal incidentalomas  517 
4.2.1 Assessment of autonomous cortisol secretion in relation to clinical outcomes 518 
(Question 2a, Appendices I and II) 519 
Studies were eligible for inclusion independent of the criteria used to define autonomous 520 
cortisol secretion. Three different hormonal profiles were distinguished to describe 521 
autonomous cortisol secretion associated with adrenal adenomas; Profile 1: serum cortisol > 522 
50 nmol/l (>1.8 µg/dl) after 1-mg, 2-mg, or 8-mg overnight dexamethasone suppression 523 
tests, or 2-day low dose dexamethasone test, and one of the following additional endocrine 524 
alterations: increased 24-h urinary free cortisol (UFC), low plasma ACTH, elevated midnight 525 
serum or salivary cortisol; Profile 2: serum cortisol > 83nmol/l (>3.0 µg/dl) after 1-mg 526 
overnight dexamethasone test and one additional endocrine alteration (same as above); 527 
Profile 3: cortisol > 138 nmol/l (>5 µg/dl) after 1-mg overnight dexamethasone test as sole 528 
criterion. The defined profiles do not fit completely with the specific criteria used in all of the 529 
studies included. Virtually all diagnostic algorithms are, however, variations of these profiles.  530 
 531 
In total, twelve studies were included: seven cross-sectional studies (38, 42, 43, 45, 139-141) 532 
and five cohort studies (40, 46, 142-144). In eight studies, a comparison was made between 533 
patients with elevated (group 1) or normal (group 2) cortisol levels after a 1-mg 534 
dexamethasone test. Two studies used the biochemical profile 1 and four studies used the 535 
biochemical profile 2 with a variation since the post-dexamethasone serum cortisol cutoff 536 
was not a mandatory criterion. Three studies identified 3 subgroups of patients (38, 142, 537 
143), normal, intermediate and frankly altered cortisol suppression corresponding to cortisol 538 
levels after 1-mg dexamethasone of < 50 nmol/l (< 1.8 µg/dl), between 50 to 138 nmol/l (1.8 539 
µg/dl - 5.0 µg/dl), and > 138 nmol/l (> 5.0 µg/dl), respectively.  540 
In the cross-sectional studies, the risk of bias is estimated as high, given the inability to 541 
assess causality and the potential for residual confounding factors, and these issues hamper 542 
the ability to make firm conclusions from these studies. Differences in diagnostic protocols, 543 
definitions of outcome, and duration of follow-up were associated with considerable 544 
heterogeneity between and within studies.  545 
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 546 
Outcome measures 547 
Change in biochemical profile 548 
In three studies with a median follow-up of 3, 6.9, and 7.5 years no patient progressed to 549 
overt Cushing’s syndrome during follow-up (40, 143, 144).  550 
 551 
Change in metabolic and cardiovascular profile 552 
The risk of type 2 diabetes was higher in patients with impaired cortisol suppression after 1-553 
mg dexamethasone test and increased further during follow-up (38, 143, 144). Also, the risk 554 
of hypertension was higher in patients with impaired cortisol suppression and increased 555 
further with follow-up (38, 140, 144, 145). A smaller study did not confirm the increase in 556 
diabetes and hypertension with time (40).  557 
 558 
Major cardiovascular incidents  559 
In two cohort studies (143, 144), the incidence of cardiovascular events was higher in 560 
patients with altered cortisol suppression. 561 
 562 
Mortality 563 
Two studies reported on mortality (142, 143) and found an increased mortality risk in patients 564 
with higher cortisol levels after 1-mg dexamethasone. However, the results were adjusted for 565 
other prognostic factors only in the first study, and effect estimates were uncertain due to low 566 
number of events.  567 
 568 
Risk of vertebral fractures  569 
Four studies reported a higher prevalence of vertebral fractures (38, 42, 43, 45) in patients 570 
with impaired cortisol suppression. In a cohort study (46), the incidence of new vertebral 571 
fractures was higher in patients with impaired cortisol suppression. However, most of the 572 
detected vertebral fractures were minor and of uncertain clinical impact.  573 
 574 
 575 
4.2.2. Surgery vs. conservative management in patients with autonomous cortisol 576 
secretion (Question 2b, Appendices III and IV) 577 
For question 2b, four studies were included in which surgery was compared to a 578 
conservative approach: one randomized controlled trial and three observational studies. The 579 
randomized trial (146) reported on patients with autonomous cortisol secretion who 580 
underwent surgery (n=23) or were treated by a conservative approach (n=22). The mean 581 
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follow up was 7.7 years and the results were only a qualitative description of changes in 582 
hypertension, diabetes mellitus or dyslipidemia.  583 
Tsuiki et al. included patients with autonomous cortisol secretion and compared a group 584 
treated by surgery (n=10) and a group treated conservatively (n=10) (147). Follow up was 7-585 
19 months. The second cohort study included 41 patients with autonomous cortisol secretion 586 
(25 treated by surgery and 16 conservatively treated) (44). Outcome measures included: 587 
proportion of patients with steady, improved, or worsened blood pressure, fasting glucose or 588 
LDL cholesterol. In the third study by Iacobone et al, 372 patients with autonomous cortisol 589 
secretion (20 treated by surgery and 15 conservatively treated) (148). Outcomes were blood 590 
pressure, glucose and cholesterol.  591 
The quality of evidence from these studies is low to very low, mainly due to confounding 592 
factors. Only one study was randomized, and none of the studies reported blinded outcome 593 
assessment. Most studies were also downgraded for imprecision, due to low number of 594 
events. Differences in diagnostic protocols, definitions of outcome, and duration of follow-up 595 
were associated with considerable heterogeneity between and within studies.  596 
 597 
 598 
Outcome measures 599 
 600 
Change in metabolic and cardiovascular profile in patients with autonomous cortisol 601 
secretion 602 
In the randomized trial, 25% of patients with type 2 diabetes mellitus had normalized 603 
glycemic control after surgery (146), compared to none in the conservative group. The cohort 604 
studies (44, 147, 148) reported an improvement in glucose levels in 10-48% of patients after 605 
surgery. In the conservatively treated groups, none of the patients improved.  606 
The cohort studies (44, 147, 148) reported an improvement in hypertension and dyslipidemia 607 
in some patients after surgery. In the conservatively managed group, none of the patients 608 
improved.  609 
 610 
Risk of vertebral fractures 611 
None of the included studies reported on the risk of vertebral fractures.  612 
 613 
Major cardiovascular incidents and mortality  614 
None of the included studies reported on the risk of major cardiovascular events or mortality. 615 
 616 
 617 
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4.3  Surgical approach: open vs. minimally-invasive adrenalectomy (Question 3, 618 
Appendices V and VI) 619 
As adrenocortical carcinoma is the main threat for an adverse outcome in patients with 620 
adrenal incidentaloma undergoing surgery, we focused our efforts with regards to surgery on 621 
the management of adrenocortical carcinoma. Nine cohort studies on the surgical treatment 622 
of patients with non-metastatic adrenocortical carcinoma were included (149-157). Three 623 
studies reported on the patients in whom complete resection of the tumor was achieved (151, 624 
153, 157).  625 
 626 
The quality of evidence from these observational studies is very low, mainly because patient 627 
groups were not comparable at baseline with regard to important prognostic characteristics, 628 
such tumor stage or size. Tumor stage was, on average, lower in patients with laparoscopic 629 
surgery as compared to open surgery. In few studies (149, 156), treatment effects were 630 
adjusted for differences in tumor stage. Mostly, however, only uncorrected estimates of 631 
recurrence-free and overall survival were reported. Moreover, most studies had imprecise 632 
effect estimates. 633 
 634 
Outcome measures 635 
Perioperative mortality and morbidity  636 
One study reported on perioperative mortality (149). In this study, none of the 152 patients 637 
died perioperatively. Three studies reported on intraoperative or postoperative complications 638 
(152, 153, 156). Major postoperative complications (Clavien-classification score 3-5) 639 
occurred more often in open surgeries compared to laparoscopic surgeries (RR 1.7, 95% CI 640 
0.5-6.2) but these estimates are imprecise due to low numbers of events.  641 
 642 
 643 
Completeness of resection 644 
In five studies the completeness of resection was reported (149, 150, 152, 154, 156). The 645 
pooled estimate of these five studies indicated no clear difference in complete resection 646 
between surgical approaches (RR 0.8 (95% CI 0.6 to 1.1)). The results of these studies were 647 
inconsistent, leading to much uncertainty regarding this conclusion.  648 
 649 
Recurrence-free and overall survival 650 
Eight studies reported on recurrence after surgery, but differed in the presentation of these 651 
data. These studies also provided data on overall or disease-specific survival (149-153, 155-652 
157). There is no compelling evidence that one of the approaches (laparoscopic or open 653 
adrenalectomy) is superior with regard to time to recurrence and/or survival in patients with 654 
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adrenocortical carcinoma, provided that rupture of tumor capsule is excluded. However, the 655 
studies have significant limitations, inconsistencies and imprecision precluding reliance on 656 
this conclusion.  657 
 658 
Pain / patient satisfaction 659 
None of the studies reported on pain or patient satisfaction. 660 
 661 
4.4  Natural course of apparently benign adrenal incidentaloma (risk of malignancy 662 
or development of hormone excess) (Question 4, Appendix VII and VIII)  663 
A systematic review of fourteen studies assessing the natural course of 1410 patients with 664 
apparently benign, non-functioning adrenal incidentalomas (3) and ten additional cohort 665 
studies were included (40, 44, 46, 144, 145, 158-166). The systematic review included 666 
studies reporting the follow up of adrenal incidentaloma patients, published between 1980 667 
and 2008, including publications that reported more than 20 patients, and in which the 668 
majority were referred to an endocrinologist (excluding oncology series). The additional ten 669 
studies, published between 2005 and 2014, included 1131 incidentaloma patients with 670 
apparently benign non-functioning tumors or with autonomous cortisol secretion.  671 
 672 
The quality of evidence from these studies was judged moderate or low. Selection criteria 673 
were often not reported, the duration of follow-up was heterogeneous across studies 674 
(medians ranging from 19 to 90 months) and the completeness of follow-up was difficult to 675 
assess. Information on the protocol of biochemical or radiological re-evaluation was not 676 
always provided and standardized. In addition, criteria for hormonal excess were 677 
heterogeneous across studies.  678 
 679 
Outcome measures 680 
Malignancy 681 
The estimated pooled risk for developing malignancy in the systematic review was 0.2% 682 
(95%CI 0.0 to 0.4) (3). In two cohort studies, one case of malignancy was found: one patient 683 
with adrenal non-Hodgkin lymphoma and one patient with renal cancer metastasis. In the 684 
first case, the imaging characteristics of the adrenal incidentaloma at the first evaluation were 685 
not consistent with benign characteristics and the lymphoma may have been misdiagnosed 686 
initially (22). The second case had a history of renal cell carcinoma and it is unclear whether 687 
the adrenal mass was found incidentally or during the follow-up for cancer (167). No case of 688 
malignancy was reported in the other 904 patients included in the cohort studies. Importantly, 689 
no malignant transformation of a presumably benign incidentaloma was reported.  690 
 691 
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Development of clinically overt hormone excess 692 
The risk of developing overt Cushing’ syndrome in patients without clinical signs of Cushing's 693 
syndrome at the time of initial assessment ranged in the individual studies from 0% to 4%, 694 
whereas the risk of developing autonomous cortisol secretion in the absence of clinically 695 
overt Cushing’s syndrome was low, with a pooled estimate form a systematic review of 0.3% 696 
(3). The risk of developing an aldosterone-producing adenoma in the individual studies 697 
ranged from 0% to 2%.The risk of developing a pheochromocytoma ranged from 0% to 2% 698 
but it is unclear whether an accurate initial imaging and biochemical screening was 699 
performed.  700 
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5.   Recommendations, Rationale for the Recommendations 701 
5.1. General remarks 702 
The main part of this guideline addresses the management of patients who fulfill the 703 
definition of adrenal incidentaloma (section 2.1). In addition, we discuss specific situations 704 
separately: bilateral adrenal masses (5.6.1), patients who are young or elderly and frail 705 
(5.6.2), and adrenal masses detected during evaluation for extra-adrenal malignancy (5.6.3).  706 
 707 
R.1.1  We recommend that patients with adrenal incidentalomas are discussed in a 708 
multidisciplinary expert team meeting, if at least one of the following criteria is 709 
met (Figure 1): 710 
- Imaging is not consistent with a benign lesion. 711 
- There is evidence of hormone excess (including ‘autonomous cortisol 712 
secretion’). 713 
- Evidence of significant tumor growth during follow-up imaging. 714 
- Adrenal surgery is considered.  715 
 716 
Reasoning:  717 
Although we believe that the ideal would be for all patients with adrenal incidentalomas to be 718 
managed by an expert multidisciplinary team, in many health care settings this is an 719 
unrealistic aspiration. Despite lack of compelling evidence, we aimed at identifying 720 
subgroups of patients that would be most likely to benefit from multidisciplinary team 721 
discussion, and that these discussions occur quickly for patients that meet the criteria above. 722 
The core multidisciplinary team should consist of at least a radiologist, an endocrinologist, 723 
and a surgeon, all with significant experience in adrenal tumors. Furthermore, this team 724 
should have access to anesthetists and an endocrine pathologist, who are experienced in 725 
adrenal tumors. Although it is beyond the scope of this guideline, the use of a standardized 726 
pathology report is highly recommended.  727 
There is sufficient evidence that higher surgical volume correlates with better outcome, 728 
however, for the time being no specific numbers of operations per year that result in this 729 
favorable outcome can be recommended (150, 168-170).   730 
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5.2. Assessment of the risk of malignancy 731 
R.2.1 We recommend aiming to establish if an adrenal mass is benign or malignant at 732 
the time of initial detection.  733 
Reasoning 734 
It is critical to know if an adrenal mass is malignant or benign as clinical management is 735 
dependent on establishing this fact, regardless of whether the mass is functioning or not. 736 
Malignant lesions may need urgent surgical intervention and other therapies, and delay may 737 
cause harm. 738 
 739 
R.2.2 We recommend that all adrenal incidentalomas undergo an imaging procedure 740 
to determine if the mass is homogeneous and lipid-rich and therefore benign 741 
(XOOO). For this purpose, we primarily recommend the use of non-contrast CT 742 
(XOOO)  743 
 744 
R.2.3 We suggest that if the non-contrast CT is consistent with a benign adrenal 745 
mass (Hounsfield units ≤ 10) that is homogeneous and smaller than 4 cm no 746 
further imaging is required (XOOO).  747 
 748 
Reasoning 749 
In patients with no known extra-adrenal malignancy adrenal incidentalomas are likely to be 750 
benign. The non-contrast CT value is reflective of tissue density. Benign lesions including 751 
lipid rich adenoma, myelolipoma, fluid-filled homogenous cysts, and other soft tissue tumors 752 
(ganglioneuromas, some schwanomas) have low CT density ≤ 10 HU. Based on the 753 
systematic review and meta-analysis (75), in patients presenting without known malignancy a 754 
non-contrast CT with HU of ≤10 was only found in those with benign disease, whereas in 755 
patients with extra-adrenal malignancy 7% of cases with non-contrast HU ≤10 turned out to 756 
be malignant. 757 
Similar to CT, the results of MRI with chemical shift imaging are based on the lipid content of 758 
masses (171, 172). Unlike CT (or FDG-PET) MRI has the advantage of avoiding ionizing 759 
radiation and its attendant risks to the patient. However, the quantitative assessment of loss 760 
in signal intensity is not well standardized between the different studies and, therefore, 761 
evidence base for performance of MRI in the diagnosis of malignancy is insufficient to make 762 
strong recommendations. Moreover, the interpretation of the images might be more 763 
dependent on the experience of the radiologist than for CT assessment. In addition, the 764 
meta-analysis was not able to determine the diagnostic value of MRI due to the low number 765 
and quality of eligible studies. 766 
 767 
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In conclusion, the panel felt - despite the limited evidence - confident about the negative 768 
predictive value of non-contrast CT to recommend that additional imaging was not necessary 769 
when benign characteristics were found in an adrenal mass < 4 cm, especially as additional 770 
imaging may also risk false positive results and significant psychological and financial burden 771 
for patients and the health system, respectively. We acknowledge that the cutoff of 4 cm is 772 
not based on good evidence from clinical studies, but the panel felt it is necessary to provide 773 
clear guidance based on clinical experience.  774 
MRI with chemical shift has an even poorer evidence base with regard to its diagnostic value 775 
in excluding malignancy and therefore should be first choice only where a CT is less 776 
desirable (e.g. pregnancy, children). However, if an MRI with chemical shift is already 777 
performed and the results are unambiguous, a multidisciplinary expert team might judge this 778 
as sufficient for an individual patient.  779 
 780 
 781 
R.2.4 If the adrenal mass is indeterminate on non-contrast CT and the results of the 782 
hormonal work-up do not indicate significant hormone excess, there are three 783 
options that should be considered by a multidisciplinary team acknowledging 784 
the patient’s clinical context: immediate additional imaging with another 785 
modality, interval imaging in 6 to 12 months (non-contrast CT or MRI), or 786 
surgery without further delay. 787 
 788 
Reasoning 789 
Evidence of targeted evaluation for “second or third-line” imaging in patients with 790 
indeterminate adrenal mass is very poor (see section 4.1 and (75) for details). However, the 791 
panel considered it important to provide some guidance for daily clinical practice (Table 4), 792 
although consensus was not reached other than agreeing that such discussions needed to 793 
be individualized and should take place within a multidisciplinary team meeting.  794 
The advantages and limitations of MRI with chemical shift are already discussed at R 2.3.  795 
Contrast washout CT has very limited and low quality evidence from studies (75). CT 796 
washout is widely available but there is huge variability in the protocols applied and therefore 797 
poor comparability between studies and centers; in addition, the meta-analysis could only 798 
identify a single eligible study reporting CT washout study results, carried out in patients 799 
without a history of extra-adrenal malignancy.  800 
FDG-PET/CT has the advantage that the risk of false negative results (namely missing a 801 
malignant adrenal tumor) is quite low, and this refers mainly to a few subtypes of extra-802 
adrenal malignancies with low uptake (173-176). This procedure is, however, more 803 
expensive, not always easily available, and has the disadvantage that several benign adrenal 804 
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tumors (e.g. functional adenomas or benign pheochromocytoma) may be FDG-positive (177, 805 
178).  806 
 807 
Whilst the panel was in favor of attempts to fully characterize the adrenal mass on imaging, 808 
due to the limitations summarized above, it considered that in patients with indeterminate 809 
results on non-contrast CT further imaging by one of the modalities detailed above should be 810 
arranged. Due to the lack of evidence and studies reporting direct comparison the panel was 811 
not able to clearly judge one method over another. Alternatively, in patients without a strong 812 
suspicion of malignancy and older patients, follow-up imaging 6-12 months after the initial 813 
scan could be undertaken. The rationale for a follow-up scan at 6-12 months is based on the 814 
principle that either primary adrenal malignancies or adrenal metastases are likely to 815 
increase in size over this time period; lack of growth may be taken as an indicator of benign 816 
disease in radiologically indeterminate lesions. The exact timing of this imaging should be 817 
individualized. However, especially in cases with a low likelihood of a malignant tumor the 818 
panel favors a time interval of 12 months. There are no published size or volume cut-offs 819 
commonly agreed or with evidence base to support that they indicate growth suggestive of 820 
malignancy; the expert panel agreed that an increase in > 20% of the largest tumor diameter 821 
together with an at least 5 mm increase in this diameter should be considered as suspicious. 822 
 823 
 824 
R.2.5 We recommend against the use of an adrenal biopsy in the diagnostic work-up 825 
of patients with adrenal masses unless there is a history of extra-adrenal 826 
malignancy (see R6.3.5).  827 
 828 
Reasoning 829 
Adrenal biopsy has a limited role in evaluation of adrenal masses – mainly in diagnosis of 830 
extra/adrenal malignancy, lymphoma, infiltrative or infectious process. Even in such 831 
situations, adrenal biopsy should only be performed by an experienced radiologist and when 832 
it is required to guide further care. We particularly recommend against an adrenal biopsy if 833 
an adrenal mass is likely to be an adrenocortical carcinoma, because a biopsy of such a 834 
tumor runs the risk of tumor dissemination precluding an R0 resection (although this risk 835 
seems to be low (179)). The only exception might be if a formal confirmation of the diagnosis 836 
is needed in an inoperable tumor to inform oncological management or as part of a clinical 837 
trial.   838 
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5.3. Assessment for hormone excess  839 
 840 
R.3.1 We recommend that every patient with an adrenal incidentaloma should 841 
undergo careful assessment including clinical examination for symptoms and 842 
signs of adrenal hormone excess.  843 
 844 
Reasoning 845 
All patients should undergo a careful evaluation with detailed history and physical 846 
examination since a second round evaluation may detect clues of overt hormone excess that 847 
were overlooked initially. For the clinical assessment and subsequent diagnostic procedures 848 
for Cushing’s syndrome, primary aldosteronism, and pheochromocytoma, we refer to 849 
guidelines of other societies (69, 70, 180).  850 
Rapidly developing hirsutism or virilization is a clinical indicator for an androgen-producing 851 
tumor, and should be addressed by measuring testosterone and androgen precursors, 852 
whereas recent onset of gynecomastia should trigger measurement of estradiol (181-184) 853 
(see also R.3.10).  854 
 855 
 856 
R.3.2 We recommend that all patients with adrenal incidentalomas undergo a 1-mg 857 
overnight dexamethasone suppression test to exclude cortisol excess (XXOO). 858 
R.3.3 We suggest interpretation of the results of the 1-mg overnight dexamethasone 859 
test as a continuous rather than categorical (yes/no) variable (XOOO). However, 860 
we recommend using serum cortisol levels post dexamethasone ≤ 50 nmol/l (≤ 861 
1.8 µg/dl) as a diagnostic criterion for the exclusion of autonomous cortisol 862 
secretion (XXOO).  863 
R.3.4 We suggest that post dexamethasone serum cortisol levels between 51 and 138 864 
nmol/l (1.9 - 5.0 µg/dl) should be considered as evidence of ‘possible 865 
autonomous cortisol secretion’ and cortisol levels post dexamethasone > 138 866 
nmol/l (> 5.0 µg/dl) should be taken as evidence of ‘autonomous cortisol 867 
secretion’. Additional biochemical tests to confirm cortisol secretory autonomy 868 
and assess the degree of cortisol secretion might be required (Figure 2). 869 
However, for the clinical management the presence of potentially cortisol-870 
related comorbidities (Table 2) and age of the patient are of major importance 871 
(Figure 2).  872 
 873 
Reasoning 874 
Page 26 of 122
eje@bioscientfica.com
Manuscript submitted for review to European Journal of Endocrinology
For Review Only
27 
ESE and ENSAT guideline on adrenal incidentaloma 
A variety of diagnostic algorithms have been used to exclude cortisol excess or to define so-875 
called ‘subclinical hypercortisolism’, but in the literature there are no head to head 876 
comparisons between tests to assess their diagnostic performance (see section 4.2.1). 877 
However, the panel recommends the use of the 1-mg overnight dexamethasone test based 878 
on pathophysiological reasoning, simplicity, and the fact that the test was incorporated in the 879 
diagnostic algorithms of most studies. It is important to consider drugs or conditions that 880 
interfere with this test (see Appendix Table A9). In published guidelines and reviews variable 881 
thresholds have been recommended (5, 8-10). Several studies have used post 882 
dexamethasone serum cortisol values between 50 and 138 nmol/l (1.8 - 5.0 µg/dl) and/or 883 
required further tests to secure the diagnosis of ‘autonomous cortisol secretion’. However, in 884 
none of these additional tests was the performance convincing enough to ultimately establish 885 
diagnostic criteria.  886 
The panel appreciated that this ongoing debate reflects a biological continuum with no clear 887 
separation between non-functioning adenomas and functioning adenomas associated with 888 
some degree of cortisol excess. However, a value of ≤ 50 nmol/l (≤ 1.8 µg/dl) may be 889 
regarded as normal, excluding cortisol excess. This cut-off is supported by studies 890 
demonstrating that patients with post dexamethasone cortisol values > 50 nmol/l (> 1.8 µg/dl) 891 
have an increased morbidity or mortality (142, 143). Since the probability of clinically relevant 892 
cortisol excess increases the higher the post-dexamethasone serum cortisol value and that 893 
the principle of dexamethasone testing is based on pharmacological suppression of ACTH 894 
secretion, we propose the following terminology be used on biochemical grounds. For 895 
patients without overt Cushing's syndrome and a serum cortisol post dexamethasone 896 
between 51 and 138 nmol/l we propose the term ‘possible autonomous cortisol secretion’ 897 
and for higher values the term "autonomous cortisol secretion". However, for the clinical 898 
management, the presence of potentially related comorbidities (Table 2) and age of the 899 
patient are of major relevance (Figure 2).  900 
The majority of panel members (but not all) preferred additional biochemical tests to confirm 901 
cortisol secretory autonomy and assess the degree of cortisol secretion. However, we 902 
acknowledge that use of several tests may be associated with an increased likelihood of at 903 
least one being a false positive result Nevertheless, we suggest measurement of basal 904 
morning plasma ACTH and to repeat the dexamethasone test after 3-12 months in all 905 
patients with ‘possible autonomous cortisol secretion’ and comorbidities. In patients with 906 
‘autonomous cortisol secretion’ we suggest the additional measurement of 24-h urinary free 907 
cortisol and/or late-night salivary cortisol (although few studies suggest a poor performance 908 
of this parameter in patients with incidentaloma). Following the concept that cortisol secretion 909 
in patients with 'autonomous cortisol secretion' is independent of ACTH, a higher dose of 910 
dexamethasone (e.g. 3mg, 2x2mg, or 8mg) might also be reasonable as additional test. 911 
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However, the published literature is too limited and controversial to make a clear statement 912 
on these tests.  913 
 914 
 915 
R.3.5 We recommend against considering ‘autonomous cortisol secretion’ as a 916 
condition with a high risk for the development of overt Cushing’s syndrome 917 
(XXOO). 918 
 919 
Reasoning 920 
Studies reporting on follow-up of patients with adrenal incidentalomas have uniformly found a 921 
very low percentage (< 1%) of patients with ‘autonomous cortisol secretion’ progressing to 922 
overt Cushing’s syndrome (1-3, 20-25). 923 
 924 
 925 
R.3.6 We recommend screening patients with ‘possible autonomous cortisol 926 
secretion’ or ‘autonomous cortisol secretion’ for hypertension and type 2 927 
diabetes mellitus (XOOO) and suggest offering appropriate treatment of these 928 
conditions. 929 
 930 
Reasoning 931 
Studies from different research groups have consistently demonstrated an association 932 
between cortisol excess and hypertension and hyperglycemia (23, 31-39). The association 933 
with dyslipidemia is less proven, although biologically plausible. There is also evidence that 934 
patients with cortisol excess are at increased risk of cardiovascular events and excess 935 
mortality (142, 143). 936 
Therefore, the panel recommended screening for these conditions, which are well known 937 
independent cardiovascular risk factors and which may be driven by cortisol excess, and to 938 
treat them according to current guidelines. 939 
 940 
 941 
R.3.7 We suggest screening patients with ‘autonomous cortisol secretion’ for 942 
asymptomatic vertebral fractures (XOOO) and to consider appropriate 943 
treatment of these conditions (XOOO).  944 
 945 
Reasoning  946 
Several studies, although mainly from a single research group, have demonstrated an 947 
association between autonomous cortisol secretion and an increased risk of vertebral 948 
Page 28 of 122
eje@bioscientfica.com
Manuscript submitted for review to European Journal of Endocrinology
For Review Only
29 
ESE and ENSAT guideline on adrenal incidentaloma 
fractures (41-46). Although most of the fractures are asymptomatic, the panel suggests 949 
screening patients with ‘autonomous cortisol secretion’ for vertebral fractures at least once at 950 
the time of diagnosis. This may be done by re-evaluating the available images (if a CT was 951 
performed) or by plain X-ray. The panel did not reach consensus on recommending 952 
assessment of bone mineral density by dual-energy x-ray absorptiometry (DXA). If 953 
osteoporosis is present, active treatment should be considered. If there is no other likely 954 
explanation for the osteoporosis, removal of the adrenal adenoma might be considered (see 955 
R3.8).  956 
 957 
 958 
R.3.8 We suggest an individualized approach in patients with ‘autonomous cortisol 959 
secretion’ due to a benign adrenal adenoma and comorbidities potentially 960 
related to cortisol excess for adrenal surgery (XOOO). Age, degree of cortisol 961 
excess, general health, comorbidities and patient’s preference should be taken 962 
into account. In all patients considered for surgery, ACTH-independency of 963 
cortisol excess should be confirmed.  964 
 965 
Reasoning 966 
Due to the limitations of current literature, especially the lack of high-quality randomized 967 
trials, the panel could not reach consensus on the exact indication for surgery for 968 
‘autonomous cortisol secretion’. The panel appreciated that there is some evidence of 969 
improvement of hypertension, hyperglycemia and dyslipidemia with surgery but this is based 970 
on low quality data. However, no data are available on clinically relevant endpoints (e.g. 971 
mortality or major cardiovascular events). Thus, the decision to undertake surgery should be 972 
individualized taking into account factors that are linked to surgical outcome, such as 973 
patient’s age, duration and evolution of comorbidities and their degree of control, and 974 
presence and extent of end organ damage. Because it is not possible to be sure that surgical 975 
intervention will normalize or improve the clinical phenotype of an individual patient, there 976 
was no complete agreement within the panel with regard to the optimal management of 977 
these patients. Approaches varied between two ends of the spectrum. Overall, the group 978 
agreed that there is an indication of surgery in a patient with post dexamethasone cortisol > 979 
138 nmol/l (> 5 µg/dl) and the presence of at least two comorbidities potentially related to 980 
cortisol excess (e.g. type 2 diabetes, hypertension, obesity, osteoporosis), of which at least 981 
one is poorly controlled by medical measures. Conversely, there is no reason for surgery, 982 
when serum cortisol post dexamethasone is < 138 nmol/l (< 5 µg/dl) and no comorbidities 983 
are present. However, some panel members favor a more proactive approach, for example 984 
considering surgical intervention, especially in younger patients with ‘possible autonomous 985 
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cortisol’ secretion and less comorbidities potentially related to cortisol excess, even if 986 
controlled by medical therapy. 987 
However, there was consensus that when surgery is considered due to ‘autonomous cortisol 988 
secretion’, ACTH-independency has to be proven by a suppressed or low basal morning 989 
plasma ACTH. If not, other reasons of cortisol excess have to be considered.  990 
 991 
 992 
R.3.9 We recommend excluding pheochromocytoma by measurement of plasma free 993 
metanephrines or urinary fractionated metanephrines. 994 
 995 
Reasoning:  996 
For details we refer to the most recent guidelines of other societies (e.g. (70)). Of note, there 997 
are clinically silent pheochromocytomas (185-187) that might lead to hemodynamic instability 998 
during surgical excision (188). Thus, metanephrines should be measured in normotensive 999 
patients and the diagnosis of pheochromocytoma should be considered in patients with 1000 
borderline values of metanephrines and indeterminate imaging features on CT.  1001 
In adrenal lesions with imaging criteria of an adenoma the likelihood of a pheochromocytoma 1002 
is extremely low (189, 190). Thus, it seems to be reasonable to avoid measuring 1003 
metanephrines in patients with clear evidence of an adrenal adenoma, but definitive data in 1004 
this area are lacking. 1005 
 1006 
 1007 
R.3.10 In patients with concomitant hypertension or unexplained hypokalemia, we 1008 
recommend the use of the aldosterone / renin ratio to exclude primary 1009 
aldosteronism. 1010 
 1011 
Reasoning:  1012 
For details we refer to the most recent guidelines of other societies (e.g. (180)). 1013 
 1014 
 1015 
R.3.11 We suggest measurement of sex hormones and steroid precursors in patients 1016 
with imaging or clinical features suggestive of adrenocortical carcinoma.  1017 
 1018 
Reasoning:  1019 
Adrenocortical carcinoma is associated in more than half of cases with elevated sex 1020 
hormones and steroid precursors (183, 184, 191, 192). The panel does not recommend 1021 
measurement of these hormones in patients with adrenal incidentalomas on a routine basis, 1022 
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but in cases with indeterminate adrenal mass by imaging or clinical signs for androgen 1023 
excess, significantly increased sex hormones or precursors might clearly point towards 1024 
adrenocortical carcinoma. Thus, measurement of serum DHEA-S, androstenedione, 17-1025 
hydroxyprogesterone as well as testosterone in women and estradiol in men and 1026 
postmenopausal women can prove the adrenocortical nature of the adrenal mass. However, 1027 
the panel acknowledges that the published evidence for this suggestion is very low (192, 1028 
193). A very promising new tool to discriminate benign from malignant adrenocortical tumors 1029 
appears the analysis of a comprehensive urinary steroid profile measured by GC-MS or LC-1030 
MS (193, 194).  1031 
 1032 
 1033 
 1034 
5.4. Surgical treatment  1035 
 1036 
R.4.1 We recommend adrenalectomy as the standard of care for unilateral adrenal 1037 
tumors with clinically significant hormone excess.  1038 
 1039 
Reasoning:  1040 
As covered by several other guidelines, there is consensus that adrenal tumors leading to 1041 
clinically significant hormone excess (e.g. primary aldosteronism, Cushing syndrome or 1042 
pheochromocytoma) should be surgically removed (30, 70, 180). The guideline group is 1043 
convinced that for these tumors the same rules regarding the surgical approach should apply 1044 
as for endocrine inactive tumors (see below). There are no substantiated reasons why the 1045 
surgical approach for hormone-producing tumors should differ from that in endocrine inactive 1046 
tumors (R4.3-5). 1047 
 1048 
 1049 
R.4.2 We recommend against performing surgery in patients with an asymptomatic, 1050 
non-functioning unilateral adrenal mass and obvious benign features on 1051 
imaging studies (XOOO). 1052 
 1053 
Reasoning: 1054 
Most adrenal incidentalomas are non-functioning benign lesions (e.g. adenomas, 1055 
myelolipomas) that do not cause harm. Therefore, there is broad consensus that the majority 1056 
of these adrenal masses do not require surgery. The guideline group defined two criteria that 1057 
need to be fulfilled to allow characterization of a unilateral adrenal lesion as not harmful: (i) 1058 
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imaging criteria indicating a benign lesion (see section 5.2, Table 4) (ii) no relevant endocrine 1059 
activity (see section 5.3).  1060 
There was considerable discussion by the group if a certain cutoff of size should be a factor 1061 
to consider surgery. There was consensus that a tumor with a diameter of ≤ 4 cm with benign 1062 
imaging features does not require surgery, accepting that this size cutoff is arbitrary. 1063 
However, due to the paucity of follow-up data on the natural history of large apparently 1064 
benign adrenal incidentalomas the panel was divided on the approach to the management of 1065 
patients with larger lesions. One approach is to rely on imaging criteria only to determine if a 1066 
lesion is benign irrespective of size. Alternatively, because of clinician or patient uncertainty 1067 
about the increasing incidence of malignancy the larger is size, surgery may be considered in 1068 
larger lesions (e.g. > 4 cm) even if imaging characteristics suggest a benign nature of the 1069 
mass, allowing for an individualized approach. We voted against a certain cutoff which 1070 
indicates that surgery has to be performed. However, we acknowledge that with a larger 1071 
tumor size patients and clinicians might feel increasingly uncomfortable, but again an 1072 
individualized approach was deemed most appropriate. 1073 
 1074 
 1075 
R.4.3 We suggest performing laparoscopic adrenalectomy in patients with unilateral 1076 
adrenal masses with radiological findings suspicious of malignancy and a 1077 
diameter ≤ 6 cm, but without evidence of local invasion (XOOO). 1078 
R.4.4 We recommend performing open adrenalectomy for unilateral adrenal masses 1079 
with radiological findings suspicious of malignancy and signs of local invasion 1080 
(XOOO). 1081 
R.4.5 We suggest an individualized approach in patients that do not fall in one of the 1082 
above mentioned categories (XOOO).  1083 
 1084 
Reasoning: 1085 
The main threat of a unilateral adrenal mass, which is suspected to be malignant, is 1086 
adrenocortical carcinoma. For adrenocortical carcinoma without metastases, surgery is the 1087 
most important single therapeutic measure. Thus, the high expertise of the surgeon is of 1088 
major importance. Although we cannot provide a specific number of required operations per 1089 
year, we have no doubts that surgical volume correlates with better outcome. As summarized 1090 
above (section 4.1.3) there are nine cohort studies on surgery for localized adrenocortical 1091 
carcinoma comparing laparoscopic versus open adrenalectomy, each with more than ten 1092 
patients per group (149-157), but these studies are, however, hampered by methodological 1093 
flaws, and importantly none was randomized. Nevertheless, based on these data and the 1094 
clinical experience of the guideline group members, it was judged that laparoscopic 1095 
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adrenalectomy may be justified for tumors with radiological signs of malignancy but only 1096 
where there was no evidence of local invasion. For this approach the group arbitrarily chose 1097 
a cut-off size for the adrenal tumor of ≤ 6 cm, because for this size it is believed that 1098 
laparoscopic adrenalectomy is feasible without rupture of tumor capsule (a major risk factor 1099 
for recurrence), and is beneficial for the patient (e.g. less pain, shorter hospital stay). 1100 
However, with increasing tumor size risk of tumor capsule rupture may increase. If during 1101 
surgery there is a risk of tumor capsule rupture, conversion to open procedure should be 1102 
performed. We acknowledge that the cutoff of 6 cm for laparoscopic vs. open adrenalectomy 1103 
is not based on good evidence from clinical studies, and we recognize that laparoscopic 1104 
adrenalectomy for tumors < 6 cm is common practice in most centers. However, this cutoff 1105 
by no means indicates that every tumor smaller than 6 cm has to undergo laparoscopic 1106 
adrenalectomy and every tumor larger than 6 cm open adrenalectomy. We are convinced 1107 
that in many cases an individualized decision process is required to find the best surgical 1108 
approach for a given patient. This is also true for all patients that do not fall in one of the 1109 
categories described in R.4.2 - 4.4.  1110 
 1111 
There are no sufficiently powered studies published on the approach to patients with stage III 1112 
adrenocortical carcinoma (local invasion, lymph nodes metastases, or tumor thrombus in the 1113 
renal vein or vena cava). However, the guideline group unanimously voted for open 1114 
adrenalectomy as standard procedure for this stage of disease.  1115 
 1116 
 1117 
R.4.6 We recommend perioperative glucocorticoid treatment at major surgical stress 1118 
doses, as recommended by guidelines, in all patients undergoing surgery for 1119 
an adrenal tumor where there is evidence of ‘possible autonomous cortisol 1120 
secretion’ or ‘autonomous cortisol secretion’.  1121 
 1122 
Reasoning: 1123 
Autonomous cortisol secretion may lead to adrenal insufficiency after removal of the adrenal 1124 
source of cortisol (even in patients with incompletely suppressed ACTH (195)). Therefore, 1125 
the group unanimously recommends intra- and post-operative glucocorticoid replacement, 1126 
preferably by hydrocortisone in patients with an adrenal tumor and evidence for ‘(possible) 1127 
autonomous cortisol secretion’ (post dexamethasone cortisol > 50 nmol/l (> 1.8 µg/dl)) even 1128 
if there are no clinical sign of cortisol excess. This should follow the suggestions for major 1129 
stress dose replacement as per a recent international guideline (196). Postoperatively, the 1130 
glucocorticoid dose should be tapered individually by a physician experienced in this clinical 1131 
scenario.   1132 
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 1133 
5.5 Follow-up of patients not undergoing adrenal surgery after initial 1134 
assessment 1135 
 1136 
R.5.1 We suggest against further imaging during follow-up in patients with an adrenal 1137 
mass < 4cm with clear benign features on imaging studies (XOOO).  1138 
 1139 
Reasoning 1140 
Amongst more than 2300 patients included in published follow-up studies (3, 9) there is no 1141 
report of occurrence of adrenal malignancy in adrenal incidentalomas displaying typical 1142 
features of adrenocortical adenomas at initial imaging studies. Therefore, the panel does not 1143 
support repeating imaging investigations if the initial work-up is unequivocally consistent with 1144 
a benign lesion. However, many patients with adrenal incidentalomas > 4 cm in diameter 1145 
have undergone adrenalectomy in the past and the literature on follow-up of non-operated 1146 
large adrenal incidentalomas is scarce. Thus, and similar to the discussion on the surgical 1147 
treatment (R.4.2), some panel members argued that one follow-up imaging (non-contrast CT 1148 
or MRI) after 6-12 months might be considered in lesions > 4 cm.  1149 
 1150 
 1151 
R.5.2 In patients with an indeterminate adrenal mass (by imaging), opting not to 1152 
undergo adrenalectomy following initial assessment, we suggest a repeat non-1153 
contrast CT or MRI after 6-12 months to exclude significant growth (XOOO). We 1154 
suggest surgical resection if the lesion enlarges by more than 20% (in addition 1155 
to at least a 5 mm increase in maximum diameter) during this period. If there is 1156 
growth of the lesion below this threshold, additional imaging again after 6-12 1157 
months might be performed.  1158 
 1159 
Reasoning 1160 
Contrary to benign adrenal tumors that may exhibit a slow growth tendency with time, 1161 
malignant adrenal lesions (mostly adrenocortical carcinoma and metastases) are almost 1162 
invariably characterized by a rapid growth within months (184, 191, 192). Consequently, the 1163 
panel recommends performing follow-up imaging studies in adrenal incidentaloma, in which 1164 
the benign nature cannot be established with certainty at initial evaluation, in order to 1165 
recognize early a rapidly growing mass. Many clinicians would opt for surgical removal if the 1166 
mass is of larger size and cannot be determined as benign with certainty.  1167 
Lack of growth of an adrenal mass over a period of 6-12 months makes a malignant mass 1168 
highly unlikely while surgery is recommended if significant rapid growth is observed. There is 1169 
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no generally accepted definition of significant growth of an adrenal tumor. However, the 1170 
panel proposes an adaptation of the RECIST 1.1 criteria (197). These criteria, which are 1171 
used in most oncological trials, define progress by an increase of 20% of the largest 1172 
diameter. Although RECIST 1.1 criteria are not validated for the differentiation between 1173 
benign and malignant adrenal tumors, the 20% cut-off together with an absolute increase of 1174 
at least 5 mm in diameter may serve as warning for significant growth and reconsideration 1175 
then given for surgical excision.  1176 
The panel is aware that there are exceptional cases of malignant adrenal tumor without 1177 
significant growth for several years (198, 199). However, this can be considered a very rare 1178 
exception and does not justify following all patients with an adrenal mass with repeated 1179 
imaging over years. However, in case there is some measurable growth (10-20%) that does 1180 
not qualify for the above-mentioned criteria, additional follow-up imaging should be 1181 
considered.  1182 
 1183 
 1184 
R.5.3 We suggest against repeated hormonal work-up in patients with a normal 1185 
hormonal work-up at initial evaluation unless new clinical signs of endocrine 1186 
activity appear or there is worsening of comorbidities (e.g. hypertension and 1187 
type 2 diabetes) (XOOO). 1188 
 1189 
Reasoning 1190 
The pooled risk of developing clinically relevant hormonal excess (e.g. primary 1191 
aldosteronism, Cushing’s syndrome and pheochromocytoma) is below 0.3% in patients with 1192 
initial hormonal work-up consistent with a non-functioning lesion (3, 9). 1193 
Development of ‘autonomous cortisol secretion’ without signs of overt Cushing’s syndrome is 1194 
the most frequently reported event during the follow-up and may occur in 8 to 14% of 1195 
patients with non-functioning adrenal incidentalomas. Owing to the risk of false positive 1196 
results (200) the panel does not recommend systematic follow-up hormonal investigations in 1197 
patients with non-functioning adrenal incidentalomas at initial evaluation (ie cortisol ≤ 50 1198 
nmol/l (≤ 1.8 µg/dl) post 1-mg overnight dexamethasone test).  1199 
 1200 
 1201 
R.5.4 In patients with ‘autonomous cortisol secretion’ without signs of overt 1202 
Cushing’s syndrome (see Figure 2), we suggest annual clinical re-assessment 1203 
for cortisol excess and comorbidities potentially related to cortisol excess 1204 
(XOOO). Based on the outcome of this evaluation the potential benefit of 1205 
surgery should be considered.  1206 
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 1207 
Reasoning 1208 
As discussed above, it is extremely rare that patients will develop overt Cushing’s syndrome 1209 
during follow-up. However, as elaborated in section 5.3, the panel considers ‘autonomous 1210 
cortisol secretion’ as a condition associated with several comorbidities (Table 2). Therefore, 1211 
the panel recommends annual clinical follow-up in patients with ‘autonomous cortisol 1212 
secretion’ and in patients with both ‘possible autonomous cortisol secretion’ and potentially 1213 
associated comorbidities, in whom an initial decision against surgery was made (Figure 2). 1214 
Clinical follow-up should include evaluation of potentially cortisol excess-related 1215 
comorbidities. The presence or worsening of these conditions should prompt hormonal re-1216 
evaluation at any time during follow-up. Appropriate symptomatic treatment and 1217 
reconsideration of surgical removal of the adrenal mass is recommended, in line with the 1218 
observed changes in the clinical and hormonal status of the patient.  1219 
In the absence of evidence, we suggest that follow-up by an endocrinologist beyond 2-4 1220 
years is not needed in patients with no relevant change during this time.   1221 
 1222 
 1223 
 1224 
5.6. Special circumstances 1225 
 1226 
5.6.1 Patients with bilateral adrenal incidentalomas 1227 
R.6.1.1 We recommend that for patients with bilateral adrenal masses each adrenal 1228 
lesion is assessed at the time of initial detection according to the same 1229 
imaging protocol as for unilateral adrenal masses to establish if either or both 1230 
lesions are benign or malignant. 1231 
 1232 
Reasoning: 1233 
In most cases bilateral adrenal masses represent benign bilateral adrenocortical disease: 1234 
either bilateral adenomas, macronodular hyperplasia, or distinct bilateral nodules with normal 1235 
or atrophic cortex intervening. The possibility of metastases (especially in patients with 1236 
known malignancy), adrenal lymphoma or bilateral pheochromocytomas should also be 1237 
considered. Moreover, bilateral adrenal masses may represent co-occurrence of different 1238 
entities, such as adenoma, pheochromocytoma, cyst, myelolipoma, adrenocortical 1239 
carcinoma, etc. Therefore the best approach is to separately characterize each lesion 1240 
following the recommendations in R.2.2 and R.2.3.  1241 
 1242 
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 1243 
R.6.1.2 We recommend that all patients with bilateral adrenal incidentalomas should 1244 
undergo clinical and hormonal assessment identical to that in patients with 1245 
unilateral adrenal incidentaloma. The same applies for the assessment of 1246 
comorbidities that might be related to ‘autonomous cortisol secretion’ (Table 1247 
2). In addition, 17-hydroxyprogesterone should be measured to exclude 1248 
congenital adrenal hyperplasia, and testing for adrenal insufficiency should 1249 
be considered if suspected on clinical grounds or if imaging suggests 1250 
bilateral infiltrative disease or hemorrhages. 1251 
 1252 
Reasoning: 1253 
Hormonal excess in patients with bilateral adrenal masses may originate either from one of 1254 
the lesions or bilaterally. Cushing’s syndrome, primary aldosteronism, and 1255 
pheochromocytoma(s) may all be encountered. For the clinical assessment of these entities 1256 
we refer to guidelines of other societies (69, 70, 180). As for unilateral lesions, subtle 1257 
autonomous cortisol secretion is the most common secretory abnormality and, therefore, 1258 
requires a full assessment of related comorbidities. Occasionally, bilateral adrenal 1259 
enlargement is due to congenital adrenal hyperplasia and therefore the additional 1260 
measurement of 17-hydroxyprogesterone should be performed (201). However, the 1261 
measurement of 17-hydroxyprogesterone to identify the most common cause of congenital 1262 
adrenal hyperplasia, 21-hydroxylase deficiency, as the cause of bilateral adrenal hyperplasia 1263 
should be interpreted with caution. In some cases increased levels of 17-1264 
hydroxyprogesterone may represent increased secretion of steroid precursors from the 1265 
lesion(s) (202) especially in malignant tumors or in bilateral macronodular adrenal 1266 
hyperplasia. In these cases low/suppressed ACTH levels may argue against congenital 1267 
adrenal hyperplasia. Bilateral adrenal enlargement due to metastatic disease rarely causes 1268 
adrenal insufficiency (for details see R.6.3.6).  1269 
 1270 
 1271 
R.6.1.3 We suggest that for patients with bilateral incidentaloma the same 1272 
recommendations regarding the indication of surgery and follow-up are used 1273 
as for patients with unilateral adrenal incidentalomas. 1274 
 1275 
Reasoning: 1276 
‘Autonomous cortisol secretion’ is more frequently encountered in patients with bilateral 1277 
adrenal incidentalomas, compared to those with unilateral lesions, but there is no published 1278 
evidence that they should be managed differently. However, in the few cases, in whom 1279 
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bilateral surgery is potentially indicated (e.g. bilateral pheochromocytomas), one can 1280 
consider adrenal-sparing surgery (203).  1281 
 1282 
 1283 
R.6.1.4 We suggest that in patients with bilateral adrenal masses bilateral 1284 
adrenalectomy is not performed for ‘autonomous cortisol secretion’ without 1285 
clinical signs of overt Cushing’s syndrome. In selected patients a unilateral 1286 
adrenalectomy of the dominant lesion might be considered using an 1287 
individualized approach considering age, degree of cortisol excess, general 1288 
condition, comorbidities and patient preference. 1289 
 1290 
Reasoning: 1291 
Surgery is a complex decision for patients with bilateral adrenal incidentalomas. This is 1292 
because, in the absence of clinical signs of overt Cushing’s syndrome, the clinical situation 1293 
may not be severe enough to prompt surgical management. Moreover, bilateral 1294 
adrenalectomy is associated with higher morbidity compared to unilateral surgery, the patient 1295 
is dependent lifelong on adrenal replacement therapy and at risk for life-threatening adrenal 1296 
crisis. In addition, glucocorticoid replacement is frequently sub-optimal and cannot mimic the 1297 
diurnal profile of endogenous cortisol, and may result in persisting exposure to subtle cortisol 1298 
excess. In bilateral macronodular adrenal hyperplasia there is limited evidence of beneficial 1299 
effects of unilateral adrenalectomy (204, 205). In most published studies excision of the 1300 
largest lesion was performed, based on observations that the size of the adrenal lesion 1301 
correlates with the degree of cortisol excess (204). Adrenal venous sampling may aid in the 1302 
lateralization of cortisol excess but the data are very weak (206). Due to the limited available 1303 
evidence, an individualized approach, considering age, degree of cortisol excess, general 1304 
condition, comorbidity status and patient’s preference is suggested. However, when bilateral 1305 
surgery is potentially indicated, cortical sparing adrenalectomy might be considered (207). 1306 
In cases of bilateral macronodular hyperplasia, especially in younger patients or those with 1307 
relevant family history, family screening with 1 mg dexamethasone test can be considered.  1308 
A number of patients will have evidence of the presence of aberrant receptors, but routine 1309 
assessment by the complex testing (27, 208-214) that is needed to establish the presence of 1310 
these receptors is hard to justify based on the fact that in the majority of patients long-term 1311 
management will not be based on knowledge of receptor activity, and therefore we suggest 1312 
that these tests should be confined to clinical studies. 1313 
 1314 
 1315 
5.6.2 Adrenal incidentalomas in young or elderly patients 1316 
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R.6.2.1 We recommend urgent assessment of an adrenal mass in children, 1317 
adolescents, pregnant women and adults < 40 years of age because of a 1318 
higher likelihood of malignancy.  1319 
R.6.2.2 We suggest the use of MRI rather than CT in children, adolescents, pregnant 1320 
women and adults < 40 years of age if dedicated adrenal imaging is required. 1321 
R.6.2.3 We recommend that the management of patients with poor general health and 1322 
a high degree of frailty be kept in proportion to potential clinical gain. 1323 
 1324 
Reasoning 1325 
The incidence of adrenal incidentaloma shows clear variation with age, with the majority of 1326 
patients presenting in the 5th to 7th decade of life. Overall incidence of adrenal incidentaloma 1327 
in a population undergoing routine imaging not related to suspected adrenal disease is 1328 
reported as 1-4 % (15, 72, 74, 215). While 10 % or more of individuals older than 70 years 1329 
harbor an adrenal mass detectable upon imaging or autopsy, adrenal nodules in individuals < 1330 
40 years are much less prevalent and are a rarity in children and young adults. 1331 
Consequently, work-up in young patients including pregnant women has to be pursued with 1332 
urgency as the risk of malignancy in this cohort is much higher. Conversely, a smaller 1333 
adrenal incidentaloma in an elderly patient can be assumed to have a very low pre-test 1334 
probability of malignancy. Thus work-up in elderly patients only needs to be expedited if 1335 
there are clear signs of suspicion of malignancy and the extent of imaging work-up should be 1336 
kept in proportion to the clinical performance status of the individual and the expected clinical 1337 
gain of further work-up in an affected patient. 1338 
As radiation safety is even more important in the young patient, we suggest MRI as the 1339 
preferred imaging technique. However, adapted low-dose unenhanced CT protocols can 1340 
limited radiation exposure and can be considered as an alternative (especially if the 1341 
availability of MRI is limited). 1342 
 1343 
 1344 
5.6.3  Patients with a newly diagnosed adrenal mass and a history of extra-1345 
adrenal malignancy (Figure 4) 1346 
 1347 
General remarks:  1348 
In principle, for adrenal masses in patients with known extra-adrenal malignancy the same 1349 
recommendations apply as described above. However, in this situation it is particularly 1350 
important to consider the different pre-test probabilities and the life expectancy of the patient. 1351 
In patients with underlying extra-adrenal malignancy and an indeterminate adrenal mass, 1352 
studies revealed a high rate of malignancy, up to 70%. Although age specific subgroup 1353 
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analysis is not available, it can be assumed that older patients have a higher likelihood of co-1354 
existent benign adenomas. Conversely younger patients with an underlying malignancy are 1355 
more likely to have a metastasis. 1356 
 1357 
 1358 
R.6.3.1  We recommend measurement of plasma or urinary metanephrines to exclude 1359 
pheochromocytoma in patients with extra-adrenal malignancy with an 1360 
indeterminate mass, even if the adrenal mass is likely to be a metastasis. We 1361 
suggest additional hormonal work-up based on an individualized approach.  1362 
 1363 
Reasoning 1364 
Pheochromocytomas are almost impossible to distinguish from metastasis by conventional 1365 
imaging (including FDG-PET/CT). Furthermore, pheochromocytomas can lead to life-1366 
threatening complications, especially in the context of medical interventions (surgery, 1367 
biopsies etc.) (70, 216, 217). Additional hormonal work-up should depend on the stage of the 1368 
extra-adrenal malignancy and life expectancy. Evidence of adrenal hormone excess 1369 
indicating that the mass is a primary adrenal lesion can influence management of the extra-1370 
adrenal malignancy.  1371 
 1372 
R.6.3.2 We suggest that in patients with a history of extra-adrenal malignancy FDG-1373 
PET/CT, performed as part of investigations for the underlying malignancy, 1374 
can replace other adrenal imaging techniques.  1375 
 1376 
Reasoning: 1377 
18FDG-PETCT may add additional value in the assessment of an indeterminate adrenal 1378 
mass, however, the evidence base is insufficient to make strong recommendations (75). Both 1379 
qualitative and quantitative interpretations of 18FDG-PETCT imaging have been studied, but 1380 
these vary considerably. An adrenal lesion / liver ratio of 1.53-1.8 were investigated in 1381 
patients with history of extra-adrenal malignancy (2 studies (92, 93), 117 lesions) and found 1382 
to have sensitivity of 82% (95%CI 41-97%) and specificity of 96% (95%CI 76-99%) to detect 1383 
malignant disease.  1384 
 1385 
 1386 
R.6.3.3 We recommend that in patients with a history of extra-adrenal malignancy 1387 
adrenal lesions characterized as benign by non-contrast CT require no further 1388 
specific adrenal imaging follow-up. 1389 
 1390 
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Reasoning 1391 
See details R2.2-4. However, we acknowledge that the currently available data suggest a 1392 
false negative rate of 7% in this population.  1393 
 1394 
 1395 
R.6.3.4 For indeterminate lesions in patients with a history of extra-adrenal 1396 
malignancy, we recommend imaging follow-up assessing the potential growth 1397 
of the lesion at the same interval as imaging for the primary malignancy. 1398 
Alternatively, FDG-PET/CT, surgical resection or a biopsy (see also R.6.3.5) 1399 
can be considered. 1400 
 1401 
Reasoning: 1402 
In many patients with advanced extra-adrenal malignancy (e.g. with multiple metastases) the 1403 
knowledge of the origin of the adrenal mass will not alter the clinical management of the 1404 
patient. If, however, clinical management would be altered by the demonstration that the 1405 
adrenal lesion is a metastasis, then every effort should be made to allow this discrimination. 1406 
If the adrenal mass is potentially the only metastasis and if resection of this metastasis 1407 
seems to be reasonable from an oncological point of view, then surgery should be 1408 
considered. Regarding biopsy, we recommend applying the criteria provided in R.6.3.5.  1409 
 1410 
 1411 
R.6.3.5 We suggest performing a biopsy of an adrenal mass only if all of the following 1412 
criteria are fulfilled: (i) the lesion is hormonally inactive (in particular, a 1413 
pheochromocytoma has been excluded), (ii) the lesion has not been 1414 
conclusively characterized as benign by imaging, and (iii) management would 1415 
be altered by knowledge of the histology.  1416 
 1417 
Reasoning: 1418 
Adrenal biopsy may present with a significant non-diagnostic rate and a potential for 1419 
complications (76). Biopsy is only recommended for masses not characterized as benign on 1420 
cross-sectional imaging and where a biopsy result would affect clinical treatment decisions. 1421 
In patients with no other obvious metastatic lesions and when surgical removal of the lesion 1422 
is an option, FDG-PET/CT should be considered in order to exclude metastases outside the 1423 
adrenal that were not visualized by CT or MRI. Adrenal biopsy presents with lower diagnostic 1424 
performance for ACC and therefore is not recommended in this setting (76).  1425 
 1426 
 1427 
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R.6.3.6 We recommend assessment of residual adrenal function in patients with large 1428 
bilateral metastases. 1429 
 1430 
Reasoning 1431 
In rare cases, bilateral adrenal metastases can lead to adrenal insufficiency. Thus, in all 1432 
patients with potentially bilateral metastases, adrenal insufficiency should be considered and 1433 
clinically evaluated. If adrenal insufficiency seems to be possible, we recommend first to 1434 
measure a morning serum cortisol and plasma ACTH. In case of adrenal insufficiency, 1435 
plasma ACTH is clearly elevated in parallel to low cortisol. In uncertain cases, a synacthen 1436 
test should be performed (196).  1437 
If only one adrenal metastasis is present, adrenal insufficiency is extremely unlikely and we 1438 
recommend no specific assessment of adrenal reserve.  1439 
  1440 
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6. Future directions and recommended research 1441 
 1442 
The NIH conference on the management of the clinically unapparent adrenal mass in 2002 1443 
formulated several research questions for future studies (5). Although some of these issues 1444 
have been addressed, only few questions have been conclusively answered. From the 1445 
current perspective we see need for clinical trials in all four areas particularly addressed in 1446 
the guideline (see section 3.5). Given that most recommendations in this guideline are based 1447 
on weak evidence, there is clearly room for studies aiming to improve the evidence base of 1448 
management of adrenal incidentalomas. 1449 
Among many important research questions, we selected five as particularly important. All of 1450 
them can only be answered in a collaborative interdisciplinary manner.  1451 
1) Large, cohort study in patients with an adrenal mass > 2 cm to investigate the most 1452 
suitable imaging methods to determine if an adrenal mass is benign or not. It will be crucial to 1453 
establish a definitive diagnosis either by histopathology or by long-term follow-up (> 2 years).  1454 
2) Large, long-term study to define whether or not ‘autonomous cortisol secretion’ is 1455 
associated with increased mortality and other hard clinical endpoints (e.g. myocardial 1456 
infarction or stroke). Such a study will also provide evidence for a suitable biochemical 1457 
definition of ‘autonomous cortisol secretion’.  1458 
3) Randomized trial on the potential benefit of surgery in patients with "autonomous cortisol 1459 
secretion". To make such a trial feasible it is probably wise to define a surrogate endpoint 1460 
(e.g. hypertension or type 2 diabetes) that can be well controlled (including standardized 1461 
treatment regimens) throughout the study. A similar trial could evaluate the value of drugs 1462 
targeting the cortisol excess.  1463 
4) Prospective study (laparoscopic vs. open surgery) in patients with potentially malignant 1464 
adrenal mass (<10 cm) without pre-operative evidence of local invasion and metastases to 1465 
learn which surgical approach is the most suitable one for this patient cohort.  1466 
5) We propose a long-term study with annual biochemical work-up of patients with adrenal 1467 
incidentalomas to clarify if such a long-term hormonal assessment is justified. This study 1468 
should also help to define the true incidence of relevant diseases like adrenocortical 1469 
carcinoma and pheochromocytoma among incidentalomas. 1470 
 1471 
Several other research questions deserve future research. Of particular importance seems to 1472 
us the establishment of biomarkers to determine non-invasively the origin of the adrenal 1473 
mass (adrenal cortex, medulla, extra-adrenal) and whether or not the mass is malignant. 1474 
Currently, urine steroid metabolomics for non-invasive and radiation free detection of a 1475 
malignant ‘steroid fingerprint’ in adrenocortical carcinoma patients (193) and the combination 1476 
of functional imaging methods (e.g. metomidate-based imaging and FDG-PET/CT) are the 1477 
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most promising tools that should be further investigated. Similarly, for patients with 1478 
‘autonomous cortisol secretion’ new methods to stratify on an individual basis to intervention 1479 
(or observation) are needed.   1480 
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Table 1: Adrenal incidentalomas - frequency of the different underlying tumor 1496 
types (adapted according (9)) 1497 
 1498 
Tumor entity 
Median (%) Range (%) 
Series including all patients with an adrenal mass* 
 
Adenoma 80 33-96 
Non-functioning 75 71-84 
Autonomously cortisol-secreting  12 1.0-29 
Aldosterone-secreting 2.5 1.6-3.3 
Pheochromocytoma 7.0 1.5-14 
Adrenocortical carcinoma 8.0 1.2-11 
Metastasis 5.0 0-18 
Surgical series** 
  
Adenoma 55 49-69 
Non-functioning 69 52-75 
Cortisol-secreting 10 1.0-15 
Aldosterone-secreting 6.0 2.0-7.0 
Pheochromocytoma 10 11-23 
Adrenocortical carcinoma 11 1.2-12 
Myelolipoma 8.0 7.0-15 
Cyst 5.0 4.0-22 
Ganglioneuroma 4.0 0-8.0 
Metastasis 7.0 0-21 
 1499 
* Data from references: (2, 6, 14) 1500 
** Data from references: (2, 3, 6, 7, 10, 14, 17, 18) 1501 
Due to the nature of these studies a selection bias is very probable (the populations studied not 1502 
reflecting a random sample of all patients with an adrenal incidentalomas) and most likely leads to an 1503 
overestimation of the frequency of some tumor entities. 1504 
 1505 
 1506 
  1507 
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Table 2: Comorbidities possibly associated with adrenal incidentalomas with 1508 
‘autonomous cortisol secretion’  1509 
Comorbidities Reference 
Hypertension (23, 31-36) 
Glucose intolerance / type 2 diabetes mellitus (23, 31-39) 
Obesity (23, 31-33) 
Dyslipidemia (23, 31, 32, 36, 40) 
Osteoporosis (35, 38, 41-46) 
 1510 
  1511 
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Table 3: Overview of the key clinical questions and predefined outcome parameters 1512 
Clinical Question Predefined selection criteria and key outcome 
parameters1 
Metrics of the literature search 
Question 1a)  
What is the most accurate diagnostic imaging 
procedure to determine whether an adrenal 
mass is benign in patients with unilateral or 
bilateral adrenal mass(es) on imaging with or 
without history of other malignant lesions? 
• Original studies on imaging in patients with 
incidentally discovered adrenal mass(es), 
including those undergoing staging for known 
extra-adrenal malignancy. 
• Diagnostic intervention: CT (non-contrast, 
contrast-enhanced, washout), MRI, FDG 
PET(CT) 
• Reference standard: at least 50% of 
population had imaging-guided follow-up of 
any duration (for benign adrenal tumors), or 
histology after surgery or biopsy (for benign or 
malignant adrenal tumors) 
• Reporting 2x2 contingency table data or at 
least two indices of diagnostic accuracy 
(sensitivity, specificity, negative or positive 
predictive value) and disease prevalence.  
• 5496 abstracts2 
• 525 potentially relevant articles 
• 37 studies included in systematic 
review, 18 in meta-analysis 
• Major reasons for exclusion of 
articles were lack of test accuracy 
data, inadequate or unclear 
reference standard and ineligible 
populations. Other reasons for 
exclusion data collection pre-1990, 
sample size <10, < 50% histology 
in malignant group, >30% 
pheochromocytomas in malignant 
group, >10% pheochromocytomas 
in benign group, no differentiation 
of children versus adults 
Question 1b) 
What is the diagnostic accuracy of adrenal 
biopsy? 
• Original studies on patients with adrenal 
masses undergoing an adrenal biopsy 
procedure 
• Outcomes: non-diagnostic rate, diagnostic 
accuracy data, complication rate 
• For studies included in the diagnostic 
accuracy analysis: 1) Reference standard: at 
least 50% of population either histology from 
adrenalectomy or autopsy, imaging follow up 
3-12 months or clinical follow up of 2 years 
and 2) Reporting 2x2 contingency table data 
or at least two indices of diagnostic accuracy 
(sensitivity, specificity, negative or positive 
predictive value) and disease prevalence.  
 
• 175 abstracts3 
• 80 potentially relevant articles 
• 32 studies included in systematic 
review of at least one outcome.  
• Diagnostic accuracy data included 
from 8 studies 
• Major reasons for exclusion 
overall were: no outcomes of 
interest, fewer than 10 patients, 
abstract only, patient overlap. 
• Major exclusions from diagnostic 
accuracy analysis were: 
suboptimal reference standard 
and >30% non-adenomas 
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Question 2a)  
Are certain biochemical profiles (see 4.2.1) 
associated with an increased cardiovascular, 
metabolic and fracture risk in patients with 
adrenal mass(es), in whom endocrine work-
up for glucocorticoid excess was performed?  
Question 2b)  
Should surgery or a conservative/medical 
approach be recommended in patients with 
adrenal mass(es) and with defined 
biochemistry and cardiovascular, metabolic 
and fracture risk potentially indicative of mild 
glucocorticoid excess? 
• Original studies on patients with adrenal 
mass(es), in which endocrine work-up for 
glucocorticoid excess was performed. Studies 
independently of their respective definition of 
‘autonomous cortisol secretion’ were eligible. 
• Comparison between patients based on 
biochemical profiles (including post-
dexamethasone serum cortisol level) 
(question 2a)  
• Comparison between surgery and 
conservative approach (question 2b) 
• Reporting at least one of the crucial outcome: 
major cardiovascular events or mortality, 
vertebral fractures, metabolic profile, 
cardiovascular profile 
Question 2a:  
• 201 abstracts 
• 23 potentially relevant articles 
• 12 studies included 
Question 2b 
• 152 abstracts 
• 18 potentially relevant articles 
• 4 studies included 
• Excluded articles were not 
relevant for outcome parameters 
(n=17), no relevant design (n=4), 
overlapping populations (n=2), 
position paper (n=1), poorly 
defined patient cohort (n=1) 
Question 3)  
Should laparoscopic (=minimally-invasive) or 
open surgery be used for patients with non-
metastastic adrenal masses suspected to be 
malignant?  
• Original studies on adults with suspected non-
metastatic adrenocortical carcinoma 
• Comparison between laparoscopic versus 
open surgery 
• Reporting at least one of the crucial 
outcomes: perioperative morbidity and 
mortality; completeness of resection; 
recurrence-free and overall survival; pain or 
patient satisfaction 
• Publications with less than 10 patients per 
study arm were excluded.  
 
• 377 abstracts 
• 13 potentially relevant articles 
• 3 excluded due to samples size < 
10 patients per arm, 1 excluded as 
review 
• 9 studies included 
Question 4)  
What is the optimal follow-up in patients with 
an apparently benign adrenal incidentaloma 
in order to detect malignant transformation 
and/or development of overt hormone 
excess? 
 
• Original studies on patients with an adrenal 
mass without hormone excess and no clear 
evidence of malignant adrenal tumor at time of 
primary diagnosis 
• Reporting at least one of the following 
outcomes: malignancy in the adrenal (any 
kind); development of clinically relevant overt 
hormone excess (Cushing’s syndrome, 
• 133 abstracts 
• 19 potentially relevant articles 
• 9 excluded due to overlapping 
population (n=3), not relevant to 
question (n=3), not available in 
full-text (n=2), unclear methods 
(n=1) 
• Included: 
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pheochromocytoma, primary 
hyperaldosteronism) 
• 1 systematic review of 14 studies  
• 10 additional cohort studies 
   
 1513 
1
 For each question we searched separately for systematic reviews between 2000 and February 2014 in NHS Economic Evaluation Database (NHSEED), 1514 
Cochrane Database of Systematic Reviews, and Database of Abstracts of Reviews of Effects. This revealed no relevant systematic review. Then, we 1515 
searched for original articles in Medline published between 2000 and July 2014 (Question 3), October 2014 (Question 4), November 2014 (Question 2), and 1516 
August 2015 (Question 1). 1517 
2
 Summary of separately published meta-analysis (75).  1518 
3 
Summary of separately published meta-analysis (76) 1519 
 1520 
 1521 
 1522 
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Table 4: Imaging criteria suggesting a benign adrenal mass1  1523 
Non-contrast CT 
 
≤ 10 HU 
 
MRI - chemical shift2 Loss of signal intensity on out-phase 
imaging consistent with lipid-rich 
adenoma 
CT with delayed contrast media 
washout2, 3 
Absolute washout > 60% 
Relative washout > 40% 
18F-FDG-PET2 Absence of FDG uptake or uptake less 
than the liver4 
 1524 
1
 these criteria apply only for masses with homogenous appearance, or masses that have other clear 1525 
characteristics consistent with benign disease, e.g. myelolipoma. A homogeneous mass is defined as a lesion 1526 
with uniform density or signal intensity throughout. The measurements/region of interest (ROI) should include at 1527 
least 75% of a lesion without contamination by tissues outside the adrenal lesion. Inhomogeneous lesions 1528 
should not be subjected to MRI or washout CT for further characterization.  1529 
2 
Evidence is weak for MRI, CT with contrast washout, and FDG-PET and no comparative studies on "second line 1530 
imaging" are available. Thus, in this guideline we clearly recommend non-contrast CT as imaging procedure of 1531 
choice.  1532 
3
 There is no clear evidence about the best time interval. We recommend 10 or 15 min.  1533 
4
 Certain metastasis (e.g. from kidney cancer or low grade lymphoma) may be FDG negative  1534 
 1535 
  1536 
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Figure Legends 1537 
 1538 
Figure 1: Flow-chart on the management of patients with adrenal incidentalomas 1539 
(overview) 1540 
 1541 
1
 For patients with history of extra-adrenal malignancy, see special section 5.6.4 1542 
2
 only in patients with concomitant hypertension and /or hypokalemia 1543 
3
 only in patients with clinical or imaging features suggestive of adrenocortical carcinoma 1544 
 1545 
Figure 2: Assessment and management of ‘autonomous cortisol secretion’ in patients 1546 
with adrenal incidentalomas 1547 
  1548 
1
 The majority of but not all panel members preferred additional biochemical tests to better judge the degree of 1549 
cortisol secretion. In patients with comorbidities, we suggest to measure plasma ACTH and to repeat the 1550 
dexamethasone test in 3-12 months. 1551 
2
 We suggest additional biochemical tests to better judge the degree of cortisol secretion: plasma ACTH, 24-h 1552 
urinary free cortisol, (and/or late-night salivary cortisol), and repetition of the dexamethasone test in 3-12 1553 
months.  1554 
3
 See Table 2 for potentially cortisol-related comorbidities. 1555 
4
 Choice for surgery should always be individualized. 1556 
5
 Need of follow-up by an endocrinologist for 2-4 years 1557 
 1558 
Figure 3: Flow-chart on the management of adrenal masses considered for surgery 1559 
 1560 
1
 ‘autonomous cortisol secretion’ is not automatically judged as clinically relevant (see section 5.3 for details). 1561 
2
 in tumors with benign radiological features and a tumor size > 4 cm, surgery might also be individually 1562 
considered (see text) 1563 
 1564 
Figure 4: Evaluation of patients with adrenal mass and known extra-adrenal 1565 
malignancy 1566 
 1567 
1
 Always take life expectancy in consideration. 1568 
2
 If there is hormone excess, treat individualized. 1569 
3
 FDG-PET/CT should be considered to exclude other metastatic deposits in patients with no other obvious 1570 
metastatic lesions for whom surgical removal of the lesion is an option. 1571 
  1572 
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Supplementary Data 1573 
Tables Appendices 1-8: Description of analyzed studies and Results of the 1574 
GRADE analyses 1575 
 1576 
Table Appendix 9: Selected drugs that may interfere with results of the 1577 
dexamethasone test 1578 
 1579 
Table Appendix 10: Reviewers comments and responses by the authors 1580 
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Adrenal incidentaloma1 
Potentially malignant? 
 
• Non-contrast CT   
• if uncertain: consider FDG-PET, MRI 
with chemical shift, washout CT 
 
Functionally active?  
• Clinical assessment 
• 1mg dexamethasone test 
• Plasma or urinary metanephrines 
• Aldosterone/renin ratio2 
• Sex-hormones and steroid precursors3 
Aim at the establishment of a definitive diagnosis 
Non-functioning,  
benign lesion 
e.g. adenoma, lipoma.. 
Indeterminate  
mass 
Clinically relevant  
hormone excess  
or malignant tumor 
e.g. pheochromocytoma,  
Conn, Cushing, ACC 
Adrenal adenoma  
with autonomous  
cortisol secretion 
Assess in parallel  
No further  
investigations 
See Figure 2 
Surgery, details  
see Figure 3 
Consider additional  
investigations, surgery  
or follow-up 
Discuss in multidisciplinary team 
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Re-assess cortisol excess and co-
morbidities2during follow-up in 
patients without surgery? 5  
Consider surgical removal?4 
Comorbidities potentially related to 
autonomous cortisol secretion? 3 
Interpretation1 
1mg dex test result 
1-mg dex 
test 
≤50 nmol/l 
≤ 1.8 mg/dl 
Normal 
No 
No 
No 
Yes 
No 
No 
51-138 nmol/l 
1.9-5.0 µg/dl1 
Possible autonomous 
cortisol secretion 
No 
No 
No 
Yes 
Rarely3 
Yes 
>138 nnoml/ 
> 5.0 µg/dl2 
Autonomous 
cortisol secretion 
No 
Rarely3 
Yes 
Yes 
More 
often3 
Yes 
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Unilateral  
adrenal mass  
Radiological suspicion  
of malignancy?2  
Yes Local  
    invasion ?      
Relevant  
hormone excess?1 
No 
No  
    Surgery    
Open  
Adrenalectomy 
Laparoscopic  
adrenalectomy 
Individualized  
surgical  approach  
Diameter  
≤ 6 cm ?  No Yes 
No Yes 
No Yes 
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Adrenal mass in a patient  
with extra-adrenal malignancy1 
Benign radiological  
features   
No Exclude pheochromocytoma, 
other tests individualized2 
Adrenal hormone  
excess ? 
Yes 
Adrenal biopsy  
or resection 
Management as for  
primary malignancy 
No Yes 
Would the result of pathological  
assessment alter  
clinical management?3  
Yes 
Consider  
individualized  
treatment 
No 
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Supplementary data to Fassnacht et al., Management of adrenal incidentalomas - a European Society of Endocrinology Clinical Practice Guideline in 
collaboration with the European Network for the Study of Adrenal Tumors 
 
Appendix I 
Question 2A: cardiovascular, metabolic and fracture risk compared between subgroups adrenal incidentaloma patients (by biochemical profile) 
Description of included studies 
 
Reference 1, study 
design 
Study population and study period Subgroups 
according to 
biochemical 
profile 2 (sample 
sizes) 
 
Follow-up Outcomes Number of events 
per subgroup (%) 
Effect (95%CI) Remarks  
Cross-sectional studies 
Androulakis et al; 
Journal Clinical 
Endocrinology and 
Metabolism 2014  
 
Cross-sectional study 
 
Adrenal incidentaloma patients 
between 2008 and 2011; exclusion: 
DMII, hypertension, hyperlipidemia, 
history of malignancy, medication 
affecting any of the outcomes, and 
pheochromocytoma. 
 
1. Normal N = 34 
(LDDST < 1.09 
µg/dL) 
2. Abnormal N = 
26 (LDDST > 1.09 
µg/dL) 
 
 
Not 
applicable 
Impaired glucose 
tolerance (OGTT) 
1. 6/34 (18 %) 
2. 5/26 (19 %) 
 
Risk ratio (unadjusted) 
1.09 (0.37 to 3.18) 
Assessment of prevalent disease 
 
Cut-off based on mean + 2SD 
values of control group 
 
 
Chiodini et al;  
Journal Clinical 
Endocrinology and 
Metabolism 2004  
 
Cross sectional study 
 
Female adrenal incidentaloma patients 
from 1997 to 2002; exclusion: 
treatments affecting bone or diseases 
interfering with bone metabolism. 
 
Premenopausal 
1. Normal N =14 
2. Abnormal 
(profile 2) N = 7 
 
Postmenopausal 
1. Normal = 35 
2. Abnormal 
(profile 2) N = 14 
Not 
applicable 
Prevalence of 
fractures  
Premenopausal 
1. 1/14 (7%) 
2. 3/7 (43%) 
 
 
Postmenopausal 
1. 15/35 (43%) 
2. 11/14 (79%) 
OR (age adjusted) 
5.8 (1.6 to 20.6) 
Assessment of prevalent disease  
 
 
Chiodini et al;  
Journal Clinical 
Endocrinology and 
Metabolism 2009  
 
Cross sectional study  
 
Patients with adrenal incidentaloma; 
enrolled between 1997 and 2008; 
exclusion criteria: (i) hypogonadism 
and diseases known to affect bone 
metabolism; (ii) administration of drugs 
influencing bone and cortisol 
metabolism; (iii) signs or symptoms 
specific of cortisol excess 
 
1. Normal N = 202 
2. Abnormal 
(profile 2) N = 85 
Not 
applicable 
Prevalence of 
vertebral fractures 
1. N = 44/202 
(21.8%) 
2. N = 60/85 (70.6)  
OR (adjusted for age, 
BMI, testosterone, BMD) 
7.3 (3.9 to 13.4) 
Assessment of prevalent disease  
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Reference 1, study 
design 
Study population and study period Subgroups 
according to 
biochemical 
profile 2 (sample 
sizes) 
 
Follow-up Outcomes Number of events 
per subgroup (%) 
Effect (95%CI) Remarks  
Di Dalmazi et al; 
European Journal 
Endocrinology 2012, 
 
Cross-sectional study  
 
Adrenal incidentaloma patients 
between 2000 to 2010. Excluded:  
suspicion of malignancy, myelolipoma, 
ganglioneuroma, pheochromocytoma; 
history of steroid use, Cushing’s 
syndrome; hyperaldosteronism;  oral 
contraceptives and hormone 
replacement therapy.  
1. Normal N = 203 
2. Abnormal 
(profile 1 1.8 - 5 
µg/dl) N = 126 
3. Abnormal 
(profile 3 = >5 
µg/dl ) N = 19 
 
 
 
Not 
applicable  
Fractures 1. 5/203 (2.5%) 
2. 4/126 (3.2%) 
3. 3/19 (15.8%) 
OR3 
1.1 (0.3 to 4.4) 
6.5 (1.3 to 33) 
Assessment of prevalent disease 
Hypertension 1. 146/203 (73%) 
2. 101/126 (80%) 
3. 18/19 (94%) 
Not reported 
 
 
T2DM 1. 31/203 (15%) 
2. 31/126 (25%) 
3. 8/19 (42%) 
OR3 
1.7 (0.94 to 3.1) 
3.4 (1.2 to 10.0) 
Stroke 1. 1/203 (0.5%) 
2. 5/126 (4%) 
3. 1/19 (5%) 
Not reported 
Coronary heart 
disease 
1. 6/203 (3%) 
2. 15/126 (12%) 
3. 5/19 (26%) 
OR3 
4.1 (1.5 to 11.4) 
6.1 (1.4 to 26.5) 
Eller-Vainchier et al; 
JBMR 2012  
 
Cross-sectional study 
 
Patients with adrenal incidentaloma; 
exclusion criteria: (i) hypogonadism 
and diseases known to affect bone 
metabolism; (ii) administration of drugs 
influencing bone and cortisol 
metabolism; (iii) signs or symptoms 
specific of cortisol excess 
 
Study period 2010-2011 
 
1. Normal N = 68 
3. Abnormal 
(profile 2) N = 34 
Follow-up 
in 40 
patients; 
however 
relation 
fracture risk 
and cortisol 
not 
assessed 
Vertebral fractures 1. 31/68 (46%) 
2. 28/34 (82%) 
Relative risk (unadjusted) 
1.81 (1.34 to 2.45) 
Assessment of prevalent disease  
 
No adjusted risk estimates 
provided 
 
 
Olsen et al;  
Endocrine 2012  
 
Cross-sectional study 
 
Adrenal incidentaloma patients 
diagnosed 2005–2007 
 
1. Normal N = 105  
2. Abnormal 
(profile 1 1.8 - 5 
µg/dl) N = 30 
3. Abnormal 
(profile 3 = >5 
µg/dl ) N = 10 
 
Not 
applicable 
Hypertension  1. 68/105 (65%) 
2. 24/30 (80%) 
3. 9/10 (90%) 
Relative risk (unadjusted) 
1.24 (0.98-1.55) 
1.39 (1.08-1.78) 
Assessment of prevalent disease  
 
No adjusted risk estimates 
provided 
Vassilatou et al; 
European Journal of 
Endocrinology 2014  
 
Cross-sectional study 
 
 
Adrenal incidentaloma patients 
between 2002 and 2012. Exclusion: 
overt Cushing’s syndrome; 
corticosteroid use; malignancy; primary 
hyperaldosteronism, and 
pheochromocytoma  
 
1. Normal N = 232 
2. Abnormal 
(profile 1): N = 66  
 
Not 
applicable 
Hypertension 1. 141/232 (61%) 
2. 47/66 (71.%) 
 
Risk ratio (unadjusted) 
1.17 (0.97-1.41) 
Assessment of prevalent disease 
 
No adjusted risk estimates 
provided T2DM 1. 48/232 (21%) 
2. 18/66 (27%) 
Risk ratio (unadjusted)  
1.32 (0.82-2.10) 
Cohort studies 
 
Debono et al; 
Journal Clinical 
Endocrinology and 
Adrenal incidentaloma patients 
between  2005 and 2013;  
Exclusion: pheochromocytoma, 
1. Normal N = 95 
(< 1.8 µg/dl)  
2. Abnormal 
Mean 4.2 
years   
Mortality risk and 
mortality rate  
1. 1/95 (1%) 
2. 12/92 (13%) 
3. 5/19 (26%) 
Hazard ratio4 
12.0 (1.6-92.6) 
22.0 (2.6-188.3) 
Adjusted time-to-event analysis 
not possible due to limited number 
events 
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Reference 1, study 
design 
Study population and study period Subgroups 
according to 
biochemical 
profile 2 (sample 
sizes) 
 
Follow-up Outcomes Number of events 
per subgroup (%) 
Effect (95%CI) Remarks  
Metabolism 2014  
 
Cohort study 
 
primary hyperaldosteronism, suspicion 
of adrenal malignancy and  
glucocorticoid treatment 
 
(profile 1 1.8 - 5 
µg/dl) N = 92 
3. Abnormal 
(profile 3 = >5 
µg/dl ) N = 19 
 
Di Dalmazi et al; 
Lancet Diabetes and 
Endocrinonolgy 2014  
 
Cohort study 
 
Adrenal incidentaloma patients 
from1995 to 2010. Exclusion: 
suspected malignant disease; 
pheochromocytoma, 
primary hyperaldosteronism, overt  
Cushing; corticosteroid use 
1. Normal N = 129 
2. Abnormal 
(profile 1 1.8 - 5 
µg/dl) N = 59 
3. Abnormal 
(profile 3 = >5 
µg/dl ) N = 10 
 
 
 
Mean 7.5 
yrs (26 
months- 5 
yrs) 
Cardiovascular 
events 
 
 
Univariable analysis: 
mean cortisol DST (10 
nmol/ L increase) 
HR=1.04 (0.93 to 1.16)  
No comparison between baseline 
defined subgroups   
 
Mortality   Multivariable: mean 
cortisol DST (10 nmol/ L 
increase) 
HR=1.10 (1.01 to 1.19) 
(adjusted for age and 
myocardial infarction) 
Giordano et al; 
European Journal of 
Endocrinology 2010  
 
Cohort study 
 
Adrenal incidentaloma patients; 
excluded: overt endocrine disease or 
CT/MRI malignant features  
1. Normal N = 102 
2. Abnormal 
(profile 1) N = 16  
1-10 years, 
median 3 
years 
Incident T2DM 1. 3/102 (3%) 
2. 0/16 (0%) 
Risk ratio not estimable  
Incident 
dyslipidemia 
1. 3/102 (3%) 
2. 0/16 (0%) 
Risk ratio not estimable 
Incident 
hypertension 
1.  0/102 (0%) 
2.  0/16 (0%) 
Risk ratio not estimable 
Morelli et al;  
JBMR 2011  
 
Cohort study  
 
 
Adrenal incidentaloma patients; 
enrollment period 2005-2007. 
Exclusion: hypogonadism, diseases and 
drugs known to affect bone 
metabolism, corticosteroid use 
1. Normal N=76 
2. Abnormal 
(profile 2) N=27 
24 months Incident vertebral 
fractures  
1. 10/76 (13%) 
2. 13/27 (48%) 
OR 12.3 (4.1 to 36.5)3 Outcome assessment blinded 
 
All patients received vitamin D 
 
Morelli et al;  
Journal Clinical 
Endocrinology and 
Metabolism 2014 
   
Cohort study 
 
Adrenal incidentaloma patients 
included between 1996 and 2012. 
Exclusion: overt hypercortisolism, 
psychiatric diseases, alcoholism, 
corticosteroids, history of malignancy, 
pheochromocytoma, 
primary hyperaldosteronism 
1. Normal N=167 
2. Abnormal 
(profile 2) N = 39 
Mean 83 
months, 
range 60–
186  
Worsened 
glycaemic control 
1. 39/167 (23%) 
2. 12/39 (30%) 
Odds ratio (unadjusted) 
1.5 (0.7 to 3.1) 
Patients with > 5 year follow-up 
enrolled 
 
Outcome assessment not blinded 
 
* Risks based on incident cases, 
with exclusion of prevalent disease 
at baseline.  
 
Worsened blood 
pressure control 
1. 52/167 (31%) 
2. 18/39 (46%) 
Odds ratio (unadjusted) 
1.9 (0.9-3.8) 
* Incident 
cardiovascular 
events  
1. 11/164 (7%) 
2. 4/35 (11%) 
  
Odds ratio 3  2.7 (1.0-7.1) 
 
                                                            
1 See for full bibliographical details main paper 
2   Biochemical profiles to define autonomous cortisol secretion:  
1.  Cortisol after dexamethasone suppression >1.8 mcg/dl (50 nmol/l) (1-mg overnight dexamethasone suppression test, 2-mg or 8-mg overnight dexamethasone suppression test, 2-days low dose dexamethasone 
suppression test -LDDST) and ONE additional endocrine alteration among the following ones: increased 24-h urinary free cortisol (UFC), low ACTH, elevated midnight serum or salivary cortisol.  
2. Cortisol after 1-mg dexamethasone suppression test >3.0 mcg/dl (83 nmol/l) and ONE additional endocrine alteration (same as above).  
3. Cortisol after 1mg dexamethasone > 5 mcg/dl (138 nmol/l) as sole criterion.  
3 Adjusted for confounding variables 
4 Univariate findings; multivariable modeling limited by small number of events, “tentative models including covariates confirmed univariate findings” 
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Appendix II 
Question 2A: cardiovascular, metabolic and fracture risk compared between subgroups AI patients (by biochemical profile) 
 
GRADE table 
 
Quality assessment Effect estimates per study 
(95% confidence intervals)1  
 
Pooled effect estimate 
(95% confidence interval) 
Quality 
Studies 2 Design Risk of bias Inconsistency Indirectness Imprecision 
Glucose regulation  
 
Androulakis 
2014 
Di Dalmazi 2012 
Giordano 2010 
Morelli 2014 
Vassilatou 2014 
 
3 cross-sectional 
studies, 2 cohort 
studies 
Potential 
(residual) 
confounding  
No serious 
inconsistency 
Serious indirectness 
(different definitions of 
exposure and outcome) 
Serious 
(imprecise 
estimates) 
 
Androulakis  (Impaired 
glucose tolerance) 
Risk ratio (unadjusted) 1.09 
(0.37 - 3.18) 
 
No pooled estimate due to 
heterogeneity in design and 
analysis and indirectness 
⊕ΟΟΟ 
VERY 
LOW 
Di Dalmazi 
 (prevalent diabetes) 
Odds ratio (adjusted) 
1.7 (0.94 - 3.1) 
3.4 (1.2 - 10.0) 
Gioradano 
(incident diabetes) 
 3/102 (3%) vs  0/16 (0%) 
Morelli 
(worsened glycaemic 
control) 
Odds ratio (unadjusted)  
1.5 (0.7 - 3.1) 
Vassilatou 
(prevalent diabetes) 
Risk ratio (unadjusted)  
1.32 (0.82-2.10) 
 
                                                            
1 Comparing groups with autonomous cortisol secretion to non-secreting patients. See for details the description of included studies 
2 For full bibliographical details: see main paper 
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Blood pressure regulation 
 
Di Dalmazi 2012 
Olsen 2012 
Giordano 2010 
Morelli 2014 
Vassilatou 2014 
 
3 cross-sectional 
studies, 2 cohort 
studies 
Potential 
(residual) 
confounding  
No serious 
inconsistency 
Serious indirectness 
(different definitions of 
exposure and outcome) 
Serious 
(imprecise 
estimates) 
Di Dalmazi  
(prevalent hypertension) 
Risk ratio (unadjusted) 
1.1 (1.0-1.3) 
1.3 (1.1-1.5)3 
No pooled estimate due to 
heterogeneity in design and 
analysis and indirectness 
 
Giordano  
(Incident hypertension) 
0/102 (0%) vs  0/16 (0%) 
Morelli 
(worsened blood pressure 
control) 
Odds ratio (unadjusted) 
 1.9 (0.9-3.8) 
Olsen  
(prevalent hypertension) 
1.24 (0.98-1.55) 
1.39 (1.08-1.78) 
Vassilatou  
(prevalent hypertension) 
Risk ratio (unadjusted) 
1.17 (0.97-1.41) 
Fractures 
 
Chiodini 2004 
Chiodini 2009 
Di Dalmazi 2012 
Ellen-Vainchier 
2012 
Morelli 2011 
4 cross-sectional 
studies, 1 cohort 
studies 
Potential 
(residual) 
confounding 
No serious 
inconsistency 
Serious indirectness 
(different definitions of 
exposure and outcome) 
Serious 
(imprecise 
estimates) 
 
Chiodini 
(prevalent fractures) 
Odds ratio (adjusted) 7.3  
(3.9 - 13.4) 
No pooled estimate due to 
heterogeneity in design and 
analysis and indirectness 
⊕ΟΟΟ 
VERY 
LOW 
Chiodini 
(prevalent fractures) 
Odds ratio (age adjusted) 
5.8 (1.6 - 20.6) 
Di Dalmazi  
(prevalent fractures) 
Odds ratio (adjusted) 
1.1 (0.3 - 4.4) 
6.5 (1.3 - 33) 
Ellen-Vainchier  
(prevalent fractures) 
Relative risk (unadjusted) 
1.81 (1.34 - 2.45) 
Morelli 
                                                            
3 Risk ratio is constrained 
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(prevalent fractures) 
Odds ratio (adjusted) 
12.3 (4.1 - 36.5) 
Cardiovascular events 
 
Di Dalmazi 2012 
Morelli 2014 
 
 
 
1 cross-sectional 
study, 1 cohort 
study 
Potential 
(residual) 
confounding 
No serious 
inconsistency 
Serious indirectness 
(different definitions of 
exposure and outcome) 
Serious 
(imprecise 
estimates) 
Di Dalmazi 
(Prevalentt cardiovascular 
disease) 
Odds ratio (adjusted) 
4.1 (1.5 - 11.4) 
6.1 (1.4 - 26.5) 
No pooled estimate due to 
heterogeneity in design and 
analysis and indirectness 
⊕ΟΟΟ 
VERY 
LOW 
Morelli 
(incident cardiovascular 
disease) 
Odds ratio (adjusted) 
 2.7 (1.0-7.1) 
Mortality 
Debono 2014 Cohort study Potential 
(residual) 
confounding 
Not applicable Not applicable Serious 
(imprecise 
estimates) 
Hazard ratio (adjusted) 
12.0 (1.6-92.6) 
22.0 (2.6-188.3) 
 ⊕ΟΟΟ 
VERY 
LOW 
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Appendix III 
Question 2B: surgical (group I) versus conservative approach (group II) in autonomous cortisol secretion 
Description of included studies 
 
Reference 1, study 
design 
 
Study population and  study period Follow-up 
 
Outcomes Number of event per 
subgroup (%) 
Effect estimate (95%CI) Remarks  
Chiodini et al; Journal 
Clinical Endocrinology 
and Metabolism 2010  
 
Cohort study 
 
41 patients with adrenal 
incidentalomas and subclinical Cushing 
Subclinical Cushing defined as 
dexamethasone suppression test > 3 
mcg/dl.  
 
Study period 2002-2007 
 
Operated patients (group I) N=25 
Non-operated patients (group II) N=16 
Range 18-
48 months 
Improvement 
blood pressure 
I: 14/25 (56%) 
II: 0/16 (0%) 
Odds ratio (adjusted): 
26 (2 to 300) 
 
Residual confounding is potentially 
a bias, imprecise estimates, non-
collapsibility of the odds ratio 
might play a role 
Improvement 
fasting glucose 
I: 12/25 (48%) 
II: 0/16 (0%) 
Odds ratio (adjusted): 
26 (2 to 2) 
 
Improvement LDL 
cholesterol 
I: 9/25 (36%) 
II: 3/16 (19%) 
Odds ratio (adjusted): 
3 (0.2 to 40) 
Iacobone et al, Surgery 
2012 
 
Cohort study 
 
35 patients with adrenal 
incidentalomas and subclinical Cushing 
Subclinical Cushing defined as 
dexamethasone suppression test > 5 
mcg/dl. 
 
Study period 2000-2009 
 
Operated patients (group I) N=20 
Non-operated patients (group II) N=15 
 
 
Mean 
follow-up 
55 months 
Normalization 
hypertension 
I: 2/15 (13%) 
II; 0/12 (0%) 
Risk difference 13% 
(-3 to 30%) 
Confounding is potentially a bias, 
imprecise estimates 
Normalization 
diabetes mellitus 
I: 1/10 (10%) 
II: 0/6 (0%) 
Risk difference 10% 
(-9 to 29%) 
Normalization 
hypercholesterole
mia 
I: 2/10 (20%) 
II: 0/7 (0%) 
Risk difference 20% 
(-5 to 45%) 
Toniato et al, Annals of 
Surgery 2009 
 
Randomized 
controlled trial 
Patients with adrenal incidentalomas 
and subclinical Cushing. Subclinical 
Cushing defined as dexamethasone 
suppression test > 2.5 mcg/dl.  
 
Inclusion between 1991 and 2005. 
 
Patients randomized between 
laparoscopic surgery (group I, n=23) 
and a conservative approach (group II, 
n=22)  
 
Mean 7.7 
years 
Normalization 
dexamethasone 
test  
I: 23/23 (100%)3 
II: not reported 
 Study randomized, no blinded 
outcome assessment, imprecise 
estimates 
 
 
Normalization 
hypertension 
I: 5/18 (28%) 
II: 0/15 (0%) 
Risk difference 28%  
(7 to 48%) 
Normalization 
diabetes mellitus 
I: 2/8 (25%) 
II: 0/6 (0%) 
Risk difference 25%  
(-5 to 55%) 
Normalization 
hypercholesterole
mia 
I: 3/8 (38%) 
II: 0/7 (0%) 
Risk difference 38%  
(4 to 71%) 
                                                            
1 See for full bibliographical details main paper 
2 Confidence interval from table 5 conflicting with effect estimate 
3 Within 12 months 
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Reference 1, study 
design 
 
Study population and  study period Follow-up 
 
Outcomes Number of event per 
subgroup (%) 
Effect estimate (95%CI) Remarks  
Tsuiki et al, Endocrine 
Journal 2008 
 
Cohort study 
20 patients with adrenal 
incidentalomas and subclinical Cushing 
Subclinical Cushing defined as 
dexamethasone suppression test > 3 
mcg/dl.  
 
Study period: 1995-2006. 
 
Operated patients (group I) N=10 
Non-operated patients (group II) N=12 
 
Range 7-69 
months 
Improvement 
hypertension 
I: 5/6 (83%) 
II: 0/4 (0%) 
Risk difference 83% 
(55 to 100%) 
Confounding is potentially a bias, 
imprecise estimates 
Improvement 
glucose 
metabolism 
I: 2/9 (22%)  
II: 0/6 (0%) 
 
Risk difference 18% 
(-4 to 41%) 
Improvement 
hypercholesterole
mia 
I: 6/9 (66%) 
II: 0/6 (0%) 
Risk difference 66% 
(36 to 97%) 
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Appendix IV 
Question 2B: surgical (group I) versus conservative approach (group II) in autonomous cortisol secretion 
GRADE tables 
 
Quality assessment Study effects per study for 
surgical versus conservative 
approach 
Pooled effect estimate 
(95% confidence interval) 
Quality 
Studies1  Design Risk of bias Inconsistency Indirectness Imprecision 
Improvement glucose regulation  
 
Chiodini 2010 
Iacobone 2012 
Toniato 2009 
Tsuiki 2008  
 
3 cohort studies, 
1 randomized 
trial 
Potential (residual) 
confounding by indication 
(cohort studies), no blinding 
(randomized trial) 
No serious 
inconsistency 
Serious indirectness 
(different definitions of 
exposure and outcome) 
Serious 
(imprecise 
estimates) 
 
Chiodini 
Odds ratio (adjusted): 
26 (2 to 2 ) 
No pooled estimate due to 
heterogeneity in design and 
analysis and indirectness 
⊕ΟΟΟ 
VERY 
LOW 
Iacobone 
Risk difference 10% 
(-9 to 29%)  
Toniato 
Risk difference 25%  
(-5 to 55%) 
Tsuiki 
Risk difference 18% 
(-4 to 41%) 
Improvement hypertension 
 
Chiodini 2010 
Iacobone 2012 
Toniato 2009 
Tsuiki 2008  
 
3 cohort studies, 
1 randomized 
trial 
Potential (residual) 
confounding by indication 
(cohort studies), no blinding 
(randomized trial) 
No serious 
inconsistency 
Serious indirectness 
(different definitions of 
exposure and outcome) 
Serious 
(imprecise 
estimates) 
 
Chiodini 
Odds ratio (adjusted): 
26 (2 to 300) 
No pooled estimate due to 
heterogeneity in design and 
analysis and indirectness 
⊕ΟΟΟ 
VERY 
LOW 
Iacobone 
Risk difference 13% 
(-3 to 30%) 
Toniato 
Risk difference 28%  
(7 to 48%) 
Tsuiki 
Risk difference 83% 
(55 to 100%) 
                                                            
1For full bibliographical details: see main paper 
2 See table description of included studies 
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Improvement hypercholesterolaemia  
 
Chiodini 2010 
Iacobone 2012 
Toniato 2009 
Tsuiki 2008  
 
 
3 cohort studies, 
1 randomized 
trial 
Potential (residual) 
confounding by indication 
(cohort studies), no blinding 
(randomized trial) 
No serious 
inconsistency 
Serious indirectness 
(different definitions of 
exposure and outcome) 
Serious 
(imprecise 
estimates) 
Chiodini 
Odds ratio (adjusted): 
3 (0.2 to 40) 
No pooled estimate due to 
heterogeneity in design and 
analysis and indirectness 
⊕ΟΟΟ 
VERY 
LOW 
Iacobone 
Risk difference 20% 
(-5 to 45%)  
Toniato 
Risk difference 38%  
(4 to 71%) 
Tsuiki 
Risk difference 66% 
(36 to 97%) 
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Appendix V 
Question 3: open (OA) vs laparoscopic adrenalectomy (LA) for adrenal incidentaloma 
Description of included studies 
Reference 1, 
Study design 
Study population 
 
Study Period 
and follow-up 
Interventions  
(OA = open 
adrenalectomy, LA 
= lapraoscopic 
adrenalectomy) 
 
Outcome  
Measures 
 
Results 
 
Remarks  
Brix et al; 
European 
Urology 2010 
 
Cohort study 
 
ACC stage I-III and 
Tumor size<10 
cm;  
1996-2009 
 
FU 6-131 mo 
LA (n=35) 
OA (n=117) 
Survival 
 
Hazard ratio mortality LA vs OA 0.98 (95% CI 0.5-1.92) 
 
Analysis adjusted for baseline 
imbalances. Residual confounding 
potentially a bias 
 
Disease-free survival  
 
Hazard ratio recurrence LA vs OA 0.91 (95% CI 0.56-
1.47) 
 
% R0 resection LA 24/35=69%; OA 64/117=55%; p= 0.45 
 
Cooper et al; 
Surg Endosc 
2013.  
 
Cohort study 
 
ACC patients; 
metastatic 
disease excluded; 
T1-T4 stage; size 
1-30 cm) 
1993-2012 
 
Median follow-
up 34 months  
LA (n=46) 
Two OA groups: 
OA other hospital 
(n=210) (OA1) 
OA from index 
hospital (n=46) 
(OA2) 
% margin positive 
resection 
LA 28.3%, OA1 17.6% and OA2 8.7%; p=0.01 
 
Analysis local recurrence: R2 
resections excluded; 
 
Analysis adjusted for baseline 
imbalances. Residual confounding 
potentially a bias 
 
Recurrence free survival 
(months) 
 
LA 11, OA1 10, OA2 20 (p=0.005) 
Overall survival (months) 
 
LA 54 (95% CI 28-79), OA1 46 (95%CI 39-53), OA2 110 
(95% CI 20-199); p=0.07 
After adjusting for T stage survival was better for OA 
(P<0.001) 
 
Donatini et al; 
Annals of 
Surgical 
Oncology 2014,  
 
Cohort study 
 
Stage I or II ACC, 
Tumor size<10 
cm; no 
radiological sign 
of local invasion; 
R0 resection 
 
1982-2011 
 
Follow-up 0-132 
months 
LA (n=13) 
OA (n=21) 
Overall and disease free 
survival  
 
Overall survival: LA 11/13 (85%); OA 17/21 (81%); 
p=0.6 
Disease free survival (months): LA 46, OA 47; p=0.9 
Selected on complete resection in 
stage I/II tumor 
 
Residual confounding potentially a 
bias 
 
Low power to detect difference in 
effect due to small sample size 
 
 
Recurrence Recurrence: LA 4/13 (31%); OA: 5/21 (24%); p=0.7 
 
                                                            
1 See for full bibliographical details main paper 
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Reference 1, 
Study design 
Study population 
 
Study Period 
and follow-up 
Interventions  
(OA = open 
adrenalectomy, LA 
= lapraoscopic 
adrenalectomy) 
 
Outcome  
Measures 
 
Results 
 
Remarks  
Fossa et al;  
Acta Oncologica 
2013,  
 
Cohort study 
Stage I-III ACC, 
tumor size 4-24 
cm; 
 
1998-2011 
 
Follow-up range 
0-227 months 
MIA (n=17) 
OA (n=15) 
 
 
Intraoperative 
complications (Grade III) 
 
Intraoperative complications: MIA 3/17, OA 12/15 
 
Residual confounding potentially a 
bias 
 
Low power to detect difference in 
effect due to small sample size 
 
 
 
Postoperative 
complications (Grade III-
IV) 
Postoperative complications: MIA 2/17, OA 3/15 
% R0 resection 
 
MIA 12/17; OA 12/15; p=1.0 
 
Overall and progression-
free survival, median 
 
Progression-free survival (months): MIA 15.2; OA 8.1; 
p=0.06 
Overall survival (median, months): MIA 104, OA 37;  
p=0.22 
Lombardi et al; 
Surgery 2012 
 
Cohort study 
 
ACC patients who 
underwent 
radical surgery 
(R0 resection) for 
stage I/II; tumor 
size 3-21cm 
 
2003-2010 
 
Follow-up: 
mean 42 
months, range 
1-192 
LA (n=30) 
OA (n=126) 
Overall survival 
(median/5yrs) 
 
Median overall survival (months):  
LA 108; OA 60; p=0.2; p=0.12 
 
Selected on R0 resection in stage I/II 
tumor 
 
Residual confounding potentially a 
bias 
 
 
Disease free survival 
(median/5yrs) 
 
Median disease free survival (months): LA 72; OA 48, 
p=0.12 
Postoperative 
complications 
LA 1/30 (3%); OA 7/126 (6%), p=0.9 
Miller et all; 
Surgery 2012  
 
Cohort study 
 
ACC stage I-III; 
size 3-28 cm 
2005-2011 
 
Follow-up 
median 
(months) 26.5, 
range 1-188 
LA (n=46) 
OA (n=110) 
% positive margins LA 30%, OA 16%; p=0.4 
 
Stratified analyses performed for 
stage II and III and for patients with 
R0 resection 
 
Residual confounding potentially a 
bias 
 
Time to recurrence 
 
Time to local recurrence, Stage II (months): LA 12 vs 
OA 31; (p=0.002) 
Time to local recurrence, Stage III (months): LA 6 vs 
OA 13 (p=0.19) 
 
Survival Survival Stage II (months): LA 51 vs OA 103 (p=0.002) 
Survival Stage III (months): LA 28 vs OA 44; (p=0.77) 
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Miller et al; 
World Jou 
Surgery 2010;  
 
Cohort study 
ACC, stage IV 
excluded, range 
tumor size 4-27 
cm 
2003-2008 
 
FU median 36.5 
months 
MIA (n=17) 
OA (n=71) 
% positive margins MIA 50%, OA 18% 
  
Residual confounding potentially a 
bias 
 
Low power to detect difference in 
effect due to small sample size 
 
Analysis according to tumor size 
included (small subgroups) 
 
Recurrence  
 
% recurrence MIA 63%, OA 65% (p=0.22) 
Mean time to local recurrence (months): MIA 9.6; OA 
19.2 (P<0.005) 
Mir et al;  
Annals of 
Surgical 
Oncology 2012 
 
Cohort study 
 
44 ACC patients, 
13% with 
metastasis at 
baseline 
1993-2011; 
 
Median follow-
up 26 months 
LA (n=18) 
OA (n=26) 
Intraoperative 
complications  
Intraoperative complications OA 1/26 LA 2/18, p=0.3 
 
Cohort including metastasized 
patients 
 
Analysis adjusted for baseline 
imbalances. Residual confounding 
potentially a bias 
 
Low power to detect difference in 
effect due to small sample size 
 
% positive margin  
 
% positive margin: LA 7/18 (39%), OA 10/26 (38%); 
p=0.5 
 
Overall and recurrence 
free survival 
 
2 yr overall survival: LA 39%, OA 60%; p=0.7 
2 yr recurrence free survival: LA 58%, OA 54 %; p=0.6 
Hazard ratio mortality OA vs LA =0.5 (95% CI 0.2-1.2) 
Hazard ratio recurrence OA vs LA=0.4 (95% CI 0.2-1.2) 
 
Porpiglia et al; 
European 
Journal Urology 
2010  
 
Cohort study 
 
Stage I or II ACC, 
complete 
resection, size 
tumor 2-17 cm 
2002-2008 
 
FU median 35 
mo, range 11-
72 
LA (n=18) 
OA (n=25) 
 
Surgical approach 
based on surgeon 
preference and 
expertise 
 
Recurrence free survival 
 
Median disease free survival (months):  LA 23; OA 18 
(p=0.8); 
Hazard ratio for recurrence OA vs LA= 0.57 (95% CI 
0.2-1.8) 
Selected on complete resection in 
stage I/II tumor 
 
Residual confounding potentially a 
bias 
 
Overall survival 3yrs survival LA 100%; OA 84% (p=0.3) 
 
 
Abbreviations: ACC = adrenocortical carcinoma; 95%CI = 95% confidence intervals;  
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Appendix VI 
Question 3: Open (OA) vs laparoscopic adrenalectomy (LA) for adrenal incidentaloma 
GRADE tables 
 
Quality assessment 
Numbers and events per study  Pooled effect estimate (95% confidence interval) Quality 
Studies 1 Design Risk of bias Inconsistency Indirectness Imprecision 
Perioperative mortality  
 
Brix 2010 Cohort 
studies 
Potential (residual) confounding by 
indication 
Not applicable  No serious 
indirectness 
Serious (imprecise 
estimates) 
 
OA 0/117 vs LA 0/35  
 
 
 ⊕ΟΟΟ 
VERY 
LOW 
Intraoperative complications 2 
 
Fossa 2013 
Mir 2013  
Cohort 
studies 
Potential (residual) confounding by 
indication 
Serious No serious 
indirectness 
Serious (imprecise 
estimates) 
12/15 vs 3/17 (Fossa) 
1/26 vs 2/18 (Mir) 
 
Relative risk OA vs LA  
2.6 (1.1-6.1) 
⊕ΟΟΟ 
VERY 
LOW 
Major postoperative complications 3  
 
Fossa 2013 
Lombardi 
2012 
 
Cohort 
studies 
Potential (residual) confounding by 
indication 
No serious 
inconsistency 
No serious 
indirectness 
Serious 
 
3/15 vs 2/17 (Fossa) 
7/126 vs 1/30 (Lombardi) 
Relative risk OA vs LA  
1.7 (0.5-6.2) 
⊕ΟΟΟ 
VERY 
LOW 
Completeness of resection (Absence of positive margins) 
 
Brix 2010  
Cooper 2013  
Fossa 2013 
Miller 2012  
Mir 2013 
Cohort 
studies 
Potential (residual) confounding by 
indication 
Seriousf No serious 
indirectness 
Serious 
 
OA 64/117 LA 24/35 (Brix) 
OA1 37/210 and OA2 4/46 LA 
13/46 (Cooper) 
OA 12/15 LA 12/17 (Fossa) 
OA 19/117 LA 14/46 (Miller) 
OA 10/26 LA 7/18 (Mir) 
Complete resection OA vs LA 
0.8 (0.6-1.1)4 
 
⊕ΟΟΟ 
VERY 
LOW 
                                                            
1 For full bibliographical details: see main paper 
2 Undefined in Mir et al, Grade III in Fossa et al 
3 Undefined in Lombardi et al, Grade III-IV in Fossa et al 
4 Random effects model, two control groups in Cooper merged 
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Median survival (months)5 
 
Cooper 2013 
Fossa 2013 
 
 
Cohort 
studies  
Potential (residual) confounding by 
indication 
Serious No serious 
indirectness 
Serious (imprecise 
estimates) 
Time (in moths) 
LA 54 OA1 46 OA2 110 
(Cooper)6 
LA 104 OA 37 (Fossa) 
No pooled estimate due to 
inconsistency  
⊕ΟΟΟ 
VERY 
LOW 
Mortality risk (time to event analysis) 
 
Brix 2010 
Mir 2013  
Cohort 
studies 
Potential (residual) confounding by 
indication 
Seriousf No serious 
indirectness 
Serious (imprecise 
estimates) 
Mortality risk OA vs LA 
1.0 (0.5-2.0) (Brix) 
0.5 (0.2-1.2) (Mir) 
 
Pooled estimate mortality risk OA 
vs LA:  
0.8 (0.5-1.4) 
⊕ΟΟΟ 
VERY 
LOW 
Recurrence or progression-free survival (months) 
 
Cooper 2013  
Fossa 2013 
Cohort 
studies  
Potential (residual) confounding by 
indication 
Serious inconsistency No serious 
indirectness 
Serious (imprecise 
estimates) 
Time (in months) 
LA 11, OA1 10, OA2 20 
(Cooper) 
LA 15.2; OA 8.1 (Fossa) 
 
No pooled estimate due to 
inconsistency  
⊕ΟΟΟ 
VERY 
LOW 
Recurrence risk (time to event analysis) 
 
Brix 2010 
Mir 2013  
Cohort 
studies 
Potential (residual) confounding by 
indication 
Serious inconsistency No serious 
indirectness 
Serious (imprecise 
estimates) 
Recurrence risk LA vs OA 
HR 0.91 (0.56-1.47) Brix  
HR 2.5 (0.83-5) Mir 
 
No pooled estimate due to 
inconsistency 
⊕ΟΟΟ 
VERY 
LOW 
 
 
 
                                                            
5 Only studies reporting median survival in all operated patients 
6 Two OA control groups included with inconsistent results 
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Appendix VII 
Question 4: Natural course of apparently benign AI (risk of malignancy or development of hormone excess) 
Description of included studies 
Reference 1, study design 
 
Study population and study 
period 
Follow up Outcome measures Results  Remarks 
Anagnostis et al, Exp Clin 
Endocrin Diabetes (2009) 
 
Cohort study 
Inclusion: adrenal 
incidentalomas without 
clinical and biochemical 
evidence of hormonal activity 
at baseline. 61 patients 
included.  Mean maximum 
diameter 3 cm. 
 
Patients enrolled between 
1989 and 2008 
Mean 3.1 yrs  
(range 0-19) 
 
 
Adrenal Malignancy 0/61 (0%) 
 
 
 
 
Maximally 31 patients 
evaluated at year 1. High risk 
of bias due to attrition bias. 
 
Autonomous cortisol 
secretion (cortisol >1.8µg/dl 
after DST) 
0/61 (0%) 
 
Phaeochromocytoma 0/61 (0%) 
 
Hyperaldosteronism  1/61 (2%) 
 
Cawood et al, European 
Journal Endocrinology (2009) 
 
Systematic review 
Inclusion: studies on follow-
up after a diagnosis of 
nonfunctioning adrenal 
incidentalomas.  publication 
1980-2008;  
 
20 studies were included in 
the systematic review; 
n=1410 patients in total with 
benign, nonfunctioning 
adrenal incidentalomas 
1.8 to 7.1 yrs 
 
No information on the use of 
protocols for follow up in 
original studies 
Adrenal Malignancy 0.2% (95 CI 0.0 to 0.4)* 
 
 
 
No information on 
methodological quality of 
included studies 
 
Individual studies included in 
the Cawood review not 
assessed 
 
*Pooled estimates 
Autonomous cortisol 
secretion 
0.3% (0.0 to 0.7)* 
 
 
Phaeochromocytoma 0.2% (0.0 to 0.4) * 
Cho et al, Korean Journal 
Internal Medicine (2013) 
 
Cohort study   
Cohort of 282 adrenal 
incidentaloma patients. 
Follow-up data in 147 
(imaging)/72 (biochemical 
analysis) 
 
Study period 2004 to 2011 
Mean FU 23.1 months  
 
 
Adrenal malignancy 
 
0/72 (0%) Selection of patients with 
follow-up data unclear  
Autonomous cortisol 
secretion (post DST cortisol 
>2.0 µg/dL) 
2/47 (4%) 
Pheochromocytoma 1/47 (2%) 
Comlekci et al, Endocrine 
(2010) 
 
Cohort study 
Patients referred to institute 
with AI since 2002; 
malignancy excluded (CT) 
 
Study period 2002 to 2008 
Median 24 months; range 6-
132 months 
 
.  
Autonomous cortisol 
secretion (post DST cortisol > 
1.8 µg/dl)  
 
 
3/162 (6.9%) Selection of patients with 
follow-up data unclear 
                                                            
1 See for full bibliographical details main manuscript 
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Reference 1, study design 
 
Study population and study 
period 
Follow up Outcome measures Results  Remarks 
Phaeochromocytoma 0/162 (0%) 
Hyperaldosteronism  0/162 (0%) 
Di Dalmazi et al, Lancet 
Diabetes and Endocrinonolgy 
2014 
Cohort study 
 
Nonfunctinong adrenal 
incidentaloma without 
malignant features  
 
N=129 
 
Study period 1995-2010 
 
 
Mean 7.5 yrs (26 months- 5 
yrs) 
Autonomous cortisol 
secretion (1.8 - 5 µg/dl after 
DST)  
14/129 (11%)  
Autonomous cortisol 
secretion (>5 µg/dl after DST) 
1/129 (1%) 
Fagour et al, European 
Journal Endocrinology (2009)  
 
Cohort study 
Consecutive nonfunctioning 
adrenal incidentalomas 
patients with benign 
appearance on CT; size ≤ 40 
mm; <10UH); 27 patients with 
nonfunctioning adenomas 
included 
 
Study period 2001-2006 
Mean 4.3 yrs ±1.6 yrs  
 
 
Autonomous cortisol 
secretion (post DST cortisol > 
1.8 µg/dl)  
3/27 (11%) 
 
(non developed clinically 
overt Cushing) 
Study aimed to assess the 
usefulness of adrenal 
scintigraphy 
 
Giordano et al, European 
Journal of Endocrinology 
(2010)  
 
Cohort study 
 
Nonfunctinong adrenal 
incidentaloma without 
malignant features (N=102)  
1-10 years, median 3 years Adrenal Malignancy 0/102 (0%) No definitions of “clear overt  
endocrine disease”  
Autonomous cortisol 
secretion (cortisol >1.8µg/dl 
after DST) 
0/102 (0%) 
Phaeochromocytoma 0/102 (0%) 
Hyperaldosteronism  0/102 (0%) 
Kim et al, Korean Journal of 
Internal Medicine (2005)  
Patients with apparent benign 
nonfunctiong adrenal 
incidentalomas. N=24 
 
Study period 1992 to 2003 
Mean 20.8 months (range 5-
72) 
Adrenal Malignancy 0/24 (0%) No information on 
biochemical analysis and cut-
off values used 
Autonomous cortisol 
secretion 
0/24 (0%) 
Phaeochromocytoma 0/24 (0%) 
Hyperaldosteronism  0/24 (0%) 
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Reference 1, study design 
 
Study population and study 
period 
Follow up Outcome measures Results  Remarks 
Morelli et al, Journal Clinical 
Endocrinology and 
Metabolism 2014 
   
Cohort study 
Patients with apparent benign 
nonfunctioning adrenal 
incidentalomas. N=167 
Study period 1996-2012 
Median 72.3 months; range, 
60–186 months 
 
 
  
Autonomous cortisol 
secretion (DST >3.0 mcg/dl) 
15/167 (9%)  448 patients excluded due to 
criteria or < 5 years follow up 
 
No standardized protocol for 
follow up 
 
 
 
Muth et al, British Journal of 
Surgery (2011)  
 
Cohort study 
Patients with apparent benign 
nonfunctioning adrenal 
incidentalomas and without 
extra-adrenal malignancy. 
N=187 
 
Study period 2002-2004 
Mean 19 months 
 
Clinical and biochemical 
evaluation at inclusion and 
after 24 months 
Adrenal Malignancy 0/187 (0%) 4 patients displaying 
biological abnormalities 
during FU but with no further 
investigation  
 
 
Endocrine active lesions 
 
0/187 (0%) 
Vassilatou et al, Clinical 
Endocrinology (2009)  
Patients with apparent benign 
nonfunctioning adrenal 
incidentalomas.  
 
N= 95 
 
Study period 1993-2007 
Median 60 months; range 12-
154 months 
 
Clinical, biochemical and 
hormonal examination after 
12 months and then every 12-
24 months 
Adrenal malignancy 
 
 
Malignancy, N=0  
 
 
39/95 lost  to follow 
up/refused follow-up;  
 
 
Autonomous cortisol 
secretion (cortisol >1.8µg/dl 
after DST) 
2/95 (2%) 
Phaeochromocytoma 2/95 (2%) 
Hyperaldosteronism  0/95 (0%) 
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Appendix VIII 
Question 4: Natural course of apparently benign AI (risk of malignancy or development of hormone excess) 
GRADE table 
 
 
 
Quality assessment Range of estimates 
 
Pooled effect estimate 
(95% confidence interval) 
Quality 
Studies1 Design Risk of bias Inconsistency Indirectness Imprecision 
Risk of adrenal maligancy  
 
Anagnostis 2009 
Cawood 2009 
Cho 2013 
Giordano 2010 
Kim 2005 
Muth 2011 
Vassilatou 2009 
6 cohort studies 
1 meta-analysis 
Attrition bias  No serious 
inconsistency 
Serious indirectness 
(different definitions 
of exposure, 
outcom ) 
Serious (imprecise 
estimates) 
 
Risk of malignancy 
during follow-up 
0-0.2% 
No pooled estimate due to 
heterogeneity in design and 
analysis and indirectness 
⊕ΟΟΟ 
VERY LOW 
Autonomous cortisol secretion 
 
Anagnostis 2009 
Cawood 2009 
Cho 2013 
Comlecki 2010 
Di Dalamzi 2014 
Fagour 2009 
Giordano 2010 
Kim 2005 
Morelli 2014 
Muth 2011 
Vassilatou 2009 
 
10 cohort studies 
1 meta-analysis 
Attrition bias No serious 
inconsistency 
Serious indirectness 
(different definitions 
of exposure and 
outcome) 
Serious (imprecise 
estimates) 
Risk of autonomous 
cortisol secretion 
during follow-up 
0-11% 
No pooled estimate due to 
heterogeneity in design and 
analysis and indirectness 
 
                                                            
1 For full bibliographical details: see main paper 
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Quality assessment Range of estimates 
 
Pooled effect estimate 
(95% confidence interval) 
Quality 
Studies1 Design Risk of bias Inconsistency Indirectness Imprecision 
Hyperaldosteronism 
 
Anagnostis 2009 
Comlecki 2010 
Giordano 2010 
Kim 2005 
Muth 2011 
Vassilatou 2009 
6 cohort studies 
 
Attrition bias No serious 
inconsistency 
Serious indirectness 
(different definitions 
of exposure and 
outcome) 
Serious (imprecise 
estimates) 
 
Risk of 
hyperaldosteronism 
during follow-up 
0-2% 
No pooled estimate due to 
heterogeneity in design and 
analysis and indirectness 
⊕ΟΟΟ 
VERY 
LOW 
Pheochromocytoma 
 
Anagnostis 2009 
Cawood 2009 
Cho 2013 
Comlecki 2010 
Giordano 2010 
Kim 2005 
Muth 2011 
Vassilatou 2009 
7 cohort studies 
1 meta-analysis 
Attrition bias No serious 
inconsistency 
Serious indirectness 
(different definitions 
of exposure and 
outcome) 
Serious (imprecise 
estimates) 
Risk of 
pheochromocytoma 
during follow-up 
0-2% 
No pooled estimate due to 
heterogeneity in design and 
analysis and indirectness 
⊕ΟΟΟ 
VERY 
LOW 
 
 
 
Page 89 of 122
eje@bioscientfica.com
Manuscript submitted for review to European Journal of Endocrinology
For Review Only
Appendix Table 9: Selected drugs that may interfere with results of the 
dexamethasone test* (adapted according (69)) 
 
Drugs that accelerate dexamethasone metabolism by induction of CYP 3A4 
Phenobarbital 
Phenytoin 
Carbamazepine 
Primidone 
Rifampin 
Mitotane 
Rifapentine 
Ethosuximide 
Pioglitazone 
Drugs that impair dexamethasone metabolism by inhibition of CYP 3A4 
Aprepitant/fosaprepitant 
Itraconazole 
Ritonavir 
Fluoxetine 
Diltiazem 
Cimetidine 
Drugs that increase CBG and may falsely elevate cortisol results 
Estrogens 
Mitotane 
 
 
- * This should not be considered a complete list of potential drug interactions. 
- Data regarding CYP3A4 obtained from http://medicine.iupui.edu/flockhart/table.htm. 
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Appendix Table 10 
Comments to the Clinical Practice Guideline on the management of adrenal incidentalomas 
by invited reviewers and members of the European Society of Endocrinology (ESE) and the European Network for the Study of Adrenal Tumors 
(ENSAT), representatives of associated societies of ESE and patient representatives 
 Comments by reviewer Response to the reviewers by the authors 
Paul Stewart 
1.  Thank for you for asking me to take a look at this. What a tour de force - it is 
truly comprehensive and will undoubtedly be a great addition to the guidelines 
literature particularly in this space where the literature remains muddled. 
I offer these comments in constructive spirit - I know how hard it is to achieve 
any consensus in this area! 
1. General style. I think at 85 pages it is too long and somewhat repetitive. It is 
at times too "chatty" - I am not sure the reader needs to know the level of 
debate or disagreement within your group on certain issues - what matters is 
that you have reached an internal compromise and all authors agree to its 
content. 
We are grateful for the overall very positive feedback.  
We agree that the guidelines are rather long (and much longer than initially 
intended). We have now shortened some sections, especially the paragraphs 
with our "internal debates".   
2.  2. At times I think you make it overly complicated. "Arterial hypertension" being 
a case in point in patients with possible cortisol excess. The important issue 
here is the flow of patients through a clinical pathway - I would hope that all 
patients would have had BP measured - without which you cannot proceed to a 
PRA/PRC ratio - so why wait until the result of the Dexa test before assessing 
this? Ditto other aspects of autonomous cortisol excess - I would have thought 
a more detailed screen for degrees of Cushing's severity in this group is 
indicated - to of course include glucose and bone mass, but also myopathy, 
skin, CVS risk over and above BP (thrombosis etc). I think stratifying additional 
tests based on the degree of cortisol excess is potentially incorrect - how many 
times have we been surprised by patients with florid phenotype yet relatively 
low levels of cortisol secretion. 
We agree that the flow of the patients is very important. However, the first 
recommendation on assessment for hormone excess R.3.1 clearly states that 
EVERY patient with an adrenal incidentaloma should undergo careful clinical 
assessment (including BP measurement). However, in the spirit of your first 
comment we want to avoid lengthening the manuscript still further and would 
prefer just to refer to the "Cushing’s guidelines" for assessment of phenotype.  
We agree that phenotype and lab values sometimes do not really correlate. 
However, as soon as the patient has clinical signs of overt Cushing’s then the 
diagnostic procedure should follow the Cushing’s guidelines. We have now 
clarified this in the Reasoning to R.3.1. 
3.  3. In terms of the pathway I am now confused as to whether or not to measure 
DHAS/ DHEA (my routine practice) on screening presentation or to wait until a 
scan shows features suspicious of adrenal ca? Again I think you make this 
overly complicated. 
After reviewing the literature, the panel felt that the value of measuring 
DHEAS in all patients with adrenal incidentaloma is too limited. Thus, we 
suggested in R.3.10 (now R.3.11) measurement of sex hormones and 
precursors only in patients imaging features suggesting of ACC. However, we 
now added in R.3.11. "clinical features of ACC".  
4.   4. Size is important! Here the literature is confusing on defining a critical size 
for action or inactivity and I am afraid your guidelines muddy the water still 
further with <4 cm (R2.3) and <6cm (R4.3) being proposed as rate limiting 
indicators. What is the evidence here? With a 4cm mass can I really get away 
We fully agree that size is an important factor. Within the guidelines we 
acknowledge that the evidence for a certain cutoff for size is limited. 
However, it seemed to us important to provide guidance on this important 
aspect.  
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with no follow up imaging when earlier data suggested a 25% risk of future 
malignancy in a mass over 3cm? Figure 3 helps but I do think this section 
needs clarity. Personally I like the "arbitrary" analysis and the fact that between 
x and x (say 3-6cm) this becomes an individual decision based on risk from 
other tests.  
However, at the time of "older data", imaging methods were less 
sophisticated and the panel is confident that a homogenous lesion < 4cm with 
"benign" radiological features is really benign.   
Thus, we prefer to stick with the arbitrary cutoff of 4cm for homogenous, lipid-
rich lesions, because we believe that too much follow-up imaging does more 
harm (psychologically, financially and due to radiation exposure) than benefit.  
5.  Nonetheless giving an indicator of size whereby ALL tumours should be 
removed would be useful. Presumably you are also saying that anything over 
6cm should be an open procedure? Capsule rupture is referred to and because 
this is so critical in determining future prognosis (your own data!) I am 
personally nervous about any known ACC having a laparoscopic procedure. 
Again not clear. 
The question, whether there is a size whereby all tumors should be removed, 
was intensively discussed. However, we opted against a fixed cutoff, because 
in many patients (not only in patients with comorbidities) it might be 
reasonable not to remove even an 8 cm obvious adenoma or myelolipoma. 
Nevertheless, to make this point clearer, we have altered the wording of the 
Reasoning in R.4.2. 
 
We share your concern of capsule rupture, but we believe that the expertise 
of the surgeon is more important than the method of surgery. Thus, we have 
added in addition to R.1.1 a statement in the Reasoning of R.4.3 that an 
experienced surgeon is required for the best outcome. 
6.  5. Phaeo and primary aldo discussion is directly to other guidelines which is 
fine. 
Thanks.  
7.  6. The nice piece of work relates to "autonomous cortisol excess" and I see this 
as a real advance from the current unsatisfactory term subclinical Cushing’s. I 
really like the move to defining autonomy (versus a physiological/ 
pathophysiological activation of an endogenous HPA axis through obesity, 
diabetes, stress - all of which of course are present ++ in this group of patients) 
and then a detailed screening for phenotypic features of any cortisol excess - 
in effect defining the degree of what is likely to be "mild" Cushings. I like Figure 
2 as well - great job. The push back here which I seriously hope you take on 
board, is the definition of "autonomous". You are well aware of sensitivity and 
specificity values for the ON Dexa test - even with a cut off of 140nmol/L, 5-
10% of the NORMAL population (higher in elderly, depressed, obese patients) 
will not suppress to such a value. These patients do not have autonomy but as 
above - physiological/pathophysiological activation of the HPA axis. 
We are very grateful for this positive judgment of our efforts to replace the 
term 'subclinical Cushing’s'.  The terminology we have used was the subject 
of very lengthy debate and despite potential shortcomings, as you mention, 
we feel that it is as good or better, as any other.  We agree that a single dex 
test is not always able to prove autonomy and that false positive results might 
be an issue. However, there are no convincing results that any other test can 
solve this issue convincingly. Furthermore, addition of several other tests 
result in the so called ‘multiple testing’ problem. In this respect it is crucial that 
our guidelines state that a single mildly elevated dex test is not a proof of 
autonomous cortisol secretion, which is an informal way of saying that 
specificity is not optimal. We now modified R3.3 and R3.4 and mention 
additional biochemical tests, and have emphasized the need to have more 
than just dex tests if surgical intervention is ever considered (see below). 
 
8.  Here I do feel an ACTH measure is essential if you wish to define true 
autonomy. You also fail to mention the value (or not - but needs discussion) of 
a low DHEA/ DHAS in this context. Reading between the lines I suspect much 
debate amongst the group - but you can’t really claim "autonomy" simply on the 
ON Dexa test alone. 
Although measurement of ACTH has several limitations, we agree that ACTH 
is an important marker to define autonomy. However, in some patients 
cortisol is not only driven by ACTH. Nevertheless, it is (now) suggested in 
most patients with elevated cortisol post dex to measure plasma ACTH. 
However, the data on DHEA-S seemed to us too weak to recommend this 
test. See also comment #3.  
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Radu Mihai 
9.  Line 48 'established' is a very strong word.  Most tests give you a probability of 
malignancy rather than firmly confirming B or M 
We agree and have modified the wording.  
10.  Line 59 "the degree of cortisol excess" suggests that there would be a 
threshold over which is more likely and such a threshold is not been defined 
Later in the text we discuss this difficult issue in details, but space restrictions 
preclude it being done in the abstract. 
11.  Line 120 Do we have evidence that imaging is so reliable that biochemical 
testing for phaeo is unnecessary in some patients? 
Following comments by several reviewers we adapted this recommendation 
(see also our responses to comment #50) 
12.  Line 150 if the second scan shows no change is patient discharged from 
further followup? 
This is indeed an important point and we address this issue now in R.5.2. 
13.  Line 339 would be good to have a comment about SUV threshold that raises 
concerns for malignancy or the benefits of adrenal/liver ration as a marker of 
malignancy 
Unfortunately, current evidence for SUV threshold in incidentaloma is 
extremely poor.  We now refer to imaging meta-analysis for more detailed 
analysis of the data. 
14.  Line 546: of how many patients? And how long were the follow-up?  This information is now provided.  
15.  Line 620 This section is rather abrupt.  Until now the discussion was about 
incidentalomas and now we are dealing with confirmed ACC? 
We agree and have added a short introductory sentence.  
16.  Line 693 ‘.... when the initial assessment was normal’ Thanks, we have now clarified this.  
17.  Line 884 do these ones need further testing with 2x2 mg DXM? We have addressed this important issue of additional testing now in a 
separate recommendation R.3.4.  
18.  Line 1228 Maybe a comment about the impact of surgical expertise on the 
decision of approach and the need for those suspected as ACCs to be 
operated in a referral centre (ideally) 
In addition to the Reasoning to R.1.1, we are now referring also in the 
Reasoning to R.4.3 to this issue of “surgical volume”. 
19.  Line 1239 this leaves a gray area of having to assess worsening of 
osteoporosis (?repeat DEXA) or diabetes (?increased need for medication) or 
hypertension (increased dose/number of drugs) 
Whilst we agree with you we believe that this is a judgment call for the local 
physician and that this has to be individualized. 
20.  Line 1244 Should we have a comment that a RCT with sufficient power and 
long FU is highly desirable in this area? 
We fully agree that an RCT would be desirable and we agree with the 
reviewer that follow-up is a clinically important question, and we address 
these issues in the section on future directions.  
21.  Figure 4 : hormone excess: should NO/YES be swapped? Thanks for bringing this mistake to our attention.  
22.  Figure 4 adrenal biopsy: Here my suggestion would be to consider PET scan if 
suspicious of single adrenal metastasis - if PET excludes other metastatic 
deposits than adrenalectomy should be offered for oncological benefits.  
Thank you, we now mention PET in the legend of Figure 4.  
   
Andre Lacroix 
23.  Dear Martin 
Thank you for giving me the opportunity to review these guidelines 
These guidelines will be well received and were carefully planned. As usual, 
reaching consensus is difficult given the current level of evidence and 
difficulties to compare outcomes when no one agreed on definitions in 
particular for the “subclinical issues”. 
I suggest another terminology instead of “autonomous cortisol secretion”, e.g. 
Thank you for your positive overall judgment. We do agree that the proposed 
terminology has flaws (e.g. that autonomy is not easy to define, see also 
comments # 7, 8). However, as the concept of the dexamethasone test is to 
block pituitary ACTH secretion, we still believe that the term autonomous 
cortisol secretion is the most adequate, accepting that it is not ideal. After 
another round of intensive discussion, the panel voted against “modest or 
mild increase in cortisol secretion’, because the dex test is not really intended 
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“mild increase of cortisol”.  
At least two reasons not to use the terminology autonomous 
1.  If it was fully “autonomous”, there would not be any suppression with 
dexamethasone and in most cases of lesions secreting modest or mild 
amounts of cortisol, dex will partially suppress cortisol as low as 50 
nmol/LO 
2.  The constitutive activation of cAMP production may be true in 50% of 
overt CS cases but aberrant regulation by factors other than ACTH can 
be present and thus cortisol secretion may not be “autonomous” from 
other factors although not being regulated by ACTH 
3. Using the term modest or mild increase in cortisol production describes 
objectively the phenomenon. 
to quantify “increase of cortisol secretion”. As discussed in the guideline, we 
hope that our definition will be replaced in the future - after properly 
performed prospective studies - by a more adequate definition.  
24.  R.2.2   “We recommend that all adrenal incidentalomas undergo  an  imaging  
procedure to determine if the mass is homogeneous and lipid-rich and 
therefore benign (XOOO).” Replace ‘therefore’ by ‘most probably’ 
We agree that 100% certainty is rarely achieved in medicine. However, we 
are convinced that the likelihood that a homogeneous and lipid-rich lesion is 
malignant is too low to modify the concept of this guideline, which aims, 
amongst other things, to reduce the number of patients subjected to imaging 
follow-up (and radiation exposure) 
25.  R2.3. Add: Repeat imaging at least once at one year interval for lesions > 2 
cm;  for lesions closer to 4 cms would repeat yearly to r/o progression > 1 cm 
This is a very important point and setting a cutoff in the lack of large 
prospective studies is difficult. However, we prefer to stick with the arbitrary 
cutoff of 4cm for homogenous, lipid-rich lesions, because we believe that too 
much follow-up imaging do more harm (psychologically, financially and due to 
radiation exposure) than benefit. See also comment #4 
26.  R3.4 add:  for mild increase of cortisol secretion, this remains to be determined See our response to comment #23.  
27.  Reasoning R 2.3: Line 784 If a lesion is stable at 4 cms, I agree. If a 3.9 cm 
benign appearing nodule is present for the first time, it is very bold to 
recommend not to very again at least 6-12 months. What should be the lowest 
size without any further imaging ? < 2cms ?? Prudent to verify at least once. 
See our response to comment #25. 
28.  Reasoning R. 3.3. Line 934 add ‘and late night salivary cortisol’ Whilst the data on the value of late-night salivary cortisol in incidentaloma 
patients are conflicting, we have now added this.  
29.  Legend Figure 2 add ‘late night salivary cortisol’ Done.  
30.  Reasoning R3.6 To limit to plain X ray and detection of vertebral fractures is 
minimalist; for me this is a clear indication to do bone mineral density and not 
to wait for reaching the stage of vertebral fractures. 
This is a controversial issue and it is not obvious which method is the best to 
assess the risk for vertebral (micro-) factures in patients with cortisol excess. 
Therefore, we prefer to leave the decision on method to use up to the local 
physician.  
31.  R.3.7   modify to: In all patients considered for surgery, suppression of ACTH 
by of level of cortisol excess should be confirmed in order to recommend 
coverage with glucocorticoid replacement until recovery of HPA axis. 
As discussed above that ACTH is in theory the best marker, however, it has 
several flaws and there is evidence that even patients with normal plasma 
ACTH can experience postoperative adrenal insufficiency (Eller-Vainicher C 
Eur J Endocrinol. 2010 163(6):925-35). This has now been mentioned in the 
Reasoning of R.4.6.  
32.  Reasoning R.3.7. line 1021. Instead of ‘ACTH-independency’ write See above 
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‘suppression of HPA axis’ 
33.  R3.9 add ‘or with hypokalemia’ We have now added hypokalemia.  
34.  R.4.3. Impossible to reach consensus here I agree. In our center in suspicious 
lesions ie non homogeneous, 5 cms even without invasion we do PETCT 
before surgery; if very high SUV we do open oncologic adrenalectomy even 
without evidence of invasion even if we have very experienced minimally 
invasive surgeons. 
We are certainly aware that this is a controversial issue. However, we 
discussed this in detail and decided to keep our recommendation, which is 
also in agreement with a guideline currently developed by the European 
Society of Endocrine Surgeons (manuscript just submitted).  
35.  R.4.3. add ‘If PET scan is highly suspicious of ACC, we perform  open surgery’ See response to comment # 34.  
36.  Reasoning R4.5., line 1139 I think this discussion should be part of ACC 
guideline and not adrenal incidentaloma 
We agree that this statement fits more with an ACC guideline and have 
deleted it. 
37.  Reasoning R.4.6., line 1150 
Modify: ' evidence for ‘(possible) autonomous cortisol secretion’ (post 
dexamethasone cortisol > 50 nmol/l (> 1.8 µg/dl)) even if there are no clinical 
sign of cortisol excess.' into 'evidence of suppression of ACTH below normal 
levels and mild increase of cortisol secretion even if there are no clinical sign of 
overt Cushing’ syndrome.' 
See response to comment #23.  
38.  Figure 3: Would add high suspicion of malignancy to local invasion in right box See comment # 34.  
39.  R5.1. I would recommend at least one follow-up imaging at 6-12 months in any 
lesion > 2 cms even if HU < 10 at first examination. This is already much better 
than previous guidelines, but cutting to no imaging in a 3-3.9 cm initial image is 
very provocative. How many lesions > 3 cms have cortisol < 50 post 1 mg dex 
? they need follow-up. 
See responses to comments #4 and #25 
40.  Reasoning R.5.3. add at the end '(ie cortisol < 50 nmol/L post overnight 1 mg 
dexamethasone test).' 
We have added this as suggested.  
41.  Reasoning R.5.4. Suppression of ACTH may occur without clinical signs; in 
such patients I do annual ACTH, late night salivary cortisol or repeat dex 
suppression. 
After reviewing in detail the available literature and many discussions 
amongst the panel we conclude that the evidence showing such an approach 
is beneficial is too weak to recommend this for every patient. However, we 
have adapted the legend of Figure 2 to take account of “your direction”.  
42.  R6.1.3 In BMAH even if a lesion was 7 cm with indeterminate HU as often 
found, there is no surgical indication if there is no sufficient hormone excess 
In general this is within the spirit of our guidelines. However, if the HU are 
clearly > 10 then an individualized approach seems to be appropriate.  
43.  R.6.1.4 Many of those may be BMAH cases and once again for a differed 
reason the term ACTH-independent may be inappropriate here as local ACTH 
production may be involved 
 
Thank you, we have deleted the term “ACTH-independent”.  
44.  Line 1306 add: ' unless urinary free cortisol is increased more than 3-4 fold.' Acknowledging the limitations of measurement of urinary free cortisol, we 
would not rely on this single parameter as a decision point for surgery. 
However, we agree that most patients with urinary free cortisol > 3-4 fold 
above the upper reference value frequently have signs of overt Cushing’s.  
45.  Reasoning R6.1. line 1329 add 'family screening with 1 mg dexamethasone 
test and' 
We have added this.  
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46.  R6.2.2 why MRI in adults 20-40 years of age? Cost vs justification in adults 20-
40 yo old not clear particularly if not repeater frequently. OK for p53 mutation 
carrier but not all adults.  
We added a statement to the Reasoning of R.6.2.2. 
   
Quinton, Richard 
47.  “To exclude cortisol excess, a 1-mg overnight dexamethasone suppression 
test should be performed (applying a cut-off value of serum cortisol ≤ 50 
nmol/l.” 
 Comment:  
• It is a cardinal error to extrapolate from Dexamethasone dose and Cortisol 
cut-off used for “Cushing’s screen” in patients not known to have 
adrenocortical lesions. 
• If these proposals are adopted, it could result in lots of unnecessary 
referrals for adrenal surgery being made for alleged “adrenal Cushing’s”. 
• We should remember that the DST is actually an “ACTH suppression test” 
and that, where there is autonomous adrenocortical cortisol secretion, there 
is by definition no significant circulating ACTH. 
• Therefore, unlike the situation we face when we screen patients for 
Cushing’s syndrome (all causes), there is no loss of sensitivity by using a 
higher dose of Dexamethasone in patients with adrenal incidentaloma, but 
there is a corresponding gain in diagnostic specificity. It’s a very simple 
“mind experiment” that we can all perform. 
As discussed above we agree that the dex test is not ideal. However, we are 
convinced that it is the best evaluated test for this situation. However, as 
elaborated in R.3.8 indication to surgery should never be based only on a 
single lab value or single test.  
Please see also the responses to comments #7, 8, 23.  
48.  At the Mayo clinic, Bill Young routinely by-passes the overnight low-dose DST 
and goes straight for an 8mg DST. 
We have added a short statement on the high dose dex test.  
   
Tomasz Bednarczuk 
49.  We would like to congratulate the Authors for preparing the next ESE Clinical 
Practice Guidelines entitled Management of adrenal incidentalomas 
- a European Society of Endocrinology Clinical Practice Guideline in 
collaboration with the European Network of the Studies of Adrenal Tumors. 
The guidelines represent a novel point of view and I am certain that it will be 
very useful in daily practice. Enclosed please find our suggestions. 
  
At the same time, a Polish Society of Endocrinology expert working group 
prepared: "Adrenal incidentaloma in adults - management recommendations 
by the Polish Society of Endocrinology" which are now in press in Endocrinol 
Pol (enclosed please find the manuscript; the English version is now being 
corrected). In the majority of points, the recommendations are similar, 
supporting the notion of an individualized approach to patients with AI and 
possible referral to specialized multidisciplinary centers. Unfortunately the 
Thank you for your kind words.  
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quality of evidence concerning AI is usually low and the interpretation of the 
results may be different. In some points, especially follow-up, our 
recommendations are more "old-fashioned"; and we will attempt to change it in 
the next versions. 
   
N.N. 
50.  Dear Authors of the Guidelines, 
Thank you for these novel guidelines, and congratulations to your work. 
The guidelines are sound and well written. The initial imaging phenotype (your 
figure 4) could be divided into two, noncontrast or contrast CT. We have 
(reference 172, enclosed) previously demonstrated that you don’t need to 
hormonally screen for pheo if HU of the adrenal mass is <10 on noncontrast 
CT. This really would save a lot of money and trouble. Pheos typically have an 
imaging phenotype on noncontrast CT that is above 20 HU  
  
You might wish to indicate in you figure 4, that hormonal screening for pheo is 
not needed if HU is < 10 (enclosed is a Figure on the suggested evaluation and 
follow-up that we have been using, you can pick something from it if you so 
wish). 
As pointed out by several reviewers (see comments #11, 65, 91) the data that 
demonstrate that adrenal masses with HU<10 cannot be pheos are very 
limited. Thus, we believe it is too early to recommend waiving the pheo-
specific biochemical work-up in all these patients, nevertheless, we have now 
modified R.3.9. However, we would hope that your data will be confirmed by 
other groups and that we can make a strong statement in the next version of 
this guideline.  
51.  . I also enclose a follow-up study on adrenal incindentalomas published in 
Endocr Metabolism, indexed in PuBMed  A 5-year Prospective Follow-up 
Study of Lipid-Rich Adrenal Incidentalomas: No Tumor Growth or Development 
of Hormonal Hypersecretion. Schalin-Jäntti C, Raade M, Hämäläinen E, Sane 
T.Endocrinol Metab (Seoul). 2015 Sep 10. [Epub ahead of print).  
You might wish to include the findings – as there really are not prospective but 
rather retrospective series published on adrenal incidentalomas– that small 
lipid-rich adrenal incidentalomas (2 cm or less) do not grow during a follow-up 
of 5 years, neither do they turn into cortisol hypersecreting adenomas (not 
even subclinical). We also confirmed our finding that such incidentalomas with 
a noncontrast HU < 10 really do not secrete metanephtines/normetanephrines 
(as they typically are cortical adenomas and not adrenal medulla tumours). 
We have added this reference.  
 
   
Eystein Husebye, Ansgar Heck and Anders Jørgensen (on behalf of the Norwegian Endocrine Society) 
52.  General comment and summary on imaging 
In general, we agree to most of the recommendations regarding radiological 
examinations and follow-up. On the issue of second line imaging of lesions >10 
HU we propose to present the different modalities (CT washout, MRI chemical 
shift and FDG-PET/CT) in a neutral way as reasonable alternatives. 
We have now modified the section on “second line imaging”.  
53.  Specific comments and proposal for changes 
Page 17, line 464 – 479: Paragraph on Contrast-enhanced washout CT: 
Thank you for this careful reading and bringing this typo to our attention.  
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Line 474 and 477: The “>” “greater-than sign” must be replaced by a “<” “less-
than sign”. 
54.  Washout CT is an accurate parameter for differential diagnosis between 
adenomas and non-adenomatous lesions and is an important tool in the 
characterization of lipid poor adrenal lesions as pointed out by the references 
49, 83, 89, 90. Although they do not fulfil the criteria for literature selection, the 
evidence from these and multiple other studies should be taken into 
consideration in the paragraph “reasoning” from page 27. 
It is also the clinical experience of several panel members that washout CT is 
of great value even though the literature search did not confirm this. 
However, as indicated above we have modified this section in the 
recommendations.  
55.  Reasoning for R2.4, page 27, line 806-812; 834-836 
1) It is stated that “Contrast washout CT has very limited and low quality 
evidence from studies”, but the reference “(Bancos et al., under submission)” is 
not added to the reference list and to date (9.1.2016, pubmed search) not 
available on the internet. Reference to unavailable references makes it difficult 
to follow the reasoning. 
We fully understand this concern and agreed now with the Editor in Chief of 
EJE that we will wait for the final print version of the manuscript until the 
meta-analysis is published and can be cited.  
56.  2) In the reasoning section in its present form, there is a clear preference for 
FDG-PET/CT compared to CT washout (line 834-836). To our knowledge, 
there is no large study comparing the two methods in the setting of 
incidentalomas (line 826). The two methods both suffer from limitations in rare 
case of metastases from renal cell carcinomas and lymphomas (line: 814 and 
815, ref. 161-163). In the present draft, the disadvantages of washout CT are 
pinpointed (line 806-810). Nevertheless, the combined results from the 
underlying studies (ref. 48, 89) can be interpreted differently, thus resulting in a 
lower proportion of malignant lesions falsely classified as benign. For further 
explanation, please see appendix. Further, FDG-PET/CT suffers from 
limitations in a similar disease spectrum as washout CT. In case of the most 
common cancers, washout CT performs with high accuracy (ref. 49, 83, 89). 
With the present evidence, no superiority of FDG-PET/CT can be claimed. 
We have modified this section of the recommendations.  
57.  3) Even if FDG-PET/CT may be demonstrated to perform better than washout 
CT in the future, the limited number of scanners, waiting time and the costs per 
scan have to be acknowledged. The present guideline draft may lead to a shift 
of valuable resources towards investigation of a what will mostly turn out to be 
lipid poor adenomas in a healthy population. 
See above.  
58.  Taken together we propose to include the wash out CT into the algorithm as a 
second line modality in lipid poor rich lesions in line with FDG-PET/CT.  
We propose therefore to specify R 2.4 as highlighted:  
R.2.4 If the adrenal mass is indeterminate on non-contrast CT and the 
results of the hormonal work-up do not indicate significant hormone 
excess, there are three options that should be considered by a 
multidisciplinary team considering the patient’s clinical context: 
immediate additional imaging (washout CT, chemical shift MRI or FDG-
We agree with you and have modified this section.  
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PET/CT), interval imaging in 6 to 12 months (non-contrast CT (or 
MRI)), or surgery without further delay. 
Further, we propose to present the modalities without highlighting the panels 
preference (line 834 and 835), but rather as equal second line imaging 
methods as indicated in table 4.  
59.  We would like to comment on the accumulated numbers from reference 48 and 
89 (line 806-810). It is stated “that approximately 5/63 malignant lesions 
(especially lymphoma and metastases), were falsely characterized as 'benign" 
on contrast washout CT (48, 89)”. 
In reference 48 (Caoili et al., 2002), 3 of 36 lesions were classified as “benign” 
by washout criteria although they were non-benign lesions. These three lesions 
were: 
- one pheochromocytoma,  
- one adrenocortical carcinoma and  
- one renal cell carcinoma.  
Following good clinical endocrine routine practice and the present guideline 
draft, far more pheochmromocytomas would have been identified by screening 
with metanephrines (R3.8 and R6.3.1). More than half of adrenocortical 
carcinomas would be identified by measurement of sex hormones and steroid 
precursors (R.3.10; l.1048).  
In the setting of cancer follow up of known renal cell carcinomas, CT washout 
is not recommended (ref. 75) and in the setting of an incidentaloma, a renal or 
hepatic carcinoma most probably would have been discovered by the initial CT 
exam. 
Thus, only one non secreting adrenocortical carcinoma would not have been 
identified correctly in an incidentaloma setting, reducing the number of falsely 
identified benign lesions to 1/34 and not 3/36. 
In the other study (ref. 89) 2 of 24 non benign lesions were classified as 
benign, one patient with lymphoma and one with a metastasis of a colon 
cancer. Lymphomas usually have manifestations that would be identified by 
additional radiological features in the setting of incidentalomas.  
Thus following the present guidelines and not only isolated CT findings, the 
total combined number of lesions falsely classified as benign would not be 
5/63, but 2 of 58 patients in these two publications taken together (ref. 48 and 
89).  
We have adapted now the Reasoning of R.2.4. 
 
60.  General comment and summary on assessment for hormone excess 
We agree to most of the recommendations for assessing hormone excess and 
follow-up, and we also support the use of the term ‘autonomous cortisol 
secretion’. However, we have some comments regarding taking 1-mg 
overnight dexamethasone suppression test in every patient. 
We appreciate this positive judgment.  
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61.  Specific comments and proposal for changes 
Page 3, l ine 96-97: Paragraph on Assessment for hormone excess 
The current literature on the effect of adrenalectomy for patients with 
‘autonomous cortisol secretion’ is of low quality and hard to interpret, as 
described in the draft. Randomized studies comprising hard endpoints are 
lacking. Results from several studies are expected during the coming two 
years.  
Generally endocrine testing is indicated when the patient has symptoms or 
findings which may indicate an endocrine disease for which there is 
documented therapy, and where the test result   directly impacts the therapy, 
or further testing. ‘Screening tests’ in populations with low pretest probability of 
a disease should be avoided, considering that this leads to a high number of 
false positive test results.  
Figure 1 illustrates this principle exemplified with aldosteron/renin ratio, 
metanephrins and sex-hormones and steroid precursors. We suggest that the 
same principle should be applied to ‘autonomous cortisol secretion’. If the 
patient has hypertension and/or diabetes mellitus, the physician finds no 
contraindication for adrenalectomy, and the patient is interested in such a 
therapy based on today’s knowledge, ACTH should be measured. If ACTH is 
low, a 1-mg overnight dexamethasone suppression test should be performed 
and surveillance or operation discussed with the patient on an individual basis. 
Patients with symptoms of overt Cushing’s syndrome should be assessed and 
treated according to established guidelines. 
We propose therefore to change R 3.2 as highlighted:  
We suggest that the following patients with adrenal incidentalomas 
undergo a 1-mg overnight dexamethasone suppression test; patients 
with hypertension and/or diabetes mellitus and low ACTH where the 
physician and the patient find that the advantages of adrenalectomy 
outweigh the disadvantages if ‘(possible) autonomous cortisol 
secretion’ is documented (XXOO). 
If recommendation R.3.2 is changed as suggested other points and flowcharts 
leading up to the recommendation should be changed accordingly.  
According to the literature search and our clinical experience the pre-test 
probability of 'autonomous cortisol secretion' in patients with adrenal 
incidentaloma is NOT low (approximately 10%), which is the reason behind 
the screening proposal.  
Furthermore, we do see major limitations of measuring ACTH (see also 
comments #8, 23) and decided after another intensive discussion to stick with 
the dex test as first step of the work-up.  
   
Regis Cohen 
62.  This work is original, clear, well-constructed and well referenced. 
Congratulations. 
If I can afford some suggestions: 
I was surprised that the work does not address the orientations depending on 
the size nor presents the interests of the adrenal catheterization in primary 
hyperaldosteronism Size Malignancy risk seems increased with size. 
We thank you for this very positive feedback.  
The reason we did not discuss adrenal venous sampling is just the fact that 
this is covered by guidelines on primary hyperaldosteronism and therefore 
out of the scope of our guideline. 
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Eventhougth there may be a bias that higher sizes are more often operated. 
Likewise some have mentioned a higher prevalence of silent (or not) 
pheochromocytoma and cortisolic adenoma in larger lesions (>3 cm). 
Conversely adenomas producing aldosterone are smaller.  
  
Ambrosi, B., Peverelli, S., Passini, E., Re, T., Ferrario, R., Colombo, P., ... & 
Faglia, G. (1995). Abnormalities of endocrine function in patients with clinically" 
silent" adrenal masses. European Journal of Endocrinology, 132(4), 422-428. 
  
adrenal catheterization in primary hyperaldosteronism Young, W. F., Stanson, 
A. W., Thompson, G. B., Grant, C. S., Farley, D. R., & van Heerden, J. A. 
(2004). Role for adrenal venous sampling in primary aldosteronism. Surgery, 
136(6), 1227-1235. 
   
Michiel Kerstens, Edward Buitenwerf, Peter Bisschop 
63.  The members of the guideline development group are to be commended for 
their extensive work in preparing an ESE guideline on the management of 
adrenal incidentalomas.  A daunting task, for the quality of the currently 
available literature on this subject is rather poor. Nearly all studies are 
retrospective in design and are difficult to compare as a result of heterogeneity 
in size and composition of populations examined, methods applied and length 
of observation.  Thus, it is often not possible to make firm recommendations.  
We would like to add the following comments: 
Thanks for your positive judgment.  
64.  R. 2.4  The recommended interval of 6-12 months for a repeat CT/MRI in case 
of an indeterminate adrenal mass is rather long. Purpose of this repeat imaging 
is to detect a malignant adrenal lesion such as an ACC. These are almost 
invariably characterized by a rapid growth within months, as the authors also 
have stated (line 1187-1189). Therefore, a shorter interval (e.g. 4-6 months) is 
likely to be more appropriate in this case.    
We agree that a delayed imaging might lead to delayed diagnosis of an 
aggressive ACC. However, in our experience the likelihood of a very 
aggressive ACC that is small at the primary diagnosis and without clear 
radiological signs of malignancy is very low. We are more afraid of missing 
one of these slowly growing ACCs by imaging too early. However, we 
certainly would like to avoid a third or even fourth (unnecessary) imaging. 
Thus, we believe that the interval of 6-12 months is a good compromise, 
which allows the treating physician to choose the most suitable interval. 
65.  R.3.8.  It is recommended that measurement of metanephrines should not be 
performed in case of an adrenal lesion with imaging criteria of an adenoma. 
The authors refer to a single retrospective study by Sane et al. , containing 
only 9 patients with a pheochromocytoma. To our opinion, this is a quite a 
weak base for such a relatively strong recommendation. Moreover, intracellular 
fat-containing pheochromocytomas resulting in attenuation values of less than 
10 HU similar to adenomas have been reported (Blake et al. AJR 2003; 
181:1663–1668). 
Following this and the comments of several reviewers (see also #11, 50 and 
91), we discussed this issue once more and have now modified R.3.8. 
slightly.  
66.  R.3.10 We agree that the analysis of a comprehensive urinary steroid profile We added this reference.  
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measured by GC-MS or LC-MS seems to be a promising new tool to 
discriminate benign form malignant adrenocortical tumors. We would 
appreciate if a recent paper on this subject from our group would be added as 
a reference ( Kerkhofs et al. Horm Cancer. 2015 Aug;6(4):168-75). We found a 
sensitivity of 100% and a specificity of 99% for detecting ACC in a group of 152 
patients evaluated for an adrenal mass.  
67.  Minor detail: line 763 - …(5%) were malignant (false positives),…. This should 
be false negatives. 
Thank you for your comment. We had now fully modified the imaging section 
and refer to the imaging-meta-analysis on incidentalomas. 
   
Anna Kasperlk-Zaluska 
68.  I studied carefully your Guidelines on Adrenal Incidentaloma I have in my 
material about 2700 such cases.  My last international analysis was published 
in 2014 (ICE/ENDO 2014, June 21-24, Chicag ) as poster Board Sat-0806, 
entitled Malignant Adrenal Incidentaloma - Is It a Tumor of Old Peopl? a 
Clinical Analysis  of a Group of 2666 Patients Observed at aSingle 
Endocrinological Unit. My presentation on ENDO 2015 concerned treatment in 
a group of ACC patients. 
Your expertise is very useful, however I fear that it is a little too long. I accept a 
majority of your observations, well known from my practice. , However, I can't 
agree with tests Nr 133.. You suggest performing laparoscopic adrenalectomy 
in patients with unilateral adrenal masses with radiological findings suspicious 
of malignancy, but without evidence of local invasion. In my experience every 
adrenal tumor with density exceeding 25 j H (without any signs of invasion or 
hormonal hyperactivity) has to be removed by open adrenalectomy. 
In the nearest future a young woman (mother o 2 children), a patient of our 
Department (diagnosed less than 2 years ago as an "adenoma'", but with 
about 30 j H of density, without any sign of invasion) will be treated surgically 
for a disseminated adrenocortical carcinoma. It is a true tragedy. Only in 
patients with long-term congenital adrenal hyperplasia an adrenal tumor with 
high density could be considered as probably non malignant tumor. 
I know that I am a little in late with my letter, but I hope that you could hear my 
voice 
We are certainly aware of your large series of patients with adrenal 
incidentaloma. However, as pointed out to comment #34, we are convinced 
that laparoscopic surgery by an expert surgeon in a small ACC without local 
invasion is oncologically as good as open surgery. Importantly, we believe 
that the expertise of the surgeon is more important than the method of 
surgery. See also comment #5. 
   
Höfle Günter (on behalf of the Austrian Society of Endocrinology and Metabolism (ÖGES)) 
69.  I appreciate the important work of this guideline publication. 
Optionally, the publication team considers to comment on the different 
definitions of subclinical Cushings syndrome, including the CRF test. 
Furthermore, as a cutoff for differentiating benign from malignant tumors by 
non-contrast CT some specialists simultaneously are aware of a more specific 
cutoff of 18 HU. 
Thank you for your comments. 
The available evidence in the literature using the cutoff of 10 HU is much 
stronger than on 18 HU. 
We now refer to the imaging meta-analysis to illustrate this issue. 
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I discussed the manuscript with an expert team in Austria (ÖGES board); and 
no further comments were made. 
   
Maria Candida 
70.  Abstract lines 42 -46 
Other questions about adrenal incidentaloma  
1) The lesion is in adrenal gland? 
2) Hormone production is related to the metabolic syndrome, adrenergic 
syndrome? 
3) Is there the possibility to analyze  previous exams by any other indication (to 
evaluate the temporal evolution of  the adrenal lesion). 
We agree with you that these questions should be addressed during follow-
up. However, due to space restriction we cannot address all possible issues 
in the Abstract.  
71.  Line 49 - To exclude autonomy of cortisol production, a 1-mg overnight 
dexamethasone suppression test should be performed (applying a cutoff value 
of serum cortisol ≤ 50 nmol/l (1.8 μg/dl)). The analysis of dexa in serum should 
be indicate 
The analysis of dexamethasone in serum is not widely available. Therefore, 
we could not recommend this.  
72.  Line 51- For patients without clinical signs of overt Cushing's syndrome (add 
the more specific  features of Cushing’ syndrome on Table X): Proximal 
myopathy, Atrophic skin, Bruising due to minimal traumas, Facial plethora, fat 
cervical dorsal, Purplish striae> 1cm 
 
Due to space restriction we just refer to the dedicated Cushing guidelines.  
73.  Line 54 - 4) All patients with apparently benign disease and autonomous and 
possible cortisol’ secretion should be screened for arterial hypertension, type 
2 diabetes mellitus and dyslipidemia  to ensure these are appropriately treated. 
The surgery should be indicated in cases of uncontrolled metabolic syndrome 
in this group of patients. = R3.5 line 108 
The association with dyslipidemia is less proven, although biologically 
plausible. We discuss this in the Reasoning of the new recommendation 
R.3.6.  
74.  Bone densitometrie should aldo be indicated See response to comment #30.  
75.  Line 82 R 2.3 We suggest that if the non-contrast CT is consistent with a 
benign adrenal (UH < 10 ??) mass < 4 cm no further imaging is required 
(XOOO). 
Thanks, we added this clarification.  
76.  Line 98 R 3.3 We suggest in selected cases measured the serum 
dexamethasone  
See comment #71.  
77.  Line 235 The frequency refers to US CT MRI exams?? Most of these imaging studies were CT studies, but some also MRI and other 
techniques.  
78.  Line 239 In childhood, adrenal incidentalomas are extremely rare maybe bias 
because this group did not do frequently image exame? 
 
We agree that there might be some bias, but as incidentalomas are defined 
by incidental findings by imaging and this is just less frequently done in 
children, we feel that the statement remains correct. 
79.  Line 262 term “‘autonomous cortisol secretion’” in the context of an adrenal 
incidentaloma throughout the guideline text (for the exact definition see chapter 
5.3).  
See also our responses to comments #8 and 23.  
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I m a bit afraid with this term Autonomous cortisol secretion because this 
sounds ACTH-independent influence to produce cortisol but the majority of 
cases the ACTH is not suppressed in plasm so I suggest  Partial Autonomous 
cortisol secretion. 
80.  Line 340 I suggest add the refe and comment that PETCT  
PMAH, a benign adrenal disease, may exhibit an intense 18F-FDG uptake on 
a PET/CT and should therefore be considered in the differential diagnosis of 
adrenal lesions with increased 18F-FDG activity, such as carcinomas and 
metastases. 
(18)F-FDG-PET/CT imaging of ACTH-independent macronodular 
adrenocortical hyperplasia (AIMAH) demonstrating increased (18)F-FDG 
uptake. 
Alencar GA, Fragoso MC, Yamaga LY, Lerario AM, Mendonca BB.J Clin 
Endocrinol Metab. 2011 Nov;96(11):3300-1. doi: 10.1210/jc.2011-1397. No 
abstract available.PMID: 22058378 
High 18F-FDG uptake in PMAH correlated with normal expression of Glut1, 
HK1, HK2, and HK3.Cavalcante IP, Zerbini MC, Alencar GA, Mariani BP, 
Buchpiguel CA, Almeida MQ, Mendonca BB, Fragoso MC.Acta Radiol. 2015 
Mar 11. pii: 0284185115575195. [Epub ahead of print]PMID: 25766729 
Since the first publication is only case series of 3 patients and the second is 
published after our literature search, we cannot add it in the summary of the 
literature.  
81.  Line 936 Figure 2: Assessment and management of ‘autonomous cortisol 
secretion’ in patients with adrenal incidentalomas  
I also suggest to consider the age of patients to indicate surgical proceeds 
such as: 
Young before 40 yrs  ( They will be submitted for long time to partial 
autonomous cortisol secretion and each case should be analyzed – for 
indication of surgery 
Middle age  patients 40-65 yrs if the metabolic syndrome is in good control or 
not 
Old patients > 65 yrs of age Only observation – except surgical will be indicate 
only potential malignant nodule and severe metabolic syndrome. 
We agree that age is an important variable and include it in the new 
recommendation R.3.4. 
   
Jens Waldmann 
82.  General comment: Myelolipoma do not require surgery even if size is > 4 cm, 
because the diagnosis is radiologically 100% certain.  
In general we agree. However, sometimes abdominal discomfort, risk of 
hemorrhage or anxiety of the patients may suggest surgery on an 
individualized basis. Thus, we are trying to avoid being too dogmatic.  
83.  R4.1: what about asymptomatic pheos?? Do not operate on them ?? To avoid further lengthening of the guidelines, we refer to the new ENDO 
pheo guidelines (Lenders JCEM 2014).  
84.  R5.1: Metanalysis in BrJ Surg 2015 Iacobone et al. report a clear benefit of 
surgical treatment of subclinical Cushing!! 
Although this meta-analysis was published after our literature search, we 
reviewed this manuscript in detail.  Careful examination of the data therein 
reveals large confidence intervals precluding reliance on the data to make 
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strong recommendations.  
 
The study from Iacobone 2012 was added to our evidence tables  
85.  R6.2.1:why not adrenalectomy in the first place? No harm but potential benefit Surgery as many other procedures comes always with some risk, although 
the risk might be very low as in laparascopic procedures.. Therefore, we do 
not want to suggest surgery for all young patients. Furthermore, we believe 
the first statements of the sections should give enough guidance.  
86.  R6.3.5: Should adrenalectomy not be an option too? (as alternative to biopsy) We added a statement in the Reasoning of R.6.3.5 and the Legends of 
Figure 4.  
87.  Figure 2: Don't you think there are effects of the Cortisol secretion which 
cannot be monitored before it harms the patient. Is it not the first duty to 
prevent the disease rather than to treat it when already symptoms are present? 
Just a general comment. 
Whilst this may be true, it is speculative, and without data to support a 
recommendation. It highlights the room to address important clinical 
questions in well-designed studies. 
   
Anne-Paule Gimenez-Roqueplo 
88.  Just on the line ... Congratulations for your gorgeous work. I fully agree with R 
3.8. 
Minor comments: I suggest that you use "hypertension" or "elevated blood 
pressure" rather than "arterial hypertension" within all the text. Several times, 
you talk about hypertension without definition. It would be worth adding the 
current definition of hypertension (blood pressure >= 140/90mmHg) in the text. 
Thanks 
We have now used 'hypertension' throughout the text. However, since there 
are several slightly different definitions on hypertension are used in the 
different countries, we abstain from a definition, which would have to been 
explained. 
   
Maurizio Iacobone 
89.  I would congratulate with you and all the panelists for the terrific effort in 
preparing these guidelines and for the result: I think that it’ll be a cornerstone 
for clinical practice in the next years. However, I think that some points need to 
be clarified: 
1) On a methodological point of view, literature search has been performed 
separately for each question (see line 424-426; for some question literature 
search stopped at July 2014, for other it included more recent papers (and 
even unpublished paper). Since these guidelines will be published in 2016, and 
since some relevant article, systematic review and metanalysis have been 
recently published, my suggestion is to use a more recent deadline in order to 
allow the inclusion of such papers. I’m sure that it’ll not change the final 
recommendation of the panel, but might increase the evidence for some 
recommendations. For the same reason I would offer to the panel 2 of my 
references (a very recent systematic review - 2015 and a 2012 original paper) 
focusing on the role of adrenalectomy in “subclinical Hypercortisolism”, that 
have not been included and may be of some interest:  
- Iacobone M, Citton M, Scarpa M, Viel G, Boscaro M, Nitti D. Systematic 
Thanks a lot for this very positive feedback.  
 
 
 
This is an important point of discussion. For a stand-alone review it is a 
reasonable option to update the search and adapt the paper if necessary. 
Updating the search and review process for a guideline poses greater 
hurdles. For guideline panels to come to recommendations it needs a proper 
systematic review and the panel needs to discuss the results of such a review 
in a face-to-face meeting. Updating the search would in principle mean to re-
open the whole process. We decided not to do this, also because guidelines 
will not be set in stone, as in a few years we hope to update the guidelines 
and thus the search.  
 
Thanks for pointing to the study form Iacobone 2012. The study was added to 
our evidence tables as this study was published before the search date. 
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review of surgical treatment of subclinical Cushing's syndrome. Br J Surg. 2015 
Mar;102(4):318-30. doi: 10.1002/bjs.9742.  
- Iacobone M, Citton M, Viel G, Boetto R, Bonadio I, Mondi I, Tropea S, Nitti D, 
Favia G. Adrenalectomy may improve cardiovascular and metabolic 
impairment and ameliorate quality of life in patients with adrenal 
incidentalomas and subclinical Cushing's syndrome. Surgery. 2012 Dec;152 
(6):991-7. doi: 10.1016/j.surg.2012.08.054. 
90.  2)The Recommendation 3.8 recommend metanephrines measurement unless 
imaging clearly indicate a adenoma. In my personal opinion, this is based on a 
very low evidence. Small pheo may sometimes appear as adenoma at 
unenhanced CT ; in this condition, the lack of metanephrine measurements 
may lead to miss the diagnosis of pheo; in case of these patients will undergo 
surgery the consequences may be dangerous and life-treating. Thus, in my 
opinion Measurements should be systematically performed independently by 
radiological aspect (consider also that imaging may also be very subjective!) 
We agree. Please see our response to comment #65.  
91.  3)Finally, just a minor point concerning some typos: in references n° 38, 44, 
132 the list of the authors is incorrect or redundant. Here you’ll find the correct 
references 
 
38 - Di Dalmazi G, Vicennati V, Rinaldi E, Morselli-Labate AM, Giampalma E, 
Mosconi C, Pagotto U, Pasquali R. Progressively increased patterns of 
subclinical cortisol hypersecretion in adrenal incidentalomas differently predict 
major metabolic and cardiovascular outcomes: a large crosssectional study. 
Eur J Endocrinol. 2012 Apr;166(4):669-77. doi: 10.1530/EJE-11-1039. Epub 
2012 Jan 20. 
44 -Chiodini I, Morelli V, Salcuni AS, Eller-Vainicher C, Torlontano M, Coletti F, 
Iorio L, Cuttitta A, Ambrosio A, Vicentini L, Pellegrini F, Copetti M, Beck-
Peccoz P, Arosio M, Ambrosi B, Trischitta V, Scillitani A. Beneficial metabolic 
effects of prompt surgical treatment in patients with an adrenal incidentaloma 
causing biochemical hypercortisolism. Journal of Clinical Endocrinology & 
Metabolism 2010 95 2736-2745 
132 - Di Dalmazi G, Vicennati V, Garelli S, Casadio E, Rinaldi E, Giampalma 
E, Mosconi C, Golfieri R, Paccapelo A, Pagotto U, Pasquali R. Cardiovascular 
events and mortality in patients with adrenal incidentalomas that are either 
non-secreting or associated with intermediate phenotype or subclinical 
Cushing's syndrome: a 15-year retrospective study. Lancet Diabetes 
Endocrinol. 2014 May;2(5):396-405. doi: 10.1016/S2213-8587(13)70211-0. 
Epub 2014 Jan 29. 
Thank you for bringing these errors of the reference software to our attention.  
   
Tomáš Zelinka 
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92.  I have just only a very short comment to the Adrenal Incidentaloma Guidelines: 
- line 816-816 - pheochromocytoma is not always a benign tumor and so I 
would recommend to use for pheochromocytoma "apparently benign" 
We agree and have added this. 
   
G. P. Piaditis 
93.  1. Reading the text, the impression I obtained was that cortisol (F) is the o  
important hormone secreted by the incidentalomas and it should be conside  
as the main hormone responsible for any harmful effect of incidentalomas  
peripheral tissues. Aldosterone (ALD) secretion has virtually ignored. This  
probably related to the fact that the autonomous ALD secretion (AAS)  
incidentalomas, compared to autonomous cortisol secretion (ACS), is conside  
a rare disorder. However, this is a long lasting misleading impression, which  
directly related to the inappropriate procedure followed so far for the diagnosis  
AAS. The LDDST is usually used for the diagnosis of ACS, which is a diagnos  
test suppressive of CRH-ACTH-F axis. On the contrary the diagnosis of AAS  
based on the calculation initially of the basal ALD/RENIN ratio, which is a sim  
screening test, indicative, non-diagnostic of AAS, and if it is abnormal only the   
diagnostic of AAS saline loading test is performed, aiming to suppress the Ren
Angiotensine-Aldosterone System (RAAS). This process is based on  
assumption that the basal ALD/RENIN ratio has 100% sensitivity. However, the  
are strong evidences that this is not true, as recent studies using a diagnostic  
AAS saline-loading test from the beginning of investigation, not after a screen  
test, in unselected hypertensive patients with an adrenal incidentaloma reve  
that: a. The sensitivity of basal ALD/RENIN ratio is low and therefore A  
remains undiagnosed in a significant number of patients with incidentalomas.  
The prevalence of AAS in incidentalomas is similar (36%) to ACS, particularly  
patients with arterial hypertension, much higher than previously believed. 
2. The observed AAS in hypertensive patients with an incidentaloma,  
contrast to cortisol, is positively correlated with systolic/diastolic blood press  
and 24h urinary K + concentrations, whereas is negatively correlated with ser  
K+ levels. These data suggest that the AAS may be one of the main causes  
arterial hypertension in patients with incidentalomas. This is further supported  
the impressive blood pressure response to specific anti-hypertensive treatm  
with an ALD receptor blocker. These data suggest that ALD secretion  
incidentalomas is a major harmful factor which cannot be ignored by offic  
guideline. 
3. The official guideline recommends the calculation of basal ALD/REN  
ratio for the investigation of ALD secretion in incidentalomas, which however  
completely inadequate. I think that the use of a diagnostic saline loading t  
should be performed in those cases where incidentalomas and arte  
Thank you for your interesting comment. However, we suggest that these 
aspects be considered in the next version of the guidelines, when more 
groups have confirmed your results.  
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hypertension co-exist. 
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Zografos, Gregory Kaltsas, George Chrousos  and George Piaditis.  Eur J C  
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Jeanette Wahlberg (Swedish Society of Endocrinology) 
94.  Two suggestions for consideration from The Swedish Society of Endocrinology 
1)      According to the suggested guidelines, AI with a diameter of less than 4 
cm and HU>10 can be monitored in three ways. If you choose to perform a 
control based on size we suggest the follow up to be in 6 months and not in 6-
12 months since there might be a small risk of malignancy and it is therefore 
better to find this within 6 rather than 12 months. 
See response to comment #64.  
95.  2)      Regarding the suggested term “autonomous cortisol secretion” instead of 
the established term “subclinical hypercortisolism” there are in fact some 
studies suggesting that the cortisol secretion in “subclinical hypercortisolism in 
fact might be ACTH dependent (Olsen H et al). One might therefore reconsider 
the use of this term until it is established whether there is ACTH dependence 
or not. 
 
We agree that there might be patients with ‘autonomous cortisol secretion” 
that is not completely ACTH-independent. See also comment #8.  
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Comments by two reviewers of the American Endocrine Society 
Reviewer #1 (Tobias Else) 
96.  I truly appreciate the opportunity to review these outstanding guidelines. I 
particularly appreciate the authors’ emphasis on initial work-up with only very 
selected minimal further follow-up. I also like the clarity in which these 
guidelines differentiate between hormone excess and malignancy as the major 
concerns. The authors do a very fine job in addressing the areas of uncertainty 
with regards to ‘subclinical Cushing’s ’. I feel the differentiation of possible and 
autonomous cortisol secretion (although I would prefer the term production as 
there is no active secretion in the common sense involved). The authors make 
appropriate points about specific patient populations, the young and the 
elderly. I also feel that the panel did a remarkable job in integrating the little 
data of evidence and the obvious expert opinions that were present in their 
discussions. However, I do have some concerns, which are more in the 
category of opinion rather than evidence, but should be considered when 
making guidelines regarding a condition that affects a large proportion of the 
population.  
We are very grateful for the very positive judgment and the thoughtful 
comments thereafter.  
97.  A major concern is that after initial imaging (non-con CT) still 30% of lesions (or 
at least a significant proportion) are indeterminate. Are there any estimates 
after further work-up (MRI, wash-out) on how many lesions remain 
indeterminate. Clearly a number as high as 30% for potential surgery asks for 
more work up and surgery for all lesions would be likely overtreatment on a 
population basis. In addition the point of 10HU as a cut-off is discussed and 
described quite extensively.  
We share this concern and would have loved to give clear recommendations 
about a second-line imaging method to determine these indeterminate 
masses. However, the evidence for washout CT, MRI, or FDG-PET is too 
weak to allow a strong recommendation. However, in the Reasoning of R.2.4 
we clearly express that we are “in favor to fully characterize the adrenal mass 
on imaging”.  
98.  However, the second criterion ‘homogeneity’ needs some more attention. It 
should be made clear that only homogeneous – not heterogeneous -  masses 
can be evaluated in initial non-con CT and further evaluation by MRI and wash-
out. Perhaps an approach to the definition of homogeneous would be 
appropriate. It is a terribly neglected point even in the major studies. What area 
should there be measured in an inhomogeneous or heterogeneous lesion? 
We completely agree that ‘homogeneity” is of major importance. This aspect 
was or is now mentioned in R2.2., R.2.3, and Table 4.  
We added now a widely used definition of homogeneity in the legend of Table 
4.  
99.  I do think there needs to be some mentioning and balance with regards to 
potential radiation exposure of patients with an adrenal mass in initial, detailed 
and follow-up work-up (CT & PET). Although this area is a highly speculative 
issue, on the extreme end of the discussion one might find arguments to not 
work-up any adrenal masses as the procedures, associated risks and costs 
might cause more harm on a population basis than benefit by finding the small 
amount of prevalent cancers and pheochromocytomas. Of course this is an 
argument that may not be appropriate and certainly is difficult to sustain, when 
considering the single individual patient in clinic, where physician and patient 
usually want a definitive diagnosis. A short statement about, what the risks due 
We agree that this is an important point, however, the topic of radiation safety 
seem to be beyond the scope of this guidelines. Nevertheless, we added a 
short sentence on the risk of radiation in the Reasoning of R.2.2/2.3. 
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to radiation are would be great, possibly calling for some caution and greater 
value in utilizing non-radiation techniques, such as MRI. Even though most 
studies estimating the radiation risk are extrapolations of non-medical 
exposures, there is accumulating evidence that calls for caution or at least 
makes it necessary to mention these concerns. 
100.  A Cochrane analysis to be published by some members of the committee is 
mentioned several times. As this seems to be an integral part of decision 
making and a document available to the panel members, this data should be 
included in more detail – or the publication should be awaited before referring 
to it in the guideline. The simple mentioning of an unpublished manuscript 
makes a thorough review difficult for any referee. 
See response to comment #55 
101.  I would like to emphasize the contentious point regarding homogeneity vs. 
heterogeneity of lesions. There needs to be some more definition and 
discussion. For example, it is radiology standard that wash-out criteria cannot 
be used in cases of heterogeneous masses. This is not reflected in the 
guidelines. The authors should be clear that every heterogeneous mass (with 
the exception of probably myelolipoma and some other rare entities) is 
suspicious and further work-up with MRI or wash-out CT is not helpful. I feel 
there is a gap when discussing the further work-up of indeterminate masses. I 
am missing mentioning that further MRI or CT washout evaluation is not useful 
in inhomogeneous/heterogeneous masses, which automatically fall into the 
category of indeterminate nodules. It is also interesting that with regards to the 
differentiation of homogeneous vs. heterogeneous in times of all kinds of 
measurements conducted on cross-sectional imaging, we still seem to rely on 
the eye of the beholder (or experienced radiologist). 
Despite above criticism, I agree with the vast majority of recommendations, 
feel these are very well presented, thoughtful and practical guidelines. For the 
majority of points I comment on I would simply recommend a slightly more 
detailed discussion focusing on some of the concerns. 
We agree and added such a statement in the Legends of Table 4.  
102.  P2,45 – correct sentence D) – insert ‘recommended’ Thanks, we added “indicated”.  
103.  P7, 228 & Table 1.  – The authors must address the reoccurring discrepancy 
between the incidence of ACC (probably incidence ~ 1/mio & prevalence 
~5/1mio) and the study numbers in Table 1. If one assumes even a prevalence 
of adrenal nodules of 1% and the cited 1-11% ACCs the epidemiological 
estimates for ACC and the estimates from the cited studies are at least by 10-
100 fold different. I am well aware that this is a reoccurring problem in the 
available literature and seems to be used in whatever way is favorable for 
individual citations, but at least a mentioning of this discrepancy would be 
appropriate. 
We address this issue now in the legend of Table 1 as indeed many studies 
do not reflect a random sample of patients with an adrenal incidentalomas.  
104.  P7,232 – Even by stating ‘the vast majority is benign’, in terms of applying As suggested we added the establishment of the true prevalence of ACC to 
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screening procedures, it is a huge difference, whether we aim to find the 1 in 
10, the 1 in a hundred, or the needle in a haystick … . What matters more is 
the disease of concern (ACC, pheo, malignancy) – the disease to screen for! 
Therefore I think it would be appropriate to add as a research goal at the end 
of the guidelines: to establish the true prevalence of ACC amongst 
incidentalomas. Some less biased studies, such as Song et al. (153) do not 
find any ACCs in a large number of patients. However, I understand that their 
follow-up and work-up may not entirely suffice to clearly call a lesion benign or 
malignant. 
the future research goal.  
105.  P9,289 – This means that at least 30-40% of lesions will need an additional 
imaging work-up, which can pose significant procedure associated risk and 
costs. At least a short note regarding this issue would be helpful to provide a 
balanced perspective. In addition, it would be great to openly comment on the 
challenge of further work-up and resulting numbers of indeterminate lesion 
even when employing additional work-up. 
We agree and discuss this problem e.g. in the Reasoning of R 2.4.  
106.  P16,431 – I do think it is crucial that the Cochrane manuscript is not only under 
revision, but actually published. It is difficult to review guidelines that apply very 
stringent criteria to acceptable studies, but base their conclusions on several 
occasions on a study/meta-analysis that is not available for the reviewers. It 
also looks better in the final version, if the guidelines refer to a published and 
peer-reviewed study. 
See comment #55 
107.  P16,442-451 This is confusing. If malignant disease is ‘disease positive’ then 
true positive is all lesions >10HU, meaning sensitivity would mean all malignant 
lesions are truly malignant by imaging (and not the sensitivity to identify benign 
lesions as mentioned in the text). This would have nothing to do with the 
benign lesions as mentioned in this paragraph. Seems like specificity and 
sensitivity are interchanged here due to changes in perspectives of 
presentations – review this. I get the meaning, but it’s confusing.    
This paragraph has been modified.  
108.  P16,453 It would be important to mention that any measurement of HU is truly 
only applicable to lesions with a certain degree of homogeneity and the panel 
should make a suggestion for heterogeneous lesions, in which further work-up 
by MRI or wash-out will not be helpful. 
See responses to comments #99 and 102 
109.  P16, 454 - 462 – please review if these studies truly used the cut-off of 10HU 
in truly homogeneous lesions. At least the study by Petersenn et al. analyzes 
ACCs, which all were inhomogeneous/ heterogeneous and therefore would not 
qualify for any HU analysis. In the study of Choi et al. only 68% of metastasis 
were homogeneous and would actually have qualified for further analysis. The 
Choi et al. study also is restricted to RCC and HCC metastasis, which is a fairly 
narrow spectrum and at least clear cell RCC is likely an exception as even 
native renal primary clear cell RCC can present with similar characteristics with 
We agree that in an ideal world HU should be measured only in 
homogeneous lesions. However, if the reader is aware of this issue, even 
measurement of inhomogeneous lesions might be a value.  
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regards to wash-out (and sometimes even non-contrast) characteristics. The 
inclusion of this study might lead to an underestimation of the overall value of 
wash-out studies. Does wash-out perform better for lung cancer, melanoma 
and breast cancer than for RCC? A short comment on the short-coming of the 
evidence of all imaging analysis with respect to ACCs is also necessary. 
Hardly any of the studies included ACCs in large numbers. 
110.  P17,465 – What about the studies Caoili et al Radiology 2002 and Caoili et 
AJR 2000, which both should qualify for this analysis as well (or at least the 
follow-up study, which includes the initial 112 pts) – according to the eligibility 
criteria. Why was Szolar et al Radiology 1998 excluded? I can only imagine 
that the initial scan modality was not mentioned. However, that should be a 
secondary criteria as both studies evaluate washout criteria in adrenal 
incidentalomas. 
We have had to exclude a lot of studies mainly due to failure to clearly define 
their population and due to unacceptable reference standard (histology in 
malignant tumors, appropriate imaging follow up or histology in benign 
adrenal tumors). For more information, please refer to the meta-analysis. 
111.  P18, 501-516 – It’s of course always fairly contentious to suggest one’s own 
publications (which I will do twice in this review and I apologize for that), but I 
would like to mention the study by Williams et al EJE 2014 as this study reports 
the diagnostic performance of sensitivity separately (other than mentioned in 
the paragraph ‘None of the studies reported diagnostic performance of adrenal 
biopsy in adrenocortical carcinoma separately from other malignancies’. Of 
course this study only looks at ACCs that had a biopsy and that is of course a 
shortfall.). The main message of this study is that adrenal biopsy specimen 
most often can be classified as adrenal cell specimen, but are often difficult to 
be classified as benign or malignant (which is also the main reasoning on 
P48,1434) as even adenomas show a significant degree of pleomorphism and 
other features that might predict malignancies in other tissues, but not the 
adrenal gland.  
We now refer to this study.  
112.  P18, 519-530 It is certainly a challenge to identify studies based on the same 
criteria, which ideally should be the same ones as later used in the 
recommendations (profile 3). However, the identification of studies using very 
different criteria (all of which are somewhat suggestive of hypercortisolism), is 
concerning, particularly when later defining cut-offs and making 
recommendations based on these different studies. As I actually think the 
panel does the right thing, it would be helpful to add some criticism and 
concerns to this. 
Thanks for this positive judgment.  
113.  P21,620-633. This is the second incidence of mentioning one of our own 
studies: In Else et al. JCEM 2014 we report a difference in overall survival (but 
not recurrence free survival) with a significant increased HR for death in the 
laparoscopic group of 1.6 in ~230 evaluable patients in multivariable analysis. 
This study might not have qualified for other reasons, just felt it is worthwhile 
mentioning. I think a simple practical mentioning of the greater the lesion, the 
Your study was not included, because the patient characteristics of this 
particular subgroup were not clearly available and many patients were most 
likely reported in the two studies by Miller et al..  
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more likely an ACC and the safer an open approach might be helpful. Of 
course the true challenge is not the decision for surgical approach for a known 
ACC, but the vast amount of overtreatment, when approaching all larger 
masses (which clearly are not all ACC) with open surgery. 
114.  P23,688 correct to ‘follow up for cancer’ Thanks.  
115.  P26, 748 Homogeneous is a contentious term. If there is a definition, please 
provide. If homogeneity is what homogeneity is in the eye of a trained 
radiologist this should be mentioned and defined as such. 
See comments #99 and 101.  
116.  P26, 766 correct ‘as malignant’ Thanks you.  
117.  P27, 793 This is another place where I wonder what the committee suggests 
with inhomogeneous/ heterogeneous masses, which per definition are 
indeterminate. This is an important point to address. I do think this is also the 
place, where some concern with regards to radiation exposure might be 
warranted, which would be another argument for MRI. I do think it would be 
concerning to consider wash-out or FDG-PET for up to the 30% of all 
incidentalomas that are indeterminate when considering estimates of 1 in 1000 
CT scans causing a fatal cancer. I am not trying to argue against any of the 
recommendations, I simply think this concern has to be mentioned. 
A practical example – in application of the guidelines, what would be the next 
step for a heterogeneous lesion of 3cm (with HU majority of 9HU, but areas of 
2HU and areas of 40HU)? I doubt the right answer would be MRI or washout 
CT, which are only helpful in homogeneous lesions. I guess follow-up, surgery 
or PET would be viable options – although none is perfect. 
And to your example: The decision on such a lesion can only be made in the 
context of this patient (age, co-morbidity, patients preference etc.), and 
repeat follow up imaging if appropriate. 
118.  P29, 857 … risk of tumor dissemination … I agree that this is a risk, but really 
only a theoretical one. It truly has to my knowledge only been described in 1 
case of ACC, which was a patient with a transhepatic approach, which likely 
has a much higher seeding potential – this patient was actually cured after 
surgery for the track metastasis. All other reports are about metastatic lesions, 
where even tumor spread does not alter stage and in which the adrenal gland 
might not have been the best place for biopsy to begin with 
We agree and add now your reference Williams et al.  
119.  P30,870 correct … rapidly developing … Modified as suggested.  
120.  P31,912 correct – delete was  Thank you - changed.  
121.  P34,999-1022. I think it would be worthwhile to mention ‘patient preference’ in 
this paragraph as an influencing factor. I don’t see patient preference 
mentioned anywhere, but taken that all evidence is x0000 or xx000 a patient 
opinion is a considerable factor. 
We fully agree and we refer to 'patient preference' as important factor several 
times (e.g. Abstract, R.3.8, R.6.1.4) 
122.  P34,1028-1034. The cited study (170) only holds ~2/21 pts with completely 
normal metanephrines/ catecholamines – that would make 10% rather than 
25%. Normotensive pheochromocytomas may be clinically silent, but not 
biochemically silent – most tumors in (170,171) had biochemical metanephrine 
We have shortened this section, but we still mention that normotensive pheo 
might lead to trouble during surgery.  
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or normetanephrine production, simply no hypertension. I think it is important to 
point out that for patients with incidentalomas that have imaging characteristics 
of a pheochromocytoma any elevation of metanephrines is concerning (no 
usual rule of 2 or 4 fold – too high of a pretest probability). However, it is 
probably ok to not assume a pheochromocytoma in patients with completely 
normal metanephrines – otherwise we would have to block everybody with 
anything that could be a pheochromocytoma that does not produce 
metanephrines. But probably a;; patients with any metanephrine elevation 
should be considered for further presurgical work-up or blockade. 
123.  P34,1037-1041 – What about hypokalemia? I would suggest to consider 
aldo/renin also in patients with hypokalemia.  
We agree, and have added hypokalemia.  
124.  P35,1058 I would consider adding the citation of Kerkhofs et al Hormones & 
Cancer 2015  
Done.  
125.  P37, 1107-1138 Is there value in suggesting a resection of large adrenal 
masses by an experienced endocrine/adrenal surgeon?  
We agree and add such a statement now to the Reasoning to R.4.3-5. 
126.  P41, 1203-1206. In both studies (179,180) probably less than 50% of tumors 
would have shown growth over the course of 6-12 months. These studies are 
the only studies evaluating the growth of lesions prior to the diagnosis of ACC. 
It would be great if there was evidence suggesting that ACCs ‘usually grow 
very fast’, however I do not think there is any published evidence, particularly 
for the early stages. Both studies included all patients identifiable with a prior 
adrenal lesion in two large cohorts. I think the panel’s argument is very 
acceptable, when talking about large lesions, but both studies included fairly 
small lesion preceding the diagnosis of ACC, most of them with indeterminate 
characteristics.  I do think a recommendation for repeat imaging and follow-up 
should be more detailed. My take would be the following: We decided on the 
recommendation of 6-12 months despite published evidence that this will likely 
miss a considerable amount of ACCs weighing overall benefit (diagnosis of 
ACC) against risks (XRT induced cancers) and costs. Otherwise – what would 
is the support for the panel’s recommendation of the 6-12 month 
recommendation? 
We are pleased with your assessment which is completely in line with our 
own. We have clarified further the procedure during follow-up in Reasoning to 
R.5.2.  
127.  P43,1274-1289. It might be worthwhile to suggest measuring 17OHP in the 
morning. 
We agree that this would be ideal. However, in CAH or ACC, 17OH 
progesterone is usually highly elevated (beyond any diurnal rhythm).  
128.  P45,1328. The panel states to consider ARMC5 testing – what does that 
provide for further clinical care? As there is currently no consensus or benefit 
for a patient that is ARMC5 positive vs. negative nor is there a real established 
advantage for prospective surveillance of ARMC5 mutation carriers, I would 
abstain from suggesting any genetic testing. If kept, I would recommend 
adding a sentence, that genetic testing should only be conducted after careful 
genetic counseling. However, the panel never mentions that genetic testing for 
Thanks for these kind words. We agree with you and have deleted the 
genetic testing comment in this context.  
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patients with pheochromocytoma should be recommended, where it is much 
more important. I would suggest staying away from any genetic 
recommendation. The guidelines are great in keeping their topic focused (not 
like a lot of other guidelines that overstep their territory). Therefore I would 
keep the guidelines as beautiful as they are and keep the genetics aspect out 
of it. 
   
Comments by two reviewers of the American Endocrine Society 
Reviewer #2 
129.  Overall, it looks well done with very good table and figure illustrations that are 
important for readers and clinicians. 
 Well, in general, I think the Adrenal Incidentaloma guideline is well written. 
There are a few typographical errors I will not comment on. 
Comment 1: 
page 34: in addition to reference 170 and 171 regarding “normotensive” 
pheochromocytoma, I suggest to also consider these references, 
acknowledging that “small” (< 1 cm size) pheochromoctyomas and those in 
hereditary syndromes such as von Hippel Lindau syndrome, may not 
“oversecrete” (cutoff threshold for plasma free metanephrines)  
1. Walther, M.M., R. Reiter, H.R. Keiser, P.L. Choyke, D. Venzon, K. 
Hurley, J.R. Gnarra, J.C. Reynolds, G.M. Glenn, B. Zbar, and 
W.M. Linehan, Clinical and genetic characterization of 
pheochromocytoma in von Hippel-Lindau families: comparison 
with sporadic pheochromocytoma gives insight into natural history 
of pheochromocytoma. J Urol, 1999. 162(3 Pt 1): p. 659-64. 
[PubMed: 10458336] 
2. Weisbrod, A.B., M. Kitano, K. Gesuwan, C. Millo, P. Herscovitch, 
N. Nilubol, W.M. Linehan, and E. Kebebew, Clinical utility of 
functional imaging with 18F-FDOPA in Von Hippel-Lindau 
syndrome. J Clin Endocrinol Metab, 2012. 97(4): p. E613-7. [PMC 
free article: PMC3319180] [PubMed: 22259055] 
3. Kudva, Y.C., W.F. Young, G.B. Thompson, and e. al., Adrenal 
incidentaloma: an important component of the clinical presentation 
spectrum of benign sporadic adrenal pheochromocytoma. 
Endocrinologist, 1999. 9: p. 77-81. 
4. Motta-Ramirez, G.A., E.M. Remer, B.R. Herts, I.S. Gill, and A.H. 
Hamrahian, Comparison of CT findings in symptomatic and 
incidentally discovered pheochromocytomas. AJR Am J 
Roentgenol, 2005. 185(3): p. 684-8 
 
We are thankful for this very positive statement.  
However, we believe that the scenario in patients with known genetically 
driven disease is quite different from adrenal incidentaloma.  
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130.  Comment 2: 
Page 28/29: “…..There are no published size or volume cutoffs commonly 
agreed or with evidence base to support that they indicate growth suggestive 
of malignancy; the expert panel agreed that an increase in > 20% of the largest 
tumor diameter together with an at least 5 mm increase in this diameter should 
be considered as suspicious.” 
I suggest to include this interesting recent study, although it is done by a very 
skilled ultrasonographer (and not imaging by CT or MRI): 
Ultraschall Med. 2015 Nov 3. [Epub ahead of print] Adrenal Incidentaloma and 
Subclinical Cushing's Syndrome: A Longitudinal Follow-Up Study by 
Endoscopic Ultrasound. Collienne M1, Timmesfeld N2, Bergmann SR1, Goebel 
J1, Kann PH1. 
Abstract 
Purpose: Adrenal incidentaloma (AI) and adrenal masses in cases of 
subclinical Cushing's syndrome (SCS) initially require follow-up imaging. In this 
study we used endoscopic ultrasound (EUS) as a method for high-resolution 
imaging. The aim was to evaluate the growth rate of AI and SCS by EUS. 
Materials and Methods: This retrospective analysis included 93 out of 229 
patients with AI or SCS who were investigated longitudinally by EUS in our 
university hospital between 1997 and 2013. The longitudinal follow-up required 
at least two investigations by EUS and evaluation of endocrine function. 
Plasma renin, serum aldosterone, 24 h urinary catecholamines and 2 mg 
dexamethasone suppression test were performed. EUS was performed at 
baseline and during follow-up. Each time, the maximum diameter was 
measured. Three groups were defined: non-functioning adenomas (NFA), non-
functioning nodular hyperplasias (NFH) and SCS. Results: 86 patients had 
non-functioning masses [NFM] (59 NFA, 48 NFH) and 7 patients had SCS (10 
masses). At baseline the mean diameter was 19.4 (± 9.3) mm (NFM) and 19.6 
(± 9.2) mm (SCS). The mean follow-up period was 31.6 ± 28.7 months. The 
estimated mean growth rates per year were low: They were 0.35 mm/yr [NFA], 
0.02 mm/yr [NFH] and 0.53 mm/yr [SCS]. Furthermore, there was no malignant 
progression of any mass. Conclusion: The growth rate as determined by EUS 
was low for all tumor entities observed in this study. There was no difference in 
tumor growth between the groups. 
Thanks for bringing this interesting and very recent study to our attention. 
However, since endoscopic ultrasound is not widely available and the number 
of patients is limited, we decided not to cite this paper. 
   
Hadas Globerman (on behalf of the Israel Endocrine Society) 
131.  My comments are based on the panel's analysis. I didn't read the references. 
As the authors themselves state, the quality of the evidence is very low/low 
grade. In addition, some of the evidence is unpublished, i.e., "under 
submission". Thus, the recommendations and suggestions are not well-based.  
Thank you for these comments.  
We do not agree, however, that our guideline is in contrast to the Endocrine 
Society guidelines on the diagnosis of Cushing’s syndrome, because those 
guidelines explicitly mention that the recommended cutoff of the overnight 
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However, analysis of the literature is of value, especially if it will be used to set 
up prospective multicenter studies.  
Specific comments:  
Some recommendations may contradict the Endocrine Society Guideline 
on the diagnosis of Cushing's syndrome. According to the ESE Guideline, 
after an overnight 1 mg dexamethasone suppression test, a cortisol level of  
50-141 nmol/L, for example, should be followed only, whereas, according 
to The Endocrine Society Guideline, the result would count as 1 of 2 
abnormal tests diagnostic of Cushing's syndrome, a condition which 
requires treatment. The problem with the ESE recommendation is that in 
certain circumstances, one may miss a diagnosis of Cushing's syndrome 
including from  etiologies other than a secreting  adrenal incidentaloma, 
e.g., the patient may have Cushing's disease which may be missed and a 
non-secreting  adrenal  incidentaloma . The ESE guideline recommends 
ruling out ACTH- dependency only before adrenal surgery. I think this  
needs to be ruled out in all cases of abnormal dexamethasone 
suppression. 
1mg dex test might be not applicable to patients with adrenal incidentaloma. 
Moreover, the pre-test likelihood when testing for Cushing (you only do so in 
patients with clinical suspicion) is different from the pre-test likelihood in the 
context of an adrenal incidentaloma.   
132.  "Subclinical" Cushing's is sometimes due to cyclical cortisol secretion, and 
this may be missed with a one-time dexamethasone suppression test. It 
may be diagnosed on a repeat dexamethasone suppression test or a 24-
hour urinary free cortisol. 
The prevalence of cyclic “subclinical Cushing” is not really investigated and, 
therefore, we would like to abstain from recommendation to screen for it in an 
incidentaloma population.  
133.  In several cases, important points mentioned in the "reasoning" paragraph 
are not reflected in the recommendation itself. For example, the 
recommendation mentions "benign" imaging, whereas I think it would be 
better to specify that the term "benign" is used to mean that on adrenal CT 
the attenuation of all the lesion  is ≤10 HU. 
We agree and have modified this suggestion (e.g. R.2.3.) 
134.  Where the evidence is very low/low grade (e.g., establishing "benign" 
based on an adrenal CT), I think it would be better to err on the side of 
over-testing rather than under-testing, e.g., repeat imaging at least once 
after the initial "benign" CT.  Also, if the lesion is ≥4 cm, additional follow-
up imaging may be appropriate. Other examples are: for "indeterminate" 
incidentaloma,  (6-) 12 months until repeat imaging, seems too long an 
interval, and additional  imaging may be appropriate. 
Thank you for this comment, but we do not completely agree. As discussed in 
our response to the comments # 4 and 25 we are confident that a 
homogenous lesion < 4cm with "benign" radiological features is really benign.   
Thus, we prefer to stick with the arbitrary cutoff of 4cm for homogenous, lipid-
rich lesions, because we believe that too much follow-up imaging does more 
harm (psychologically, financially and due to radiation exposure) than benefit. 
In line with your view, for the lesions > 4cm we recommend additional follow-
up, but we conclude that the interval of 6 to 12 months is most adequate. See 
also response to comment #64 and #126. 
135.  I think the panel should reconsider recommendations that are not 
evidence-based, e.g., discuss in a multidisciplinary team, or where 
evidence is very low/low grade, e.g., recommendation against resection of 
"benign" non-functioning adrenal mass (of unspecified size). 
We are convinced that such a guideline has to provide guidance especially in 
situations in which no results from good studies are available. In this context, 
an expert opinion is not "not-evidence-based".  
136.  When stating "biopsy", I think the type of biopsy should be specified – e.g., Techniques, and routes of adrenal biopsy vary (percutaneous, ultrasound 
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needle aspiration for cytology. guided, core, FNA). 
We have tried to communicate this issue in the sentence: 
“Studies had variable population inclusion criteria, reference standards and 
biopsy techniques.” 
Data are quite poor overall and it is difficult to discern outcomes based on 
technique. Given a huge variability in above, we have decided not to go in 
much more detail than already described in the text.  
137.  "Overt" Cushing's should be defined.  Due to space restrictions we prefer to refer to the 'Cushing guidelines".  
138.  If, as the authors state, there is no evidence that a growth velocity of 5 mm 
in 6-12 months distinguishes benign from malignant, I think the panel 
should reconsider if these numbers should be included in a 
recommendation (or only mentioned in the "reasoning"). 
We did not state that there is no evidence. There is indeed no published 
evidence, however, our clinical experience says that a tumor with no growth 
in 6-12 months is extremely unlikely a malignant tumor.  
139.  In page 26 line 763, I think it should state False Negative and not False 
Positive. 
With the systematic review in press, we refer to the manuscript. This allowed 
us to significantly shorten the text.  
140.  Regarding indications for surgery, the authors might consider addressing 
the question of incidentaloma size and risk of  bleed. 
We agree that tumor size might correlate with the risk of intraoperative 
bleeding. Thus, we strongly suggest that larger tumors should be removed in 
expert centers.  
141.  Some of the recommendations are vague, e.g., "sex hormones and steroid 
precursors" (figure 1, page 25). 
We agree that a figure is only a short summary. However, in the Reasoning 
of R.3.11 we clearly specify which sex hormones and precursors we 
recommend to measure.  
142.  I think editing and proof-reading the manuscript would be of benefit. Thank you.  
   
Alicja Hubalewska-Dydejczyk 
143.  The guideline is perfectly prepared. Congratulation for this great work! 
Small remarks: 
The exact place of Contrast-enhanced washout CT in diagnostic pathway is 
not clearly explained 
Thanks a lot for this positive appraisal.  
 
We have now modified the section on 'second-line imaging'.  
144.  In section describing the PET/CT  it could be added: “18F-2-deoxy-D-glucose 
(FDG-PET/CT or FDG-PET/MR”   and “mostly combined with CT” could  be 
removed ; -  line 279  
We have added this.  
145.  In case of non-functioning begin lesion < 4 cm (adenoma, lipoma etc…) 
ultrasound examination 1 year and/or 5 years after the first evaluation could be 
considered. 
As pointed out to comment #64, we do not want to recommend regular 
imaging follow-up for obviously benign lesions. Ultrasound has the advantage 
of lack of radiation and is relative cheap, however, it is quite dependent on 
the operator's experience and patient's body composition.  
   
Marcus Quinkler (on behalf of the German Society of Endocrinology) 
146.  - R4.1 and R4.2: Due to the fact that an increasing number of surgeons is 
performing adrenal sparing surgery, the expert group should comment on 
this procedure for these specific points 
We agree that this is an increasingly debated topic. However, it is almost 
exclusively a topic for pheos and maybe aldosterone producing adenoma. 
Thus, this is clearly beyond the focus of our guidelines.  
147.  - R5.2: The sentence “We suggest surgical resection…. (in addition to at We have now clarified this section and provide clear suggestions what to do 
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least a 5mm increase in maximum diameter)…” is not clear enough. Does 
it mean increase by at least 5mm or 20% ? Please clarify. The whole 
subject is unclear: In the case that after 6 months an adrenal lesions 
shows a growth of 18% (eg 40mm to 47mm) – the expert panel would 
recommend that this is enough and the lesion should not be investigated 
again. This is a recommendation without any evidence and might oversee 
slow growing malignant tumours. A further suggestion might be: if growth is 
10% or lower in 6-12 months, then no follow-up investigation; if growth is 
10-20% in 6-12 months - an additional CT or MRI should be done after 
another 6-12 months. 
 
with lesions that grow slightly.  
148.  - The experience of diverging qualities of pathological reports on adrenal 
tumour specimen raises the question if it would be helpful that the expert 
panel gives a recommendation which aspects/parameters should be 
mentioned at least in a pathological report regarding an adrenal tumour. 
This could be done as table format.   
 
We see your point. However, detailed recommendations on pathology are 
beyond the scope of these guidelines. However, we have now included a 
short statement in the Reasoning to R.1.1. 
   
Krystallenia Alexandraki 
149.  Dear panel, 
thank you for this great job 
please find below some comments  
 lines 152-154; since we do not offer any follow-up in patients with an adrenal 
incidentaloma (AI) less than 4cm, how can we know whether new clinical signs 
of endocrine activity appear or a worsening of comorbidities? 
Thanks for your positive feedback.  
 
The available literature (although limited) suggests that the likelihood that 
new clinical symptoms appear is very low and does not justify annual follow-
up. 
150.  line 451; please add a dot at the end of the sentence. Thanks.  
151.  lines 1087-1088; since we admit that the cutoff of 4cm is arbitrary, how can we 
ask from the patients not to follow-up an adrenal lesion of 3,5cm and to follow-
up one of 4,5cm? 
 
Guidelines are not law and every physician can decide with the patient an 
individualized approach. However, we would like to give guidance and feel 
that we have provided reasonable recommendations. In line, the terminology 
is in line with the weak evidence as we mostly use ‘suggest’ and not 
‘recommend’.   
152.  1203-1205; may be it would be safer to accept this risk only after the large 
population multicenter study that the panel suggested at the end of the 
guidelines. 
 
We see your point, however, as pointed out in our response to comment #4 
follow-up imaging comes also with a downside.  
   
Pia Burman 
153.  This will be very useful guideline, congratulations! 
 Some quick questions; 
- In many hospitals a new CT scan is performed also in clearly "lipid-rich" 
Thanks you for your comments. 
 
Obvious adenomas require probably no follow-up imaging. However, many 
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adenomas if the size is above 4 cm, but this is something that you do not 
support? If so, maybe this could be mentioned?? 
patients with adrenal incidentalomas > 4 cm have undergone adrenalectomy 
in the past and the literature on follow-up of non-operated large adrenal 
incidentalomas is scarce. Thus, one follow-up imaging after 6-12 months 
might be reasonable (see also Reasoning to R.5.1). 
154.  - In my hospital some colleagues do a 2-day dexamethasone test if the 
overnight test is not normal, is this really helpful from a clinical point of view? 
We have addressed this important issue of additional testing now in a 
separate recommendation R.3.4. 
155.  - In lipid-rich rich adenomas, do metanephrines have to be checked at all? See response to comment #50.  
156.  - Recently Roche modified their serum cortisol assay that measures now 20% 
less than it used to be. How does this affect your proposed cutoffs? 
This is indeed a very important point. However, we believe that this is beyond 
the scope of these guidelines and we prefer just to keep our general word of 
caution (see section 2.4).  
   
Felix Beuschlein 
157.  Big opus 
Page 34 post-dex cutoff is given in µg/dl (<5) and once in nmol/l (<140). This 
should be standardized  
Thanks you for your comments. 
We have now standardized and provide both units.  
158.  Autonomous cortisol secretion is always in quotation marks. I would suggest to 
introduce the term once and then use without quotation mark. It looks a little bit 
you do not believe in your own terminology. Believe in yourselves :) 
We discussed this issue internally and believe that by using quotations marks 
this term is easier to recognize and, therefore, kept these.  
159.    
Rossella Libe  
160.  Thank you very much for this interesting document. 
Please see below my comment. 
Could you cited the following paper on CT density? 
Chambre C1, McMurray E1, Baudry C1, Lataud M1, Guignat L2, Gaujoux S1, 
Lahlou N1, Guibourdenche J1, Tissier F1, Sibony M1, Dousset B1, Bertagna 
X1, Bertherat J1, Legmann P1, Groussin L1"The 10 Hounsfield units 
unenhanced computed tomography attenuation threshold does not apply to 
cortisol secreting adrenocortical adenomas." Eur J Endocrinol. 2015 
Sep;173(3):325-32. doi: 10.1530/EJE-15-0036. 
Unfortunately, this paper was published after the time we stopped our 
analysis. As it did not change the recommendations nor the reasoning we 
decided not to included it, because then we would have to fulfill all requests 
for citations. 
Peter Guest 
161.  A labour of love! Very good. 
2 comments –  
1. shame the panel can’t decide whether to recommend 6 or 12 month follow-
up – obviously depends on the level of concern but this is not defined – 
size? Heterogeneity age? Actual HU? Obviously no evidence but expert  
guidance would have been good 
Thanks for your positive judgement.  
We agree that this would be desirable. We believe that we cannot 
recommend a definitive time, because the scenarios might be too 
heterogeneously. Thus, we favor an individualized approach, but we agree 
that we should provide some more guidance in the Rational; e.g. “…The 
exact timing of this imaging should be individualized. However, especially in 
cases with a low likelihood of a malignant tumor the panel favors a time 
interval of 12 months.” 
162.  2.Section 2.3 – make in clear in para 2 sentence 3 that the density suggesting 
malignancy is <10HU not just 10. Sentence 4 is clear. 
Thanks, we have adapted this.  
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N.N. Patient representative from the German ACC patient group 
163.  Recommend  and suggest  are only 2 categories of the  «advice» whereas th 
quality of evidence has 4 categories 
We decided right from the beginning that we follow the GRADE system (as 
most other clinical guidelines do) and GRADE uses these categories. The 
reason behind the apparent discrepancy between the number of quality 
categories and the two categories of advice is that there is no direct 
translation from evidence to advice. For advice many additional 
considerations come into play (costs, side-effects, value of the endpoints 
studied, preferences), not only evidence. 
164.  R.2.3 Any follow up? Hardly recommended Yes, you are right, in the group of benign tumors <4cm we recommend 
against follow-up imaging. See also our responses to comments #4 and 25.  
165.  R.2.4 I ’m missing a step by step solution. What about: 1st clarify malignancy 
by additional imaging. Depending on the  results interval imaging  or surgery 
We discussed this issue a lot, but the evidence for one of these approaches 
(including additional imaging) is just too weak to allow a clear step by step 
solution.  
166.  1mg overnight dexamethasone test or overnight 1mg dexamethasone test - Be 
consistent.  
We now use '1-mg ON dexamethasone test' throughout the text.  
167.  R.3.11  replace 'suggest' with 'recommend'  
Due to the high levels of sex hormones (testosterone) ACC was finally 
discovered in several patients (not statistical evidence, only personal 
experience from patients’ fori).  This is a very helpfully tool specially by/for 
women for the diagnosis «adrenocortical carcinoma» 
See recommendation in page 31. there you recommend, what is  of common 
sense . 
«R.3.1 We recommend that every patient with an adrenal incidentaloma 
should undergo careful assessment including clinical examination for 
symptoms and signs of adrenal hormone excess.» 
As pointed out in R.3.1 in every patient careful clinical assessment for 
hormone excess (including androgen excess) is required. However, we 
decided against the measurement of sex hormones in all patients with 
incidentaloma.  
168.  R.5.3. instead of annual follow-up, use 6-12 months We discussed this again, but believe that 'annual' is for the majority of 
patients the most suitable time interval. Of course, every physician can 
decide to do this re-assessment for cortisol excess earlier.  
169.  R.6.2.3: What is "poor general health" or "high degree of frailty"?  We agree that this terminology is vague. However, it is beyond the aim of this 
guideline to provide an exact definition.  
170.  R.6.3.2 Don’t agree. How unspecific is  a PET/CT? even when combining the 
two techniques - you only know that something is there, but not what that really  
is! 
A negative FDG-PET has a high predictive value that the lesion is benign. 
Thus, we feel comfortable to skip additional imaging in this particular case.  
171.  Section 2.3.  I would like to add something like: Other imaging techniques 
under investigation/ development have been not considered. 
We added now a sentence at the end of section 2.3.  
172.  Section 4.1. "102 lesions" or "102 patients" We clarified this now.  
173.  Section 4.1. outcome - change in biochemical profile - what is the median 
duration of the follow-up of these three studies?  
This information is now provided 
174.  Section 4.3. " Only three studies reported on the subgroups of patients in We have clarified this sentence.  
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whom complete resection of the tumor was achieved (138, 140, 144)" - of how 
many subgroups?  
175.  Section 4.3 - recurrence-free and overall survival- what was the range of 
survival time?  
PFS and OS varied between the different studies. More details will be given 
in the Appendix.  
176.  R.1.1 Reasoning - "standardized pathology report is VERY highly 
recommended".  
We agree that this is important. However, "highly recommended" is already a 
very strong statement.  
177.  Reasoning R.2.3. replace "recommend that additional imaging is not 
necessary..." by suggest.  
What about the possibility of a  false negative? 
Is the  financial burden for the health system more important than a human? 
The text is very subtle, in that way that the freedom of a physician  to CAN 
DECIDE is  going los/killed, with  a  hidden strong recommendation.! 
As discussed above it is not only the costs for the health system, but also the 
psychological burden of the patient and the risk of secondary malignancies by 
additional radiation by additional imaging procedures. See for instance the 
concern of one reviewer (see comment #100).   
178.  R.2.4 - Why imaging interval not already at 3 months?  See our response to comment #64 
179.  R.4.3 Reasoning add "high" before expertise.  Done.  
180.  R.4.3 Reasoning: Skip " Although we cannot provide a specific number of 
required operations per year, we have no doubts that surgical volume 
correlates with better outcome", because numbers make never sense.  
We do not agree, because expertise is a matter of experience and therefore 
"numbers" (although this is certainly not everything.) 
181.  R.4.6 Reasoning: Please EMPHASIZE  the need of OH-Cortison after removal 
of the tumor mass. 
We are convinced that the recommendation R.4.6. is by itself already quite 
strong.  
182.  Reasoning R.5.2. "..by an increase of 20% of the largest diameter" In which 
frame of time? 
We suggest using the recommended 6-12 months interval.  
183.  R.6.2.1 "adults < 40 years" Was  not 45 yr  the average? And especially female We discussed this cutoff a lot and agree that 40 years is completely arbitrary 
- as 45 years would be.  
N.N. Patient representative from the German patient group for pituitary and adrenal disease 
184.  From a patient perspective there are no comments and I do completely agree 
with the guidelines. We hope that from now patients will be treated according 
these recommendations.  
Thanks a lot for your positive feedback.  
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